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 ABSTRACT 
JUSTIN COREY FOWLER: Mechanisms of ligand-receptor interactions of the 
dopamine D2L receptor and their relation to functional selectivity  
(Under the direction of Richard B. Mailman, Ph.D.) 
 
Binding and functional studies indicate that some agonists are capable of 
differentially activating pathways linked to a single receptor isoform. In cases where known 
mechanisms like other receptors or receptor reserve are ruled out, this phenomenon is 
referred to as “functional selectivity,” “agonist directed trafficking,” and a variety of other 
terms. Rather than viewing receptors in a traditional way as digital entities (i.e., one or more 
active or inactive states), functional selectivity posits that a receptor can be induced into 
unique conformations that may lead to different patterns of activation of functional responses 
linked to a single receptor. This dissertation elucidates the molecular mechanisms that 
explain why some ligands can differentially activate the effector pathways coupled to the 
human D2L receptor. The focus will be to discern the structural interactions of the hD2L 
receptor with such functionally selective ligands, and how these interactions result in 
selective activation of effector pathways. Computationally-selected point mutations of the 
D2L receptor were made, and detailed analysis of both binding and function made for a series 
of rationally selected ligands, emphasizing compounds that were relatively rigid and had 
fewer degrees of freedom in possible docking poses. Functional assays tested the intrinsic 
activity and potency for GTPγS binding, inhibition of forskolin-stimulated cAMP, 
phosphorylation of MAPK, and release of [3H]-arachidonic acid. Results from this 
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dissertation provide evidence to support the hypothesis that ligand-selective interactions with 
specific residues of the receptor can induce conformational changes that lead to a 
characteristic pattern of activation of one of more signaling pathways. Developing a 
structure-based understanding of functional selectivity will provide general insight into the 
mechanisms of GPCR activation, and may also open the door to design of small molecules 
with desired patterns of functional effects at a single receptor.  
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CHAPTER 1. INTRODUCTION 
DOPAMINE RECEPTORS: THE MODEL SYSTEM FOR MY STUDIES 
History of dopamine systems 
For the first half of the 20th century, dopamine was considered to function solely as an 
intermediate in the synthesis of epinephrine and norepinephrine. It was not until the late 
1950s that Arvid Carlsson discovered the important role of dopamine itself (Carlsson et al., 
1957). This seminal work showed that reserpine could cause depletion of dopamine and a 
concomitant loss of sympathetic nerve stimulation. These effects were reversed by 
administration of 3,4-dihydroxyphenylalanine (DOPA). Most importantly, DOPA restored 
the levels of dopamine, but not norepinephrine levels, that had been depleted by reserpine, 
suggesting an independent role for dopamine. This was confirmed by subsequent 
experiments with monoamine oxidase inhibitors (MAOIs). The corollary to this work was 
discovering that dopamine distribution in the brain was localized in the basal ganglia, a 
region critical for motor control. Carlsson’s work was thus the first to suggest that dopamine 
depletion was responsible for Parkinsonism and that L-DOPA could be used to restore 
normal behavior (Carlsson et al., 1958). Additional studies were conducted on deceased 
Parkinson’s patients, where Hornykiewicz noted marked reduction in dopamine levels 
(Ehringer and Hornykiewicz, 1960). Follow up studies were then conducted with living 
patients, noting that L-DOPA treatment temporarily improved akinesia in Parkinson’s 
patients (Birkmayer and Hornykiewicz, 1961).  
Dopamine neurotransmission 
Using newly developed histochemical methods, it was soon reported that dopamine 
occupied discrete neuronal tracts (Anden et al., 1964; Anden et al., 1965; Anden et al., 1966) 
as summarized in Figure 1.3. There are four major dopamine pathways, three of which 
innervate the forebrain (the mesolimbic, nigrostriatal, and mesocortical pathways). The 
dopaminergic neurons arising from the substantia nigra (SN) and ventral tegmental (VT) area 
project to the caudate and putamen (striatum) via the nigrostriatal pathway, the nucleus 
accumbens, amygdala, and olfactory tubercle via the mesolimbic pathway, and the prefrontal 
cortex via the mesocortical pathway. The fourth pathway, the tuberoinfundibular system, is 
intrinsic to the hypothalamus (Figure 3).  
Dopamine neurotransmission in the basal ganglia plays a vital role in initiation and 
control of movement, and is an important center of integration. The mesocortical system is 
believed to be responsible for the negative symptoms of schizophrenia and is also thought to 
be involved in motivation and emotional response. The mesolimbic system, known as the 
reward center is associated with feelings of reward and desire. This system is responsible for 
the positive symptoms of schizophrenia and is the major target of antipsychotic drugs. 
Conversely, nigrostriatal pathway is responsible for many of the neurological side effects 
associated with antipsychotic drugs, and also is the pathway that degenerates in Parkinson’s 
disease. Lastly, the tuberoinfundibular pathway is responsible for controlling prolactin levels 
regulated by the anterior pituitary gland (Cooper et al., 2006).   
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Figure 1.3. Dopamine pathways in human brain 
ANTIPSYCHOTIC DRUGS AND THEIR IMPACT ON UNDERSTANDING OF 
DOPAMINE RECEPTOR FUNCTION  
Schizophrenia and the serendipitous discovery of chlorpromazine 
The psychiatric condition schizophrenia (split-mind) was described by Bleuler as a 
lack of interaction between the thought processes and perception. Schizophrenics experience 
delusions and hallucinations, exhibit disorganized speech and behavior, and exhibit negative 
symptoms such as declined emotional response, speech, and motor response (American 
Psychiatric Association, 2000). The first drug effectively used in the treatment of 
schizophrenia was chlorpromazine, a drug whose antipsychotic properties were found 
serendipitously during the search for better sedative agents. Laborit and Huguenard described 
the behavioral profiles of patients administered chlorpromazine as being in a state of 
“artificial hibernation” (Laborit and Huguenard, 1951). These observations lead to 
subsequent testing of chlorpromazine on psychiatric patients, the first of whose “erratic, 
uncontrollable behavior” significantly decreased within days after administration of 
chlorpromazine (Hamon et al., 1952). After three weeks of treatment the patient was 
released, appearing largely normal. The fact that one could achieve control of psychotic 
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symptoms that was dissociated from gross sedation was a major breakthrough, and these 
early studies with chlorpromazine opened the door for both biological psychiatry and the 
advent of the era of neuropsychopharmacology.   
Proliferation of typical antipsychotic drugs, recognition of dopamine importance, 
and recognition of side effects 
Within two years of introducing chlorpromazine to the clinic, the first studies 
reporting significant side effects were released (Steck, 1954). Chlorpromazine and the 
follow-up antipsychotics (e.g., other phenothiazines and haloperidol) all cause 
extrapyramidal side effects (EPS) such as parkinsonism, dystonias, and akathesia, as well as 
tardive dyskinesia (Meltzer and Stahl, 1976). It became clear that it would be desirable if the 
next generation of antipsychotic drugs were free of these neurological side effects. The 
accepted term for these next generation drugs that are essentially free of both EPS and 
tardive dyskinesia is now “atypical antipsychotics,” with chlorpromazine and its cousins 
being termed “typical.”  
The search for atypical agents would obviously be aided by understanding of the 
mechanisms of both therapeutic and side effects. Biochemical experiments soon 
demonstrated that the primary mechanisms were antagonist action of antipsychotics on the 
dopamine D2 receptors in the mesolimbic nuclei (Carlsson and Lindqvist, 1963; Meltzer and 
Stahl, 1976; Creese et al., 1976; Davis et al., 1991). Meltzer however described the cause for 
EPS as blockade of dopaminergic inhibition of the cholinergic neurons of the striatum. This 
blockade caused increased cholinergic activity in the basal ganglia which increased the side 
effects observed (Meltzer and Stahl, 1976). Positron emission tomography (PET) studies also 
provided quantitative evidence to suggest that occupancy of striatal D2 receptors greater than 
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80% caused significant EPS (Farde et al., 1992). Interestingly, the Germans were skeptical of 
the EPS profiles, and this led to research resulting in the development of clozapine and 
related atypical antipsychotics. 
The discovery of atypical antipsychotic drugs focuses attention on dopamine 
receptor mechanisms 
Clozapine spurs the search for atypicals 
Clozapine was the first drug developed that exhibited atypical properties, that is, 
antipsychotic activity with little or no EPS. Introduced in the late 1960s, clozapine was 
initially met with skepticism because of the high degree of efficacy coupled with an excellent 
neurological profile. Because clozapine caused a very high degree of life-threatening 
agranulocytosis (Idanpaan-Heikkila et al., 1997), the drug was shelved for more than a 
decade. Later, it was realized that despite the high toxicity of this compound, it was 
apparently the most effective antipsychotic in terms of efficacy coupled with low 
neurological side effects (Kane et al., 1988). This led to its reintroduction in the US in 1990, 
with the requirement of a concomitant blood monitoring program. Those early reports about 
the unsurpassed efficacy of clozapine against both positive and negative symptoms of 
schizophrenia (American Psychiatric Association, 2000) have been confirmed by numerous 
studies. 
The efficacy of clozapine spurred attempts to develop structurally and 
pharmacologically similar drugs having the useful properties of clozapine without its 
toxicity. This led to the development of atypical antipsychotics that now include risperidone, 
olanzapine, ziprasidone, quetiapine, and aripiprazole (the latter to be addressed later). 
Although only olanzapine is similar structurally to clozapine, all of these compounds have 
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complex pharmacology (Rauser et al., 2001). An obvious question then is what 
mechanism(s) differentiated clozapine and the other atypicals different from chlorpromazine 
and haloperidol. Meltzer (1989) has argued that atypicality is defined by drugs that exhibit 
more potent serotonin 5-HT2A receptor antagonism than D2 receptor antagonism. This 
hypothesis would explain the atypicality of risperidone, olanzapine, quetiapine, ziprasidone, 
and quetiapine, yet risperidone has greater selectivity for the D2 and 5-HT2A receptors, yet 
has a somewhat greater propensity to induce EPS at high does than the other drugs. Indeed, 
olanzapine, quetiapine, ziprasidone, and quetiapine have relatively similar affinity to a dozen 
or more receptors, making such simple hypotheses unlikely. Although PET studies has led 
one hypothesis that high levels (greater than 70%) of D2 receptor antagonist occupancy may 
correlate with increased EPS (Kapur et al., 1998; Remington et al., 1998; Kapur et al., 1999), 
little is crystal clear. Indeed, as of the writing of this dissertation, the mechanisms for both 
therapeutic and side effects of these clozapine-like drugs remains a source of controversy and 
investigation. 
Non-traditional dopamine receptor actions as a mechanism for atypicality 
In parallel with the development of drugs with dopamine and serotonin antagonist 
properties, the suggestion was made that D2 partial agonists might have utility in treating 
schizophrenia. Originally, this was based on the “dopamine hypothesis of schizophrenia” that 
proposed that excess dopamine synaptic transmission (either basal or in response to external 
perturbation) was a major cause of the disorder. Because presynaptic and autoreceptors were 
known to be much greater in sensitivity than postsynaptic receptors, it was felt that a partial 
agonist could decrease dopamine release markedly without causing changes in postsynaptic 
receptor activation, thereby improving symptoms. This intriguing idea, however, was not 
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supported by clinical studies with 3-PPP (Tamminga et al., 1992), one of the compounds I 
shall study.   
In 2004, Bristol-Myers Squibb marketed the drug aripiprazole (Abilify), a compound 
currently approved by the FDA for treatment of both schizophrenia and bipolar disorder. 
Although the drug may be slightly less effective than the compounds discussed above, it has 
a superior side effect profile. Aripiprazole clearly is differentiated from the other atypicals in 
terms of clinical action and mechanism. The prevailing view of thought-leaders in the field is 
that aripiprazole works via the partial agonist mechanism summarized above.  
Conversely, an alternate hypothesis was first proposed by Lawler et al. (1999) that 
suggested that the intrinsic activity of aripiprazole is markedly affected by the location of the 
target D2 receptor in a way that can not be explained by traditional notions such as receptor 
reserve. Later studies confirmed this milieu-dependent signaling of aripiprazole (Shapiro et 
al., 2003; Urban et al., 2006b), providing a clear example of how functional selectivity may 
actually impact on the physiological actions of drugs. It is the mechanisms behind such 
observations that are the focus of this dissertation. It should be noted, that even with 
aripiprazole, the picture is clouded by other receptors. The unique actions of this drug (and 
similar compounds) may include not only its functionally selective or partial agonist D2 
effects, but also partial agonist actions at 5-HT1A or other serotonin receptors (Lawler et al., 
1999; Corbin et al., 2000; Shapiro et al., 2003). Nonetheless, a more in-depth understanding 
of D2 signaling with ligands such as aripiprazole is of heuristic interest, and may well impact 
on the discovery of even more novel agents.  
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BIOLOGY AND PHARMACOLOGY OF DOPAMINE RECEPTORS 
The dopamine receptors belong to the G protein-coupled receptor (GPCR) 
superfamily that is of great scientific and commercial interest. GPCRs may be the largest 
superfamily of biological signaling molecules and play a critical role in the function of 
essentially all cells. Thus, it is not surprising that studies of the structure and function of 
GPCRs has been a major scientific research front covering all major disciplines. Moreover, 
nearly half of the drugs on the market target GPCRs (Robas et al., 2003). Thus, scientific 
breakthroughs may have effects on the discovery of more effective clinical agents that target 
GPCRs. 
Dopamine receptors are in the rhodopsin-like Class A family of GPCRs. Such GPCRs 
are characterized by their seven transmembrane spanning domains linked to three intra- and 
three extracellular loops. Signaling through GPCRs occurs by agonist activation of the 
receptor, and subsequent conformational changes of the receptor. This affects the interaction 
of the receptor with heterotrimeric G protein complexes, leading to the exchange of GDP for 
GTP via a conformational change of the α5 helix of the α subunit. This movement leads to 
subunit dissociation of the heterotrimeric complex, such that the α and βγ subunits can affect 
second messenger and other functions within the cell (Neve et al., 2004; Oldham et al., 
2006). First classified into the D1 or D2 pharmacological families (Garau et al., 1978; 
Kebabian and Calne, 1979), it is now known that five genes code for dopamine receptors. 
The D1 dopamine receptors stimulate adenylate cyclase through Gαs and GαOLF, whereas D2 
receptors are pertussin toxin-sensitive, inhibiting adenylate cyclase activity through Gαi/o. 
The five subtypes are classified as being either D1-like (D1 or D5) or D2-like (D2, D3, D4). In 
addition, the D2 receptor has splice variants, D2L and D2S, that differ by 29 amino acids in the 
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third intracellular loop of D2L (Missale et al., 1998; Neve et al., 2004). All of the experiments 
in this dissertation will focus on characterization of the hD2L receptor. Activation of the D2L 
receptor is known to regulate several pathways including inhibition of cAMP accumulation, 
phosphorylation of mitogen activating protein kinases p44/42, potentiation of arachidonic 
acid release, and activation of GIRK channels (Figure 4).  
 
Figure 1.4. Signaling pathways of the dopamine D2 receptor. Pathways that will be the focus of this 
dissertation include Gαi/o mediated inhibition of adenylate cyclase, Gβγ mediated phosphorylation of p42/p44 
MAP Kinase, and Gβγ, PLA2 mediated release of arachidonic acid. Figure adapted from Neve et al 2004.  
Signal transduction of dopamine receptors 
Before the myriad of signal transduction pathways was discovered, iontophoretic 
experiments conducted on the substantia nigra provided evidence to support a biphasic action 
of dopamine, suggesting that dopamine signaling occurred through two different receptors 
(York, 1970). Greengard’s group described dopaminergic activation of adenylate cyclase in 
bovine superior cervical ganglion and later in caudate nucleus homogenates, providing the 
first evidence for a biochemical consequence of dopamine receptor activation (Kebabian and 
Greengard, 1971; Kebabian et al., 1972). Studies with neuroleptic drugs were also 
conducted. Strikingly, these drugs did not activate adenylate cyclase but instead antagonized 
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dopamine-stimulated adenylate cyclase activity (Kebabian et al., 1972). Further behavioral 
experiments classified the dopamine receptors as stimulatory or inhibitory (Cools and Van 
Rossum, 1976). The human dopamine receptor (hD2L) studied in this dissertation exhibits 
inhibitory properties through the following signal transduction pathways: 
Adenylate Cyclase 
Adenylate cyclases (ACs) play an important role in signal transduction of the CNS 
including physiological responses such as learning and memory, synaptic plasticity, and 
circadian rhythms (Chern, 2000). Disruption of the expression of ACs has been linked to a 
variety of physiological and pathological conditions including circadian rhythms (Tzavara et 
al., 1996; Chern et al., 1996; Cagampang et al., 1998), alcoholism (Hashimoto et al., 1998; 
Ikeda et al., 1999), and Alzheimer’s disease (Yamamoto et al., 1996). Ten adenylate cyclases 
have been identified to date, and each is responsible for stimulating the production of cAMP. 
All mammalian isozymes of AC have been shown to be activated by Gαs and subsequently 
synthesize cAMP. In addition, AC isozymes have been shown to be inhibited by Gαi (Taussig 
et al., 1994), but there is also evidence that Gβγ can play a role in regulating cyclase (Tang et 
al., 1991). The dopamine D2L receptors that are the focus of this dissertation signal through 
Gαi/o and have been shown to inhibit AC types I, V, VI, and VIII (Robinson and Caron, 
1997; Nevo et al., 1998)  
MAP Kinase 
Mitogen-activated protein kinases (MAPK) are serine/threonine kinases whose 
activation is directly linked to control of gene expression and downstream cell growth and 
differentiation. Three MAPK subfamilies are known in mammalian cells. They are: 1) 
extracellularly-responsive kinases ERK1/ERK2 (p44mapk and p42mapk respectively); 2) c-Jun 
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N-terminal kinases (JNKs) or stress-activated protein kinases (SAPKs); and 3) p38-MAPKs. 
Several GPCRs have been shown to activate MAPK via signaling through PTX-sensitive G 
proteins Gαi/o, activating ERK1/2 (Welsh et al., 1998; Choi et al., 1999). Although the exact 
nature of D2 signaling through ERK1/2 is still incompletely understood, it is known that 
GPCR signaling through MAP kinase in general involves membrane bound Gβγ promoting 
tyrosine phosphorylation of Shc. The latter then complexes with Grb/Sos, recruiting GTP-
Ras Æ Raf Æ MEK Æ ERK1/2 (Sugden and Clerk, 1997; Lopez-Ilasaca, 1998).  
Arachidonic Acid 
Release of arachidonic acid (AA) from membrane phospholipids by phospholipase A2 
(PLA2) has generally been associated with inflammatory response (Needleman et al., 1986), 
but it also serves important second messenger functions such as long-term potentiation and 
synaptic plasticity (Williams et al., 1989). In addition, AA release may be involved in the 
pathophysiology of several neurodegenerative disorders including cerebral ischemia, stroke, 
Alzheimer’s, and Parkinson’s (Lynch, 1998; Kramer et al., 2004). PTX sensitive G protein-
coupled receptors (i.e. dopamine D2) have been shown to stimulate release of AA through 
PLA2. The exact mechanism has yet to be elucidated, but evidence exists to support GPCR 
activation of PLA2, mediated through ATP binding and subsequent activation of the P2-
purinergic receptor (Felder et al., 1991). There is also some data that is interpreted as 
showing that D2 receptors can activate PLA2 directly without ATP mediation (Nilsson et al., 
1998), but the latter findings have not been replicated in our lab. 
GIRK channels 
For some time now, dopaminergic neurotransmission has been associated with 
regulating G protein-regulated inward-rectifier potassium channels (GIRK). In mammals, 
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four subunits of GIRK (GIRK1-4, also designated Kir3.1-4) have been identified. Data 
suggests that these channels are modulated through a direct interaction between the N- and 
C- termini of the channel and a Gβγ subunit (Mark and Herlitze, 2000). In addition, 
regulators of G protein signaling (RGS) proteins have been found to accelerate both the 
activation and deactivation of GIRK currents in a CHO cell line (Doupnik et al., 1997). D2 
receptor activation of GIRK channels has been evidenced in several models including rat 
striatum, lactotrophs, and CHO cell lines expressing hD2L (Einhorn et al., 1991; Liu et al., 
1996; Kuzhikandathil et al., 1998; Liu et al., 1999). 
Dopamine receptor agonists 
Several agonists of the hD2L receptor were chosen for studying the mechanisms of 
functional selectivity within this dissertation (Figure 1.5). The endogenous ligand dopamine 
(DA) and the prototypical agonist quinpirole (QP) were chosen to serve as reference full 
agonists. Both compounds were used because dopamine is more sensitive to loss of affinity 
and/or functional activity by several of the mutations we planned to study (Mansour et al., 
1992; Cox et al., 1992). Dihydrexidine (DHX), a rigid analog, was chosen because it has 
been shown to display functional selectivity at the D2L receptor in the brain and in MN9D 
(Kilts et al., 2002) and CHO cell lines (Gay et al., 2004). In addition, the rigid analogs 
dinapsoline (DNS) and dinoxyline (DNS), whose structures differ merely by the substitution 
of an ether (DNX) for a methylene bridge (DNS) at a site believed to not be critical for 
binding, were chosen as test compounds because they are functionally selective at activating 
GIRK channels (Gay et al., 2004).  
S(-)-3-(3-Hydroxyphenyl)-N-propylpiperidine, S (-) 3-PPP, was chosen because it 
will serve as a representative D2 partial agonist. The propylnorapomorphine compounds, 
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R(+) and S(-)propylnorapomorphine (R/S NPA), were chosen because of their different 
functional profiles in the CHO expressing D2L receptor at phosphorylation of MAP kinase 
and activation of GIRK channels (Kilts et al., 2002; Gay et al., 2004). These compounds are 
the most interesting of all the test compounds because they differ merely by the orientation of 
the hydrogen atom at their chiral center, yet have such vastly different functional profiles. 
The diversity of these rigid test compounds will broaden our knowledge of the ligand-
receptor residue interactions of the hD2L receptor and provide insight regarding how specific 
structural interactions relate to function.  
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Figure 1.5. Test compounds. S(+)Dinapsoline (DNS), S(+)Dinoxyline, 6aR,12bS(+)Dihydrexidine 
(DHX), R(-)propylnorapomorphine (R(-)NPA), S(+)propylnorapomorphine (S(+)NPA), (-)Quinpirole (QP), 
Dopamine (DA), and S(-)3-PPP. 
 
I should also explain the nomenclature that will be used when referring to the 
hydroxyl groups attached to these test compounds. I will refer to each of these groups based 
upon the alpha-rotamer of dopamine. Consider DNS for example: the hydroxyl group 
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opposite the ethyl amine of dopamine will be referred to as para-OH and the remaining 
hydroxyl will be referred to as meta-OH. This rule will be applied to all of my test 
compounds and should further clarify subsequent binding hypotheses. 
Background on catecholamine receptor mutagenesis experiments 
Nomenclature and conserved residues 
Throughout this dissertation I shall refer to specific amino acid residues within the 
receptor using universal indexing nomenclature (Ballesteros and Weinstein, 1995). The most 
conserved residue of each transmembrane (TM) domain (Table 1) is given an integer value 
referring to its TM domain, and a decimal number, 0.50 referring to the most conserved 
residue in that helix. The decimal values are indexed positively (toward the carboxy-
terminus) or negatively (toward the amino terminus). Thus, the conserved aspartate in TM 2 
is designated 2.50. When referring to a specific amino acid residue, I will refer to it by the 
one letter code, followed by the universal index. When referring to an amino acid mutated to 
another residue, I will refer to the residue using the original residue one letter code followed 
by the universal index, and the one letter code of the mutated residue (e.g. threonine 3.37 
mutated to alanine: T3.37A). The following Table shows the most conserved residue in each 
TM helix, as well as the residues that will be targeted by this research.  
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Table 1.1. Universal Index. Universal Indexing of most conservative residues and 
targeted residues and their position in dopamine D2L receptor. 
Universal 
Index 
Absolute 
position 
TM# Residue
1.50 52 1 N 
2.50 80 2 D 
3.37 119 3 T 
3.50 132 3 R 
4.50 160 5 W 
5.42 193 5 S 
5.43 194 5 S 
5.46 197 5 S 
5.50 201 5 P 
6.50 388 6 P 
6.55 393 6 H 
7.50 4.23 7 P 
 
The role of TM5 serine residues in ligand-receptor interaction 
The serine residues in TM5 have been implicated in ligand binding interactions 
necessary for activation and receptor/G protein coupling for catecholamine type GPCRs. 
Strader was the first to provide evidence supporting bonding interactions with the serine 
hydroxyl groups (serines 5.43 and 5.46) of the β2-adrenergic receptor and its endogenous 
ligand (Strader et al., 1989). Studies that followed provide evidence for all three serines 5.42, 
5.43, and 5.46 in ligand-residue interactions of the β2-adrenergic receptor necessary for 
receptor/G protein coupling (Liapakis et al., 2000). In addition to the β2-adrenergic receptor, 
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these serines play essential roles in many other catecholamine receptors (Cox et al., 1992; 
Pollock et al., 1992; Woodward et al., 1996; Cavalli et al., 1996; Hwa and Perez, 1996; 
Wiens et al., 1998; Rudling et al., 1999).  
Earlier studies of the D2 receptor have provided evidence that led to the conclusion of 
important bonding interactions between dopamine agonists and serine residues 5.42, 5.43, 
and 5.46 (Mansour et al., 1992; Cox et al., 1992; Wiens et al., 1998; Lee et al., 2000). 
Although these studies showed the importance of such interactions, the data did not show 
conclusively which aspects of various ligands interacted with specific serines. For example, 
some of these previous studies suggest that serine 5.43 interactions with dopamine and the 
related non-catechol p-tyramine. Because dopamine and p-tyramine are both molecules with 
a flexible, rotatable side chain  there are many possible conformations by which serine 5.43 
interactions could occur. This residue not shown to interact with any other compounds (Cox 
et al., 1992), including rigid ligands that might have resolved some of this uncertainty. This 
issue will be addressed in this dissertation. 
Background on molecular modeling of GPCRs 
Despite a great deal of effort, only one GPCR crystal structure has been solved to 
date at high resolution. Solving the three dimensional (3D) crystallographic structure of 
bovine rhodopsin at 2.8 Å (Palczewski et al., 2000) led to numerous modeling studies on 
other rhodopsin-like class A GPCRs, using the transmembrane region of the bovine 
rhodopsin crystal structure as a template (for recent reviews, see Ballesteros et al., 2001 and 
Visiers et al., 2002). Detailed analyses of the rhodopsin structure, together with the results of 
both sequence analysis and molecular modeling, have served to probe the accuracy of these 
3D models created by homology modeling (Ballesteros et al., 2001b; Visiers et al., 2002). In 
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the absence of experimental structural information, these 3D molecular representations of 
rhodopsin-like GPCRs are used to interpret experimental results in a structural context, 
incorporating directly and consistently the many types of function-related information (for 
comprehensive review see Visiers et al., 2002). Such molecular models are also used as 
hypothesis-generators for experimental probing of functional inferences, and are 
continuously refined by the data obtained from such experiments. Refined models can 
therefore be used in computer simulations to generate and/or probe novel aspects of the 
receptor mechanisms, based on the dynamic properties of the proteins, both wild type and 
mutant constructs. Together, all the inferences from both homology modeling and computer 
simulation serve as mechanistic working hypotheses for new and more focused experiments. 
Given the success reported for several receptors (for some recent examples and reviews, see 
(Shi and Javitch, 2002; Visiers et al., 2002; Shapiro et al., 2002; Chalmers and Behan, 2002; 
Klabunde and Hessler, 2002; Singh et al., 2002; Shi et al., 2002; Ebersole et al., 2003), 
interdisciplinary studies involving collaborations between computational and experimental 
teams have become a sustained characteristic of current research on structure-function 
relations of GPCRs.  
THE CHANGING FACE OF RECEPTOR PHARMACOLOGY 
Classical receptor theory: agonists, antagonists, and partial agonists 
The field of pharmacology is based in large measure on a body of information that 
might be called “receptor theory.” The primary use of receptor theory is to provide both a 
conceptual and quantitative framework that can aid in the understanding of how ligands may 
interact with, and modulate, the function of receptors. It has been nearly a century since A.V. 
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Hill first described “receptive substances” as the vehicle by which nicotine and curare induce 
contractions of the frog rectus abdominis muscle (Hill, 1909). Hill and A.J. Clark were 
pioneers of this early theory that led to quantitative relationships to describe the 
concentration effects of drug action on receptors. It was not until the 1950s that Stephenson 
would use the term “affinity” to describe binding to the target, and “efficacy” to describe the 
production of response (Stephenson, 1956).  
The term “agonist” was coined to describe drug action whereby binding and 
activation of the receptor caused a 100% biological response as defined by the endogenous 
ligand for said receptor species. Drug action upon receptor that produces no measurable 
response, or that could block the response of the endogenous agonist was coined 
“antagonism.” Stephenson, however, erred in assuming that efficacy was always directly 
proportional to drug concentration, such that maximal occupation of receptors with drug 
would result in maximal effect (or full agonist activity). Intrinsic activity was first described 
by Ariens as a means to describe the relationship between the effect elicited by a drug and 
the concentration of drug-receptor complexes (Ariens, 1954; Ariens and Simonis, 1954; 
Ariens and De Groot, 1954). Ariens also formulated the term “partial agonist,” describing 
when certain compounds, even at receptor-saturating concentrations, do not elicit maximal 
response.  
Implicit within this framework is that characterization of drug action on a single 
receptor isoform is independent of the pathway measured (e.g. a full agonist exhibits the 
same intrinsic activity at all functional endpoints measured through a single receptor 
isoform). Unlike intrinsic efficacy, where ligand mediated effects on a single receptor are 
independent of pathway measured (Furchgott, 1966), intrinsic activity is dependent on the 
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measurement of individual pathways mediated through a single receptor isoform. These 
concepts, and the underlying concentration dependent effects, have been the foundation for 
the study of drug-receptor interactions.  
My research deals with one such situation, the notion of “intrinsic efficacy,” a 
fundamental part of pharmacological dogma. Intrinsic efficacy embodies the idea that a 
ligand that interacts with one specific receptor always has the same type of functional effect 
on that receptor. Thus, the ligand may be called a “full agonist” (activates the receptor to the 
same degree as the endogenous ligand), “partial agonist” (causes only sub-maximal effects 
even when occupying all of the receptor), and “antagonist” (causes no functional effects, and 
by occupying the receptor, blocks the effects of agonists or partial agonists). More recently, 
antagonists have been divided into neutral antagonists and inverse agonists, the latter also 
decreasing the basal level of the function being studied. I shall review the history and basis 
for these ideas below, and describe the new concept of “functional selectivity” that my 
research investigates. 
Digital nature of classical models of GPCR signaling 
Since the inception of quantitative pharmacology, mathematical models have been 
utilized to evaluate and hypothesize the physiological states of receptor 
activation/inactivation (Figure 1). Monod, Wyman, and Changeux applied the idea of a two-
state model to the interaction between oxygen and hemoglobin, where the target hemoglobin 
existed in an unbound, inactive R state or a bound, active R* (Monod et al., 1965). Later, De 
Lean et al. (De et al., 1980) described the activation of G protein coupled receptors as a 
ternary complex, where the ligand bound active state (DR*) requires an additional kinetic 
step before it can couple to G protein and activate downstream effector pathways (DR*G) 
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(De et al., 1980). Several years later, however, GPCRs were found to exhibit constitutive 
activity (basal activity in the absence of agonist),  the ternary complex model was expanded 
to what has been termed the extended ternary complex model (ETC) (Samama et al., 1993). 
When it was suggested that one must consider the possibility of a ligand-receptor-G protein 
complex that is inactive (DRiG), Kenakin et al. developed an extension of the ETC by 
incorporating this inactive state, calling their model the cubic ternary complex model (CTC) 
(Weiss et al., 1996).  
 
Figure 1.1. Models of ligand activation of GPCRs. a. Two-state model, b. ternary complex, c. extended 
ternary complex (ETC), and d. cubic ternary complex (CTC). Figure adapted from Kenakin 2002.  
Each of the previously described models intrinsically suggests that receptor activation 
of downstream effector pathways involves rigid, digital receptor states induced by ligand 
binding and conformational change. The first evidence to support agonist induced 
conformational changes to target receptors was provided by Del Castillo and Katz in 1957 
when they showed that acetylcholine binding to nicotinic acetylcholine receptors lead to 
channel opening (Del Castillo and Katz, 1957). Since that time, Kenakin and others have 
taken these mathematical models of ligand activation and applied them to graphical 
36 
representations, hypothesized as rationale to explain observed signaling profiles (Figure 1.2). 
It has been argued that agonists exhibit a frequency of specific receptor conformations and 
that preferential activation of one conformational state over another (termed “conformational 
selection”) could potentially explain the differential signaling observed with functionally 
selective ligands (Kenakin, 1997). The hypothesis continues by arguing that a multitude of 
conformational states exist in the absence of ligand binding, and that when ligand binds, it 
selects the conformational state to which it has the highest affinity. Binding removes that 
specific conformational state from the available pool of receptors and via mass action is 
replaced by a conformation with lower affinity for the ligand (Kenakin, 1997; Kenakin, 
2002; Clarke, 2005).  
 
Figure 1.2. Ligand-specific receptor conformations. a. absence of ligand, b. presence of ligand, c. 
frequency distribution in presence and absence of ligand. Figure adapted from Kenakin 2004. 
Functional Selectivity: an analog view of receptor action 
During the past two decades, pharmacological research has benefited from technical 
and research advances that have permitted the measurement of numerous effector pathways 
modulated by a single type of receptor. As the breadth of effector pathways measured has 
increased, a plethora of observations have been made that are difficult to rationalize with 
some of the concepts discussed above. Specifically, some ligands were found to cause 
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patterns of effects that were inconsistent with the idea of intrinsic efficacy. At the extreme, 
compounds were found that were full agonists at one function yet antagonists at another 
function mediated by a single receptor in a single cell type.  
Our laboratory was one of the first to recognize that there could be differential 
signaling of a single ligand working through a single receptor. We coined the term 
“functional selectivity” (Mailman et al., 1997; Mailman et al., 1998) to describe the ability of 
a ligand to activate in a differential fashion individual receptor pathways linked to a single 
receptor isoform. A plethora of recent evidence shows such differential signaling through 
single receptor isoforms of a variety of different GPCRs (Kenakin, 1995a; Kenakin, 1995b; 
Berg et al., 1998; Whistler et al., 1999; Lawler et al., 1999; Watson et al., 2000; Dutertre and 
Smith, 2000; Mottola et al., 2002; Kilts et al., 2002; Gazi et al., 2003; Mukhopadhyay and 
Howlett, 2005; Nickolls et al., 2005; McLaughlin et al., 2005). Although “functional 
selectivity” seems to be the term coming into most common use (Simmons, 2005; Urban et 
al., 2006b), the same phenomenon has been called agonist directed trafficking (Berg et al., 
1998; Brink et al., 2000; Kukkonen et al., 2001), differential engagement (Manning, 2002), 
biased agonism (Jarpe et al., 1998), and a variety of other terms.  
Functional selectivity versus intrinsic efficacy 
It is important to define a few terms that shall be used throughout this dissertation. 
The term “intrinsic activity” will be used in a purely operational sense to define the observed 
functional changes caused by a ligand in a signal system relative to a reference compound 
(e.g., the endogenous ligand or some other compound defined a priori). Conversely, the term 
“intrinsic efficacy” reflects the concept put forth by Stephenson (1956) describing functional 
effects of a ligand after binding to a specific receptor. Thus, in general use, when one labels a 
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compound a “full agonist” or “partial agonist” or “antagonist,” it means that the compound 
will always have these actions at the  target receptor although the degree of activity can be 
affected by mechanisms such as receptor reserve (Limbird, 1996). The formation of these 
concepts of quantitative pharmacology by Stephenson, Ariens, and many others have been 
extremely useful for the field for decades. Unfortunately, in almost every pharmacology 
textbook, and possibly in the minds of most pharmacologists, these concepts are considered 
fundamental principles rather than useful guideposts. It is possibly for this reason that 
examples of functional selectivity were met with great (possibly undue) skepticism.  
As an example, the stoichiometry of receptor:G protein in in vitro systems suggests 
that receptor reserve might potentially explain the observed signaling profiles otherwise 
construed as representing functional selectivity. Receptor reserve (also known as spare 
receptors) is defined as a system in which the stoichiometry of the receptor is of greater 
molar excess compared to G protein effector subunits. Within such systems, it is possible for 
a ligand of low affinity to bind and produce maximal response (full intrinsic activity) without 
occupying all receptors available. This phenomenon was demonstrated with the dopamine D1 
receptor, where three different cell lines of varying expression levels produced variable 
responses to effector pathways measured (SKF38393 and SKF82958 exhibited partial 
agonist activity in a low expressing system, but full agonist activity in a high expressing 
system (Watts et al., 1995)). Although receptor reserve does exist in the system studied 
within this dissertation, a variety of lines of evidence suggest this cannot explain the many 
instances of functional selectivity. First, several of the test compounds used in my work have 
been shown to exhibit functional selectivity in a manner not related to receptor reserve 
(Mottola et al., 2002). Moreover, even in the earliest reports of this phenomenon, ligands 
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were found that caused opposite changes than predicted by receptor reserve (Berg et al., 
1998; Mottola et al., 2002; Kilts et al., 2002).   
It has also been suggested that the observations termed functional selectivity can be 
explained by differences in “strength of signal.” Strength of signaling is best described as 
follows: upon activation of a receptor, cascading events take place, where one pathway is 
activated, followed by activation of additional pathways. It is conceivable that agonist 
activation of one pathway could be partially activated whereas another pathway by the same 
agonist could be fully activated. One potential argument is that some pathways being 
measured are downstream of earlier pathways, and that the earlier pathways would 
essentially be partially activated by agonists and the more downstream pathways could 
therefore exhibit full agonist activation. Kenakin suggests that strength of signaling can be 
ruled out by demonstrating the ability of one agonist to activate a specific effector pathway 
over another. This same agonist would also not activate a second pathway tested. Secondly, 
another agonist, capable of activating only the second pathway would be tested. This same 
agonist would likewise fail to activate the first pathway, thus ruling out strength of signaling 
(Kenakin, 1995a). 
A non-linear view of receptor theory 
The quantitative models that have dominated receptor pharmacology are based on 
discrete receptor states. Although they have been of great utility, they can only be made 
consistent with functional selectivity by the addition of so many additional states that the 
models lose their quantitative utility. One could generate a model with a discrete active state 
for every unique ligand, but the resultant complexity in the model loses heuristic value as 
was illustrated above (e.g., see Figure 1.1).  
40 
One way to conceptualize functional selectivity is to envision a nearly unlimited 
possibility for the conformational states induced by different ligands that interact with a 
single receptor. Thus, rather than thinking of ligand interaction with receptor as a digital 
phenomenon (i.e., a few active states), one can hypothesize a dynamical systems. A 
dynamical system is defined as “any process or set of processes that evolves in time and in 
which the evolution is governed by some set of physical laws” 
(http://amsglossary.allenpress.com/glossary).  
Through the use of ultrahigh x-ray crystallography at atomic resolutions < 1 Å under 
cryogenic conditions, dynamical sub-states can be frozen, allowing visualization of 
individual sub-states on electron density maps. Recent evidence with aldose reductase and 
parvalbumin at ultrahigh resolution x-ray crystallography has made possible the visualization 
of such dynamical sub-states (Declercq et al., 1999; Howard et al., 2004). Howard et al. 
found significantly different conformational states for a number of residues at 0.66 Å, 
including residues that involved intermolecular contacts in one conformation and none in the 
other. It was shown that water contacts were involved in stabilizing some conformations of 
aldose reductace in its ternary complex form, but in other areas of the structure, water 
contacts were in more disarray than necessary for contacts. Crystals comparing different 
inhibitor interactions with aldose reductase also provided evidence for distinctly different 
conformational states necessary for interaction and subsequent physiological response. 
Studies conducted by DeClercq et al. also found significantly different conformational sub-
states for specific amino acid residues at 0.91 Å. This study provided evidence for 
differential interconversions between sub-states of amino acid residues, specifically 
addressing differences in χ1 torsional angles. Each of these studies provides evidence, with 
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frozen sub-states of protein crystals, that suggests the possibility of unlimited unique receptor 
conformational states.  
It is my view that the structurally subtle differences in individual ligand interactions 
with target receptors can induce a unique conformational profile. This hypothesis is 
consistent with data from high resolution x-ray crystallographic studies such as those 
mentioned previously. Further evidence to support not only ligand-specific receptor 
conformational states, but also its relevance to functional selectivity, comes from work with 
selective estrogen receptor modulators (SERMs). Crystallographic studies of estrogen 
receptors in different states have provided significant evidence to suggest that indeed ligand-
specific receptor conformational states do exist (Shiau et al., 1998; Pike et al., 1999). 
Structural studies conducted with both ERα (2.03 Å) and ERβ (0.93 Å) show the induction of 
distinctly different conformational states by ligands of various classes including full agonists, 
partial agonists, and antagonists. In addition, these studies provide evidence to support a 
physiological role for ligand-induced conformational states.  
What currently is not well understood, however, is how these unique ligand-receptor 
sub-states affect functional measurements with G protein-coupled receptors. This question 
will be the focus of this dissertation within the framework of studying mechanisms related to 
ligand-induced functional selectivity. Although I have provided my conceptual overview of 
this arena, the work proposed below had much more discrete and circumscribed foci. It is my 
hope that the results might influence others to think about the broader mechanisms involved 
in this phenomenon.  
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GOALS OF THIS DISSERTATION 
The functional selectivity hypothesis is now being widely recognized (Simmons, 
2005; Urban et al., 2006b) if not universally accepted. Despite this, relatively little is known 
about underlying mechanisms despite robust demonstrations of this phenomenon in many 
GPCR systems. To achieve my primary goal of investigating some of the mechanisms of 
functional selectivity, I chose the dopamine D2L receptor as a model system for several 
reasons. First, although more structural studies have been done with the β2 adrenergic 
receptor, there actually is a larger group of interesting functionally selective ligands that have 
been identified for the D2 receptor. Moreover, many of these D2 ligands are relatively rigid, 
somewhat simplifying data analysis and hypothesis testing. Finally, this receptor is of great 
clinical importance (already a target for some of the most serious and prevalent neurological 
and psychiatric disorders). It is therefore important to understand the role of this receptor in 
neural function.  
The global hypothesis for my research is that functional selectivity is influenced by 
the particular range of conformational changes induced by a given ligand interacting with its 
target receptor. My goals were two-fold. First, I wanted to develop data that provided some 
understanding of how ligand-receptor interactions affect the structural basis of functional 
selectivity. Secondly, as an overall test of this idea, I hypothesize that the functional profile 
of some ligands can be altered by mutation of the receptor (i.e., the mutation can engender 
functional selectivity). These goals were addressed by examining how specific 
ligand-receptor residue interactions affected the signaling of a set of model compounds, some 
of which are functionally selective ligands at the dopamine D2L receptor. This was 
accomplished by the following aims: 
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Aim 1: Determine the role of serine residues 5.42, 5.43, and 5.46 in the binding and 
subsequent activation of the hD2L receptor by functionally selective ligands. 
Using rigid analogs that are known to exhibit functional selectivity at the hD2L 
receptor, this aim critically evaluated several hypotheses regarding the role of serines located 
in TM 5.  
Aim 2: Determine the role of a novel threonine residue 3.37 in the binding and 
subsequent activation of the hD2L receptor by functionally selective ligands.  
Previous studies including extensive cysteine scanning accessibility methods 
(SCAM) failed to suggest a role for T3.37 in agonist binding or function. Using rigid 
agonists hypothesized to interact via hydrogen bonding with T3.37, this aim tested the 
hypothesis that T3.37 played an important role in ligand interaction and receptor/G protein 
coupling to downstream effectors. 
Aim 3: Determine the role of histidine 6.55 in the binding and subsequent 
activation of the hD2L receptor by functionally selective ligands. 
Previous studies conducted at the 6.55 residue of the β2-adrenergic receptor provided 
evidence for receptor interaction at asparagine 6.55 with the β-OH of some β2 ligands 
(Wieland et al., 1996). In addition, using SCAM methods Javitch found H6.55 of D2L 
receptor water-accessible (Javitch et al., 1998). These experiments will seek to determine the 
importance of H6.55 in the interaction of ligands with the D2L receptor. 
Aim 4: Determine the role of the Na+/pH sensitive aspartate 2.50 in the allosteric 
modulation and subsequent activation of the hD2L receptor by functionally 
selective ligands. 
This aim will focus on D2.50, a known Na+/pH sensitive amino acid whose location 
is not within the active (orthosteric) binding site, yet is the most conserved residue of TM II 
(Neve et al., 1991; Neve, 1991). Previous studies have shown, however, that when mutated 
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to alanine or asparagine, this site allosterically regulates receptor activation and coupling to 
specific downstream effector pathways. Thus, this aim will focus on elucidating the role this 
residue plays in modulating ligand-induced receptor activation with our functionally 
selective test compounds. 
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CHAPTER 2. (R)-PROPYLNORAPOMORPHINE IS CONVERTED FROM A TYPICAL TO 
FUNCTIONALLY SELECTIVE LIGAND BY MUTATION OF THE DOPAMINE D2L 
RECEPTOR. 
To be submitted for publication in:  
Journal of Biological Chemistry 
PREFACE 
My first studies of functional selectivity with the dopamine D2L receptor were founded on 
hypotheses that were generated from an existing body of data concerning the classic dopamine 
agonist enantiomeric ligands (R)- and (S)-norpropylapomorphine. These data suggested that 
these semi-rigid agonists might be particularly interesting probe ligands. The experiments in this 
chapter used these two enantiomers to probe specific ligand-receptor interactions occurring with 
TM5 serines, residues known to be critical for binding and activation of catecholamine receptors. 
The goals were to determine if these specific residues influence the signaling properties of these 
ligands, and to test the hypothesis that selected receptor mutations could change the signaling 
profile of a compound, converting from a typical agonist to a functionally selective ligand (or 
vice versa).  
ABSTRACT 
The functional selectivity hypothesis states that ligands can cause differential activation 
of signaling pathways mediated by the same receptor. A corollary is that mutations to the 
receptor can convert “typical” agonists into functionally selective ligands. These hypotheses 
were tested with the dopamine D2L receptor, and two relatively conformationally restrained 
ligands (the enantiomers of propylnorapomorphine, RNPA and SNPA),. The ligands were 
docked to the hD2L receptor, and resulting hypotheses tested by binding and functional analyses 
of the point-mutated receptors. Binding studies indicate that the para(10)-OH of RNPA H-bonds 
with S5.46(197), whereas the m-OH H-bonds with S5.42(193). Conversely, the docking pose of 
SNPA is altered by 180º such that H-bonding of the p-OH and m-OH occur only with serine 
5.42(193). Functional analyses were done for GTPγS binding, adenylate cyclase inhibition (AC), 
MAPK phosphorylation (MAPK), and AA-release (AA). Relative to quinpirole, RNPA was a 
full agonist at all functions at the wildtype (WT) receptor. The S5.42A mutation decreased 
GTPγS binding for RNPA, yet RNPA still stimulated AC, MAPK, and AA fully. RNPA fully 
inhibited AC with S5.46A, whereas SNPA did not inhibit AC or AA with S5.46A, yet had 
MAPK activity similar to WT. Conversely, the S5.43A mutation decreased the affinity of all test 
ligands, yet had minimal effects or actually increased potency vs. AC or MAPK, yet dramatically 
affected AA signalng. These examples of the data provide direct evidence for the hypothesis that 
functional selectivity can be induced by changes to specific residues of the receptor.  
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INTRODUCTION 
The dopamine receptors belong to a family of transmembrane receptors known as G 
protein-coupled receptors (GPCRs). Five genes produce variants of dopamine receptors grouped 
as D1-like (D1/D5) and D2-like (D2/D3/D4). A splice variant of D2 (additional 29 amino acids of 
the third intracellular loop) yields two major expressed isoforms: D2L and D2S (see Missale et al., 
1998 for example). The D1 class generally couples to stimulatory G proteins that activate 
adenylate cyclase, whereas the D2 class couples to inhibitory G proteins that often inhibit 
adenylate cyclase activity.  
Ligand interactions with TM3 and TM5 are known to be important in binding and 
signaling for catecholamine GPCRs (Shi and Javitch, 2002) Strader first showed a role for the 
TM5 serines of the β2-adrenergic receptor (Strader et al., 1989), and later work suggested these 
serines were also critical for D2 signaling (Mansour et al., 1992; Cox et al., 1992; Woodward et 
al., 1996; Wiens et al., 1998). Both S5.42A and S5.46A mutations of the rat D2S decrease the 
potency of dopamine for inhibiting adenylate cyclase, whereas S5.43A abolished all functional 
responses (Cox et al., 1992). Binding data with the human hD2L suggested a critical role for 
S5.46 with several compounds including dopamine and (R)-propylnorapomorphine (vide infra), 
two of the ligands to be explored in this Chapter (Mansour et al., 1992). Wiens et al. (1998) later 
studied coupling of the rat D2S receptor to second messenger pathways after TM 5 serine 
mutations. They found that the S5.43A mutation caused dopamine to lose efficacy at both 
adenylate cyclase and GIRK channels, whereas quinpirole was unaffected. The functionally 
selective D2 ligand dihydrexidine (Mottola et al., 2002; Kilts et al., 2002), had decreased high 
affinity binding and concomitant loss of function with S5.42A and S5.43A. Such data can be 
interpreted to suggest that unique features by which any ligand interacts with its target receptor 
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(WT or mutant) can result in differential functional effects, a hypothesis that underlies this 
dissertation. 
This chapter focuses on the R(-)- and S(+)- enantiomers of propylnorapomorphine (NPA; 
Neumeyer et al., 1983; Neumeyer et al., 1988; Neumeyer et al., 1991), hereafter called RNPA 
and SNPA. RNPA is described as a high affinity agonist at the dopamine D2 receptor. RNPA has 
classical dopamine agonist pharmacological actions in vivo, both behaviorally [e.g., causes 
strong stereotyped sniffing, licking, and gnawing (Campbell et al., 1986)] and physiologically 
[e.g., inhibits cell firing in the substantia nigra and ventral tegmental area (Cox et al., 1988)], and 
also has expected characteristics in vitro [i.e., fully inhibits cAMP accumulation (Kula et al., 
1985)]. Conversely, SNPA, although also described as a high affinity D2 ligand (Neumeyer et al., 
1991), has a completely different profile than RNPA in vivo [e.g., selectively inhibits locomotor 
activity, and does not induce stereotypy or catalepsy (Campbell et al., 1986)] and in vitro [e.g., 
does not inhibit cAMP accumulation (Kula et al., 1985) but does inhibit cell firing in the SN and 
VTA similar to RNPA) (Cox et al., 1988)]. Later, Kilts et al. (2002) demonstrated that SNPA 
was functionally selective in vitro in MN9D cells, possibly providing a mechanism for the 
anomalous pharmacological actions of this compound.  
Further studies have been conducted with these compounds in heterologous expression 
systems. In Chinese hamster ovary (CHO) cells expressing the human D2L receptor, RNPA had 
agonist activity at both adenylate cyclase and in stimulating p44/p42 MAP kinase 
phosphorylation (MAPK), yet also had antagonist activity at G protein-coupled inward rectifying 
potassium channels (GIRK; Gay et al., 2004). These studies provided additional evidence that 
SNPA was functionally selective: it had partial D2L agonist activity at MAPK, full agonist 
activity at adenylate cyclase, and antagonist activity at GIRK channels (Gay et al., 2004).  
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Not only do such data with the NPA enantiomers suggest that RNPA and SNPA have 
different patterns of functional selectivity at the D2L receptor that might explain some of their 
unusual neuropharmacology, but they lead to the hypothesis that these ligands can be of utility in 
understanding mechanisms that result in functional selectivity. Specifically, I hypothesized that 
some mutations to the D2L receptor may turn typical agonists into functionally selective ligands, 
or that such mutations may alter the functional patterns of ligands that are already functionally 
selective. The enantiomers of NPA, by nature of their behavior with the WT receptors, and 
because of their relatively conformationally restrained structures, offered the possibility of being 
excellent tools to test these hypotheses.  
This was addressed by first using computational approaches to hypothesize specific 
binding interactions between each enantiomer-receptor complex, and then an iterative process of 
modeling and experimental validation for hypothesis testing. In this study we targeted two 
hydroxyl-containing amino acids that were predicted to interact with these ligands [S5.42(193) 
and S5.46(197)], as well as an adjacent residue [S5.43(194)] whose role is less certain. Each 
residue was mutated to alanine, and then characterized for antagonist radioligand binding. Each 
probe ligand was then tested for affinity, effects on GTPγS binding, and for three receptor-
mediated functional endpoints (cAMP inhibition, MAPK phosphorylation, and [3H]-AA release). 
These data provide direct evidence for the hypothesis that functional selectivity can be induced 
by changes to specific residues of the receptor, and provide some insight into how how ligand-
specific interactions with certain residues of the receptor may induce such changes in signaling 
patterns.  
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METHODS 
Most of the Methods described below are common to Chapters 2-6 and to a study 
described in the Appendix. They are detailed below, and later Chapters only contain 
experimental details that were not referenced in the methods described below.  
Materials 
The R(-)- and S(+) isomers of propylnorapomorphine [NPA; 6-propyl-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol], isobutylmethylxanthine, dopamine, EDTA, 
dithiothreitol, sucrose, pepstatin A, leupeptin, PMSF, fetal bovine serum and other standard 
chemical reagents were purchased from Sigma Chemical Co (St Louis, MO). [3H]-N-
methylspiperone, [3H]-arachidonic acid [or [5, 6, 8, 9, 11, 12, 14, 15-3H(N)]-AA], and [35S]-
GTPγS were purchased from Amersham Biosciences Inc. (Piscataway, NJ). [125I] for cAMP 
assays was purchased from NEN/Perkin Elmer (Boston, MA). HEPES buffer was purchased 
from Research Organics (Cleveland, OH). Quinpirole and domperidone were purchased from 
Sigma/RBI (Natick, MA). Ham’s F-12, Opti-Mem, penicillin, streptomycin, primers and 
lipofectamine were purchased from Invitrogen (Carlsbad, CA). Hygromycin B was purchased 
from Roche Applied Science (Indianapolis, IN). Primary antibody to phospho-p44/p42 MAPK 
and secondary antibody, anti-rabbit HRP-conjugated, were purchased from Cell Signaling 
Technology Inc. (Beverly, MA). cAMP primary antibody was obtained from Dr. Gary Brooker 
(George Washington University, Washington DC) and secondary antibody, rabbit anti-goat IgG, 
was purchased from Advanced Magnetics (Cambridge, MA). Dihydrexidine, dinapsoline, and 
dinoxyline (used in subsequent Chapters of this dissertation were synthesized following 
published procedures (Brewster et al., 1990; Ghosh et al., 1996; Grubbs et al., 2004). 
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Molecular biology and cell culture. 
CHO hD2L wild type and mutant cells were maintained in Ham’s F-12 media 
supplemented with 10% fetal bovine serum, 100X penicillin-streptomycin, and 100 μg/mL 
Hygromycin. Mutant cell lines were constructed using the pcDNA5/FRT plasmid obtained from 
Invitrogen. Following subcloning of the hD2L receptor into the plasmid, point mutations were 
introduced using PCR techniques. Stable transfections of point mutants into CHO K1 cells were 
conducted using modifications of a previously published protocol (Milligan, 1999). Throughout 
this paper, the identification of the mutated amino acid residue will be made using universal 
notation as proposed by Ballesteros et al. (1995). The residues (listed in both universal notation 
and absolute position) studied were S5.42A (S193A), S5.43A (S194A), and S5.46A (S197A). 
Radioreceptor assays 
Membranes for radioreceptor assays were prepared by rinsing cells with phosphate-
buffered saline, and then lysing with a solution containing 2 mM HEPES, 2 mM EDTA, 1 mM 
dithiothreitol, 1 μg/mL pepstatin A, 0.5 μg/mL leupeptin, and 0.05 μg/mL PMSF. Cell fragments 
were scraped, homogenized, and centrifuged at 30,000 g for 30 min. Following centrifugation, 
cell pellets were resuspended, homogenized and placed into storage buffer (50 mM HEPES, 0.32 
M sucrose, 1 μg/mL pepstatin A, 0.5 μg/mL leupeptin, and 0.05 μg/mL PMSF) and stored at -80 
oC. Saturation binding assays were conducted using protocols described previously (Gay et al., 
2004) but with varying concentrations of [3H]-N-methyl-spiperone to determine the Bmax and KD 
for each membrane preparation (e.g. hD2L WT; hD2L S5.42A, etc.). Domperidone (10 μM) was 
used to define non-specific binding. Competition binding assays also utilized [3H]-N-
methylspiperone.  
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Molecular Modeling 
The ligand-free model of the transmembrane region of hD2L receptor was built using 
homology modeling techniques based on constraints from the known crystal structure of bovine 
rhodopsin (Palczewski et al., 2000), and from inferences drawn from experimental probing of the 
dopamine receptor. Initial structures of all selected ligands were constructed using the 
BUILDER module of InsightII. Consistent with the parameterization of version 27 of CHARMM 
force field, atomic partial charges for these ligands that carry a formal charged amine group were 
generated by fitting the molecular electrostatic potential computed with a 6-31G* basis set using 
GAUSSIAN03. The ligands then were energy-minimized, and subsequently docked manually 
inside the putative binding site of the ligand-free model of hD2L receptor. Based on available 
data for aminergic GPCRs (see Shi and Javitch, 2002 for review), the binding site was initially 
selected to have the selected ligands interact with S5.46, S5.42, and D3.32, that were 
hypothesized to be involved in ligand recognition. Specifically, the hD2L D3.32 residue served as 
an anchoring point for the protonated amine common to all selected ligands. To construct a 
model suitable for energy minimization of the ligand, the initial conformation of each 
compounds was then hand-docked in a reasonable binding mode with the protonated amine 
group directed towards D3.32, and the hydroxyl groups oriented towards S5.46 and S5.42. Next, 
each ligand was energy-minimized in this binding site using the CHARMM force field with a 2r 
distance-dependent dielectric constant. Protein backbone atoms were held fixed, whereas all side 
chain atoms were allowed to move. After minimization, all protein residues within 5 Å of each 
ligand were identified as the interacting residues in each binding site.  
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GTPγS assay 
Measurement of [35S]-GTPγS binding was determined as described previously (Shapiro 
et al., 2003), with non-specific binding defined by 10 μM cold GTPγS. Assay tubes contained 
150-200 pM [35S]-GTPγS, binding buffer (50 mM HEPES, 100 mM NaCl, 4 mM MgCl2, 1 mM 
EDTA, 0.1% BSA, 0.1% ascorbic acid, pH 7.4 with NaOH), 10 μM GDP, and varying 
concentrations of agonists and/or antagonist. Membranes (approximately 100 μg protein/mL) 
were incubated with test compounds for 15 min at 30°C before addition of [35S]-GTPγS. After an 
additional 30 min incubation, the assay was terminated by filtration (Packard Filtermate 190 
harvester) with ice cold wash buffer (50 mM HEPES, 4 mM mgCl2, pH 7.4 with KOH), and 
radioactivity quantified by liquid scintillation spectrometry (Packard TopCount NXT).  
cAMP accumulation assay 
Measurement of dopamine receptor agonist inhibition of forskolin-stimulated cAMP 
accumulation was performed in whole cell preparations as described previously (Gay et al., 
2004). In brief, CHO cells were seeded in 24-well plates at a density of 2.5 x 106 cells/well, and 
grown for 48 hr in Ham’s F-12 media supplemented with 10% fetal bovine serum and 100X 
penicillin-streptomycin. Cells were preincubated for 5 min prior in fresh media (serum-free 
media containing 25 mM HEPES, 500 μM isobutylmethylxanthine, and 0.1 % ascorbic acid) at 
37 oC. Assay medium then was aspirated, and fresh assay media containing forskolin and/or 
various concentrations of the test compounds was added. The plates were incubated for 15 min at 
37ºC, cells rinsed with fresh assay medium, aspirated, and the reaction halted using 0.1 N HCl. 
The cAMP was quantified using a modified radioimmunoassay previously described (Harper and 
Brooker, 1975).  
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MAP kinase assay 
Measurement of dopamine receptor agonist stimulation of p44/p42 MAPK was 
performed in whole cell preparations by modifying a previously published protocol (Versteeg et 
al., 2000). CHO cells were seeded in 96-well plates at a density of 5 x 106 cells/well and grown 
for 48 hr in Ham’s F-12 media supplemented with 10% fetal bovine serum at 37 oC. Cells were 
serum starved for 6 hr prior to stimulation. Appropriate drug dilutions of the test compounds 
were added to each well at a volume of 100 μL for 10 min. The reaction then was terminated, 
and the cells fixed by aspirating the wells and adding 100 μL of 4% formaldehyde PBS solution 
for 20 min. Cells were washed three times with 100 μL wash buffer (0.1% Triton X-100/PBS 
solution), followed by a 20 min incubation with 0.6% H2O2 Triton/PBS solution to quench 
endogenous peroxidases. After washing the cells three times again with wash buffer, and after a 
1 h incubation with 10% BSA in Triton/PBS solution (to block nonspecific antibody binding), 
cells were incubated overnight (about 12 hr) with a 1:250 dilution of PhosphoPlus® p44/42 
primary antibody in the Triton/PBS solution (100 μL) containing 5% BSA at 4°C. Cells were 
washed three times with wash buffer for five min, and incubated with 100 μl HRP-conjugated 
goat anti-rabbit secondary antibody (1:100 dilution) with 5% BSA at room temperature for 1 h. 
Again, cells were washed three times with wash buffer for five min, and then twice with PBS. 
Cells were then incubated with 50 μL of an o-phenylenediamine (OPD) solution (0.4 mg/mL 
OPD, 17.8 mg/mL Na2HPO4·7H2O, 7.3 mg/mL citric acid and 0.015% H2O2) for 15 min at room 
temperature in the dark. The reaction was terminated by the addition of 25 μL of 1 M H2SO4, 
that  causes a light–to-dark orange color change (A490 - A650) that is proportional to 
phosphorylation.  
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Arachidonic acid assay 
Measurement of dopamine receptor agonist potentiation of ATP-stimulated [3H]-
arachidonic acid (AA) release was measured in whole cell preparations using modifications of a 
previously published method (Berg et al., 1998). CHO cells were seeded in 24-well plates at a 
density of 5 x 105 cells/well and grown for 24 hr in Ham’s F-12 media supplemented with 10% 
fetal bovine serum at 37 oC. Cells are serum starved with 500 μL of serum free Ham’s F-12 
containing 0.5 μCi/mL [3H]AA for 5 hr at 37 oC. Ten-μL aliquots were removed to compare with 
the original tritiated loading media to determine the time course and total cellular uptake of [3H]-
AA. Cells were washed three-times for 5 min each with Hank’s balanced salt solution (HBSS) 
containing 0.5 % fatty acid-free BSA and antagonists for respective wells (500 μL/well/wash). 
Cells then were incubated with agonists for 15 min with or without ATP dissolved in HBSS/BSA 
(ATP being added last and in timed increments of 5 sec between wells).  
Data and Statistical Analysis 
Data from all assays were analyzed using Prism 4.0. Saturation analysis was conducted 
using a one-site binding model. Competition data used non-linear regression and a sigmoidal 
equation to determine IC50 and Emax values. The IC50s were corrected for radioligand 
concentration, and are reported as corrected affinity values (K0.5). Statistical analyses were 
conducted using SigmaStat 2.03, using algorithms specified with each experiment.  
RESULTS 
Molecular modeling predictions 
RNPA, SNPA, dopamine, and quinpirole were all docked to the hD2L receptor (see 
Figure 2.1). The proposed RNPA-hD2L receptor complex predicts the involvement of the para-
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OH (i.e., C10 on RNPA, Figure 2.1) in H-bonding with S5.46, whereas the ligand meta-OH 
(C11) interacts with S5.42.  
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Figure 2.1. Three-dimensional molecular models. 3D molecular models of ligands docked to hD2L. View is 
from the extracellular surface, looking down into the receptor. A) RNPA, B) SNPA, C) quinpirole, D) dopamine E) 
Schematic of ligand structures and predicted sites of interaction derived from modeling studies. 
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In contrast, the opposite orientation of the hydrogen on the protonated amine group of 
SNPA puts the para-OH (C10) some distance from S5.46, but leads to a predicted H-bond 
interaction with S5.42, with the meta-OH (C11) also interacting with S5.42. Docking studies 
conducted with dopamine indicate the involvement of the para-OH with S5.46, and the meta-OH 
with S5.42. The N2 nitrogen of quinpirole was predicted to donate a proton to the hydroxyl 
group of the S5.46 side chain, whereas the N1 of quinpirole was hypothesized to hydrogen bond 
with S5.42. The structures of each ligand and their predicted interaction sites are shown 
schematically in Figure 2.1A-2.1E.  
Effect of S5.42A, S5.43A, and S5.46A on antagonist radioligand binding 
The hD2L WT, S5.42A, S5.43A, and S5.46A receptors were expressed stably in CHO K1 
cells, and saturation radioreceptor assays performed. The WT receptor was expressed at 4.8 
pmol/mg protein with a KD of 0.58 nM, and the S5.42A (S193A) and S5.46A (S197A) receptors 
were expressed at a similar density and affinity (Figure 2.2 and Table 2.1). Conversely, the 
S5.43A (S194A) receptor was expressed at a much higher density (20.7 pmol/mg protein), but 
with slightly lower affinity (KD = 1.4 nM). There was no specific [3H]-N-methylspiperone 
binding in untransfected WT cells. 
Effect of S5.42A, S5.43A, and S5.46A on affinity of agonist probe ligands 
The affinity for each probe ligand was determined using competition radioreceptor assays 
versus [3H]-N-methylspiperone in membranes from both WT and mutant receptors. Because the 
slopes of many of the curves were not of normal steepness, all data (e.g., Table 2.1) are 
expressed as apparent affinity constants (K0.5) determined from experimental IC50 values that 
were corrected for radioligand concentration using the bimolecular Cheng-Prusoff relationship 
58 
(Cheng and Prusoff, 1973). Competition binding studies also were conducted with several 
structurally different antagonists [domperidone, N-methylspiperone] to rule out gross structural 
changes induced by the mutation (data not shown). As was seen with [3H]-N-methylspiperone, 
all of the antagonists had only slightly decreased affinity for each mutant receptor, and retained 
the same rank order of affinity as was found with the WT receptor. These data suggest that the 
mutations did not induce profound changes to overall receptor structure.  
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Figure 2.2. Saturation assays for stably expressing mutant and WT hD2L receptors. CHO hD2L membrane 
fragments were incubated with increasing concentrations of [3H]-N-methylspiperone for 15 min. at 37 °C. Data 
shown are representative of 3-4 independent experiments conducted in triplicate.  
Representative data for the agonist probe ligands are shown in Figure 2.3, and are 
summarized in Table 2.1. S5.43A had the largest overall effect of affinity, increasing the K0.5 by 
50-fold or more for all ligands. The S5.42A mutation caused a marked, but smaller, loss of 
affinity for all ligands, but also altered rank order of affinity [WT: RNPA >>> SNPA > 
quinpirole > dopamine; S5.42A: RNPA >>> quinpirole >> SNPA >>> dopamine]. Rank order 
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was not affected by the other mutations. The S5.46A mutation caused loss of affinity that was 
intermediate between S5.42A and S5.43A.  
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Figure 2.3. Competition binding of test compounds with hD2L WT and mutant receptors. Assays were 
conducted in triplicate and data represents 3-4 independent experiments.  
Table 2.1. Saturation and competition binding data for RNPA, SNPA, quinpirole, and 
dopamine for serine mutants.  
 
Saturation Binding 
Competition Binding  
K0.5 (nM) 
Mutant 
KD  
(nM) 
BBmax 
(pmol/mg) R(-)NPA S(+)NPA Quinpirole Dopamine 
WT 0.58 4.8 1.3 ± 0.85 129 ± 30 365 ± 66 447 ± 172
S5.42A 0.59 4.0 25 ± 3.7 2,540 ± 370 1,040 ± 100 80,000 ± 3,000
S5.43A 1.4 20.7 98 ± 37 6,400 ± 1,100 27,000 ± 10,000 31,000 ± 6,000
S5.46A 0.50 2.3 42 ± 8.5 698 ± 125 2,910 ± 820 3,500 ± 1,500
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Effect of mutations on ligand-induced GTPγS binding 
An estimate of G protein turnover was conducted using ligand-induced binding of 
[35S]-GTPγS. As shown in Figure 2.4 and summarized in Table 2.2, the S5.42A and S5.46A 
mutations caused a large decrease in potency of RNPA (EC50 of 42 and 78 nM respectively 
compared to 1.0 nM for WT) whereas S5.43A was minimally affected (EC50 = 3 nM). The 
S5.42A and S5.46A mutations caused an eight fold decrease in the potency of SNPA (EC50 = 
9400 and 8800 nM respectively vs. 1200 nM for WT), but a four-fold increase with S5.43A 
(EC50 = 312 nM). Neither the S5.42A nor the S5.43A mutations markedly affected the potency 
of quinpirole (EC50 = 1700 and 203 nM vs. 735 nM for WT), whereas S5.46A caused a notable 
decrease (EC50 of 7200 nM). Both S5.42A and S5.43A caused some decrease in dopamine 
potency (EC50 =10700 nM and 4300 nM, respectively vs. 1710 for WT), whereas S5.46A 
caused a complete loss of GTPγS binding.  
It is noteworthy that there was little correlation between the effects of these mutations on 
functional potency versus their effects on intrinsic activity. Thus, whereas S5.46A caused a 
marked decrease in RNPA affinity as well as its potency to stimulate GTPγS binding, the Emax of 
RNPA was not significantly altered. Conversely, both the S5.42A and S5.46A mutations caused 
large effects on GTPγS potency, but only the former mutation affected the Emax. A similar 
contrast was seen with quinpirole, whose potency, but not intrinsic activity, was affected 
differentially by each of the three serine mutations. These data demonstrate that whereas there 
are some correlations between the effects of these mutations on agonist binding vs. their effects 
of GTPγS binding, the exceptions are numerous and notable. If these data reflect subtle 
differences in ligand-induced conformations with each receptor, it should also be reflected in 
biochemical functions mediated by the D2L receptor.  
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Figure 2.4. GTPγS turnover experiments of test compounds with hD2L WT and mutant receptors. Analysis 
was conducted using non-linear regression and a sigmoidal equation (Prism 4.0) to determine EC50s reported in 
Table 2.2. Assays were conducted in triplicate and data represents 3-4 independent experiments. 
 
Table 2.2. Potency of probe ligands in affecting GTPγS binding.  
Mutant 
R(-)NPA 
[EC50 (nM)] 
S(+)NPA 
[EC50 (nM)] 
Quinpirole 
[EC50 (nM)] 
Dopamine 
[EC50 (nM)] 
WT 1.0 ± 1.3 1200 ± 31 740 ± 120 1700 ± 1040 
S5.42A 42 ± 14 9400 ± 3900 1700 ± 860 10700 ± 1530 
S5.43A 3 ± 1.1 312 ± 102 203 ± 5 4300 ± 1600 
S5.46A 78 ± 37 8800 ± 8900  7200 ± 1900 -- 
Values represent EC50 ± S.E.M. for 3-4 independent experiments conducted in triplicate. 
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Functional analysis of the three serine mutants  
Three functional assays were used to assess the effects of each serine mutation. Examples 
of dose-response curves for each ligand, function, and mutant receptor are shown in Figures 2-5 
through 2-7. These data from 3-5 replicate experiments (each run with triplicate points) were 
then analyzed, and the summary data described in the following sections. 
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Figure 2.5. Dose response curves for AC inhibition with ligands at S5.42A, S5.43A, and S5.46A. Data are 
representative of 3-5 independent experiments conducted in triplicate. 
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Figure 2.6. Dose response curves for MAPK stimulation with ligands at S5.42A, S5.43A, and S5.46A. Data 
are representative of 3-5 independent experiments conducted in triplicate. 
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Figure 2.7. Dose response curves for stimulation of AA-release with ligands at S5.42A, S5.43A, and 
S5.46A. Curve for DA is not shown because there was no functional activity. Data are representative of 3-5 
independent experiments conducted in triplicate. 
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Functional differences caused by S5.42A 
None of these ligands had effects on forskolin-stimulated adenylate cyclase activity in 
untransfected CHO K1 cells. With the WT receptor, quinpirole, dopamine, and RNPA all fully 
inhibited forskolin-stimulated cAMP accumulation (AC), whereas SNPA had partial agonist 
activity (Figure 2.8, and Table 2.3). The D2 antagonist domperidone (10 μM) alone had no affect 
on forskolin-stimulated cAMP accumulation with either WT or S5.42A receptor. Conversely, 
domperidone completely blocked the effects of quinpirole (1 μM) at the WT receptor, consistent 
with these effects being mediated via the D2L receptor. The S5.42A mutation caused a complete 
loss of AC intrinsic activity for all of these ligands except for QP and RNPA.  
Table 2.3. Effect of S5.42A mutation on functional potencies.  
Ligand Quinpirole 
[EC50 (nM)] 
Dopamine 
[EC50 (nM)] 
RNPA 
[EC50 (nM)] 
SNPA 
[EC50 (nM)] 
Function WT S5.42A WT S5.42A WT S5.42A WT S5.42A
AC 172 ± 5.5 7.8 ± 1.4 157 ± 22 -- 0.18 ± 1.4 0.18 ± 0.01  118 ± 18 -- 
MAPK 26 ± 5 44 ± 12  28 ± 7 -- 1.85 ± 0.9 6.4 ± 1 26 ± 19 -- 
AA-release 63 ± 12 223 ± 67 49 ± 26 -- 18 ± 1.9 1,300 ± 250 1,300 ± 253 -- 
Values represent EC50 ± S.E.M. for 3-4 independent experiments conducted in triplicate. 
In the WT receptor, quinpirole, dopamine, and RNPA all fully activated the 
phosphorylation of the p44/p42 MAP kinase (MAPK), whereas SNPA was a partial agonist 
(Figure 2.8, and Table 2.3). Similar to the results with AC, the S5.42A mutation caused complete 
loss of intrinsic activity for dopamine and a dramatic decrease for SNPA. Conversely, this 
mutation caused only a slight loss of intrinsic activity and potency for quinpirole, and somewhat 
greater effects in the intrinsic activity of RNPA.  
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A quite different pattern was seen with D2L-stimulated [3H]-arachidonic acid release 
(AA). With the WT receptor, SNPA was a near-full agonist, and the other compounds had 100% 
intrinsic activity. With the S5.42A mutant, quinpirole lost some intrinsic activity, with a slight 
decrease in potency (223 vs. 63 nM in WT). Interestingly, RNPA remained a full agonist, yet 
with dramatically lower potency (1,300 vs. 18 nM in WT). Similar to MAPK stimulation (see 
above), this data suggests that subtle changes in ligand-residue interactions can sometimes cause 
significant functional effects.  
The loss of functional potency for SNPA and dopamine were consistent with the 
importance of S5.42 predicted by the modeling. On the other hand, both quinpirole and RNPA 
retained some functional potency at this receptor, although this mutation induced functional 
selectivity expressed as reversed intrinsic activities at MAPK and AA (Berg et al., 1998).  
Functional differences caused by S5.43A  
I next examined S5.43, a residue hypothesized as critical because of formation of 
intrahelical H-bonds that stabilize TM 5. I hypothesized that mutation of S5.43A would have 
little or no effect on intrinsic activity at all functional endpoints measured with these probe 
ligands. Consistent with this, RNPA, dopamine, and quinpirole fully, and SNPA partially, 
inhibited AC in both WT and S5.43A receptors with no difference in rank order of potency 
[RNPA >> quinpirole > dopamine > SNPA]. The intrinsic activity of SNPA actually was greater 
in the S5.43A mutant than in WT despite lower potency (Figure 2.8 and Table 2.4). In terms of 
MAPK function, similar results were seen. There were two noteworthy findings (Table 2.4 and 
Figure 2.6). First, SNPA had higher intrinsic activity with the S5.43A than WT receptor. Second, 
the rank order of potency was markedly altered by this mutation (S5.43A: RNPA > quinpirole > 
dopamine > SNPA vs. WT: RNPA > SNPA = dopamine = quinpirole).  
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Measurement of a third pathway, agonist-stimulated [3H]-arachidonic acid release (AA), 
led to a much unexpected finding (Figure 2.6, Table 2.3). Although all ligands were full agonists 
for AA-release with the WT receptor, only quinpirole and SNPA exhibit full agonist activity 
similar to WT.  RNPA exhibits partial agonist activity whereas DA exhibits loss of activity. 
These results are a striking contrast to the functional effects of the same ligands in the other two 
functions we assessed.  
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Figure 2.8. Ligand effects on activation of second messenger pathways of hD2L with mutations at S5.42A, 
S5.43A, and S5.46A. Top row: Ligand-mediated inhibition of forskolin-stimulated cAMP accumulation (AC); 
Middle row: Ligand-mediated activation of p44/p42 MAP Kinase (MAPK); Bottom row: Ligand-mediated 
potentiation of [3H]-arachidonic acid release (AA). Note that agonists inhibit AC, but stimulate MAPK and AA. 
Data are representative of Emax values for 3-5 independent experiments conducted in triplicate. * p < 0.05 (One 
way ANOVA, post hoc Dunnet’s).  ** p < 0.05 (Kruskal-Wallace one way ANOVA, post hoc Dunn's). 
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Table 2.4. Effect of S5.43A mutation on functional potencies.  
Ligand Quinpirole 
[EC50 (nM)] 
Dopamine 
[EC50 (nM)] 
RNPA 
[EC50 (nM)] 
SNPA 
[EC50 (nM)] 
Function WT S5.43A WT S5.43A WT S5.43A WT S5.43A 
AC 172 ± 6 3 ± 1  157 ± 22 19 ± 3 0.18 ± 1.4 0.05 ± 0.01 118 ± 18 143 ± 7 
MAPK 26 ± 5 26 ± 11 28 ± 7 114 ± 40 1.9 ± 0.9 0.73 ± 0.12 26 ± 19 340 ± 34 
AA-release 63 ± 12 35 ± 27 49 ± 26 -- 18 ± 2 7 ± 5 1,300 ± 250 190 ± 150
Values represent EC50 ± S.E.M. for 3-4 independent experiments conducted in triplicate. 
 
Functional differences caused by S5.46A 
S5.46A is predicted to be located deepest in the binding pocket of hD2L. The S5.46A 
mutation caused a complete loss of intrinsic activity for dopamine and SNPA, without affecting 
that of RNPA or quinpirole (Figure 2.8). Interestingly, the potency of quinpirole was somewhat 
greater with S5.46A, whereas that of RNPA was somewhat lower (Table 2.3). A quite different 
pattern was seen when MAP kinase activation was studied. The intrinsic activity of quinpirole 
was unaltered by the S5.46A mutation, whereas that of dopamine was abolished, and that of 
RNPA markedly decreased. Interestingly, the intrinsic activity of SNPA was unaffected (Figure 
2.7-10 and Table 2.3). The rank order of potency was also changed (WT: RNPA > SNPA = 
quinpirole vs. S5.46A: RNPA > quinpirole > SNPA). When D2L-mediated [3H]-arachidonic acid 
release was assessed, a pattern emerged similar to that seen with AC. Neither dopamine nor 
SNPA had any intrinsic activity, and quinpirole and RNPA were essentially full agonists (see 
Figure 2.8 and Table 2.3). Both RNPA and quinpirole had significantly lower potency with the 
S5.46A receptor.  
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Table 2.5. Effect of S5.46A mutation on functional potencies.  
Ligand Quinpirole 
[EC50 (nM)] 
Dopamine 
[EC50 (nM)] 
RNPA 
[EC50 (nM)] 
SNPA 
[EC50 (nM)] 
Function WT S5.46A WT S5.46A WT S5.46A WT S5.46A
AC 172 ± 6 54 ± 11 157 ± 22 -- 0.18 ± 1.4 3.8 ± 1.6 118 ± 18 -- 
MAPK 26 ± 5 193 ± 28 28 ± 7 -- 1.9 ± 0.9 41 ± 5 26 ± 19 334 ± 39
AA-release 63 ± 12 292 ± 16 49 ± 26 -- 18 ± 2 550 ± 240 1,300 ± 250 -- 
Values represent EC50 ± S.E.M. for 3-4 independent experiments conducted in triplicate. 
DISCUSSION 
The approach that was used in this work differs in philosophy from much of the earlier 
work that studied the structural features involved in ligand-GPCR interactions. The primary 
endpoint has usually been the relationship of receptor structural features to the binding of 
ligands, although in some studies (Mansour et al., 1992; Cox et al., 1992; Wieland et al., 1996; 
Wiens et al., 1998) a single functional effect (usually inhibition of adenylate cyclase, sometimes 
in combination with GTPγS binding) also was examined. The current approach was based on the 
hypothesis that whereas mutation-induced changes in affinity and functional properties can be 
closely related, frequently they will be affected quite independently. This hypothesis leads to 
several predictions as corollaries to the main functional selectivity hypothesis (Mailman and 
Gay, 2004; Urban et al., 2006a). 
First, in a given assay there is not always a direct relationship between mutation-induced 
changes in affinity and functional potency. Second, mutation-induced effects on intrinsic activity 
(i.e., Emax) and potency are independent, and do not always occur in a parallel fashion. Third, 
some mutations may affect the functional properties of a ligand differentially, essentially causing 
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“typical agonists” to become functionally selective or even functionally selective ligands to 
become typical. Each of these hypotheses is consistent with the overall notion of functional 
selectivity, but are not easily reconciled with commonly accepted precepts of quantitative 
receptor theory (Urban et al., 2006a). The current manuscript provides some novel data that 
allows testing of these notions. Because on the complex matrix of our data (four receptors by 
five pharmacological endpoints by four ligands), we have provided in Table 2.6 a summary 
format to facilitate review of key points.  
The key interaction of S5.42 and S5.46 in ligand binding and activation was first shown 
with the β2–adrenergic receptor (Strader et al., 1989) and later with other catecholamine 
receptors including the D2L (Mansour et al., 1992; Cox et al., 1992; Woodward et al., 1996; Shi 
and Javitch, 2002). Although the role of TM5 serines has been extensively studied, almost all 
prior work has focused on binding effects and possibly a single function. The current work was 
based on this foundation, but was directed at testing the hypothesis that such mutations, above 
and beyond any effects they might have on ligand affinity, could differentially affect one or more 
of several functions normally mediated by binding of ligands to the D2L receptor. If the resulting 
data were consistent with this latter hypothesis, it would provide evidence that ligand binding 
induces ligand-specific states that are manifested as functional selectivity, as opposed to the idea 
that ligands select from a set of preexisting active states of the receptor.  
The current experiments began by using a computationally refined three-dimensional 
molecular model of the hD2L receptor to predict how the test ligands interacted with the serine 
residues that were the focus of this work. This model was based on extensive prior work that 
used both alanine and cysteine scanning mutagenesis in combination with homology based 
modeling(Javitch et al., 1995a; Javitch et al., 1995b; Shi and Javitch, 2002). As with all 
70 
aminergic GPCRs, binding of almost all ligands to the D2L receptor requires the formation of a 
salt bridge interaction between the aspartate residue of TM3 (D3.32) and the amine group of the 
ligand(Shi and Javitch, 2002). The reason for selecting the NPA enantiomers as probe ligands 
were their relatively rigid backbones, and the fact that RNPA has traditionally been 
characterized as a full agonist at D2L receptor stimulation, whereas SNPA has been characterized 
as a partial agonist (Kula et al., 1985; Campbell et al., 1986; Cox et al., 1988; Neumeyer et al., 
1991) and more recently was shown to be functionally selective (Kilts et al., 2002; Gay et al., 
2004).  
The modeling data predicted that the asymmetric center of the NPA backbone (Figure 
2.1) would give quite different binding poses of RNPA and SNPA at the D2L receptor. The 
necessity of forming the salt bridge with D3.32 results in the p-OH (C10) of RNPA forming a 
H-bond with S5.46, whereas the p-OH of SNPA forms a H-bond with S5.42 (see Figure 2.1). 
The prototypical full agonist quinpirole and the endogenous ligand dopamine were used in this 
study as positive comparitors as neither compound exhibits functionally selective properties at 
D2L endpoints in WT. Interestingly, rather than the hydroxyl moieties found in the endogenous 
monoaminergic agonists, the nitrogens in the quinoline ring of quinpirole function in a similar 
fashion so that the binding pose of this ligand involves similar aspects of the D2L receptor. 
Binding data were consistent with the hypothesis that there is an interaction between the N2 
atom of quinpirole and S5.46, and between N1 and S5.42. For dopamine itself, the data suggests 
H-bond interaction between the p-OH and S5.46, and the m-OH with both S5.42 and S5.46. 
Prior studies using the flexible and relatively low affinity ligands dopamine and p-tyramine gave 
results consistent with this hypothesis (Cox et al., 1992).  
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Serine residue S5.43 has been hypothesized to play a significant role in binding (Cox et 
al., 1992), and consistent with this, SCAM analysis provided evidence for solvent accessibility 
of S5.43 in the binding site crevice (Javitch et al., 1995a). Conversely, the molecular model we 
used predicted that S5.43 forms intrahelical H-bonds with TM5 such that the S5.43A mutation 
could destabilize the intrahelical H-bonds of TM5 compromising the global positioning of this 
helix. The S5.43A mutation did markedly decrease the affinity of all test ligands, a result that 
superficially could be interpreted as being due to direct effects on the binding of each ligand. On 
the other hand, our predicted binding poses do not support the interaction of all ligands with 
S5.43 (i.e. quinpirole and RNPA are hypothesized to interact deep in the pocket). The 
elimination of a single intrahelical H-bond could introduce a kink in the TM5 helix, altering the 
binding interactions of test ligands with the remaining TM5 serines (S5.42 and S5.46). The 
functional studies seem more consistent with this latter hypothesis.  
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Despite the marked loss of affinity for all ligands with the S5.43A receptor, the 
effects on GTPγS binding were minmal, and in some cases (e.g., quinpirole and SNPA) the 
potency of ligands actually was higher with the mutant receptor. The data from the 
biochemical functions also show unexpected patterns. For example, despite the markedly 
lower affinity of quinpirole with S5.43A, its potency at inhibiting AC was greater. Globally, 
the S5.43A mutation caused relatively subtle changes for GTPγS binding, inhibition of AC, 
and MAPK stimulation despite the marked effects on binding. Conversely, the S5.43A 
mutation caused DA to be completely inactive at AA release, with RNPA having somewhat 
reduced intrinsic activity. This very unusual pattern of effect of the S5.43A mutation seems 
consistent with our modeling-derived hypothesis that this mutation decreased stability in 
TM5 helix, and therefore might have altered the spatial orientation of S5.42 via loss of 
intrahelical H-bonds to S5.43.  
As opposed to the results with S5.43, the current data are consistent with the prior 
hypotheses that S5.42 and S5.46 both interact directly with the probe ligands that were used 
in this study. In general, the S5.42A mutation not only caused marked loss of affinity, but 
consistent with the hypothesized role of S5.42 in interacting with these ligands, losses of 
function (decreased potency and/or decreased Emax) were also the most common effect that 
occurred (Table 2.6). Both mutations tended to cause decreases in potency and intrinsic 
activity of ligand-induced [35S]-GTPγS binding. All of the ligands but RNPA and QP were 
incapable of inhibiting forskolin-stimulated cAMP accumulation with the S5.42A receptor. 
The latter was somewhat unexpected as Cox et al. (1992) reported that in this mutant 
receptor dopamine mediated inhibition of forskolin-stimulated cAMP accumulation, albeit 
with significantly decreased potency. Because Cox et al. (1992), studied S5.42A in hD2S the 
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splice variant, and also used a different cell line (C-6 glioma), it may well be that the data are 
not irreconcilable. Interestingly, S5.42A resulted in complete loss of function for dopamine 
and SNPA, yet RNPA and quinpirole maintained signaling with all functional endpoints 
measured, though with decreased potency (both compounds) and decreased intrinsic activity 
(RNPA at MAPK only) relative to WT. These data demonstrate that this mutation caused 
both RNPA and quinpirole to become functionally selective. Essentially, mutation of S5.42 
created an artificial receptor whereby activation of some effector pathways are minimally 
affected, whereas others are abolished. Such data are difficult to reconcile with the notion of 
rigid receptor active states, but seem to support the hypothesis that each agonist induces a 
unique set of receptor conformations that can cause differential effects on downstream 
second messenger pathways.  
S5.46 has been reported to have a significant role in binding (Mansour et al., 1992; 
Cox et al., 1992; Woodward et al., 1996) and function (Cox et al., 1992) of the D2 receptor, 
and our data are consistent with this view. Similar to S5.42A, RNPA and quinpirole (but not 
SNPA or dopamine) fully inhibit forskolin-stimulated cAMP accumulation with S5.46A. 
S5.46A resulted, however, in differential effects at other D2L mediated pathways. RNPA and 
quinpirole both stimulate D2L mediated MAPK activation and [3H]-AA release, though with 
decreased potency (both compounds) and decreased intrinsic activity (RNPA at MAPK). 
Conversely, dopamine is inactive at both of these functions, whereas SNPA activates MAPK 
(significantly decreased potency) but does not stimulate D2L mediated [3H]-AA release. This 
is again evidence that some mutations can create artificial receptors in which the functional 
profile is modified differentially.  
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The pattern in our data clearly suggests that each of the signaling pathways we 
assessed was largely independent of each other, yet the approach we used did not address the 
many possible mechanisms of how differential activation occurs with the WT or mutant 
receptors. One such mechanism would be coupling of a different Gα (non Gαi/o) with βγ 
dimers that favor (or not) activation of MAPK and AA-release. Previous studies support βγ 
mediated activation of MAPK (Choi et al., 1999) through hD2L and AA-release through 5-
HT2A, bovine rod outer segments, and NPY Y1 (Jelsema and Axelrod, 1987; Selbie et al., 
1997; Kurrasch-Orbaugh et al., 2003). The CHO cells used in this work contain three 
inhibitory Gα subunits (Gerhardt and Neubig, 1991), three Gβ subunits, and ten Gγ subunits 
(unpublished results) that could contribute to the observed results. Although one major 
hypothesis is that βγ could significantly affect the differential signaling observed with 
mutants, we cannot rule out other possible scenarios. Scaffolding proteins (Smith et al., 
1999) could be affected by receptor mutants, thereby modifying G protein coupling . D2L is 
also known to form heterodimers (Lee et al., 2003a; Kearn et al., 2005; O'Dowd et al., 2005) 
and homodimers (Guo et al., 2003; Lee et al., 2003a; Lee et al., 2003b; Guo et al., 2005) 
whose relationship and function could be modified by receptor mutation. Together, this 
makes clear the impact of cellular background on ligand-induced functional changes, even 
when looking at WT receptors. 
In summary, the current data demonstrate clearly that one can change the relative 
pattern of functional activity of ligands either by modifying the receptor at residues directly 
involved in ligand binding, or at sites that affect the overall structure of the receptor. A clear 
example was the effects of the S5.43A. This mutation resulted in a receptor in which typical 
ligands (including the endogenous neurotransmitter) became functionally selective. The 
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S5.43A mutation did not affect function at AC or MAPK, but markedly altered select ligand 
actions at AA-release. These findings have several important consequences. From a 
terminology point of view, the use of the terms agonist, partial agonist, antagonist, or inverse 
agonist must clearly be recognized as operational definitions, referring to ligand action in a 
single system. Although the characteristics of a ligand may well be similar when the receptor 
is expressed in different cells or even cellular locales, the many exceptions require more 
restricted use of these terms. It seems to us that the functional effects of the ligand will be 
dependent on not only the target receptor, but also the immediate signaling environment of 
the receptor, including all directly associated molecules (G proteins, scaffolding molecules, 
other regulatory proteins, and the lipid environment). The growing list of examples of 
functional selectivity of native receptors (Urban et al., 2006a) underscore this complexity. 
The current study now demonstrates for the first time that not only can some ligands cause 
functionally selective activation, but also that receptor re-design can result in altered 
functional profiles. 
It is important to weigh these data against traditional receptor modeling in which a 
ligand causes trafficking of receptors to one of several discrete receptor states (Leff, 1995; 
Kenakin, 1995b; Kenakin, 1997; Leff et al., 1997). Models that involve finite numbers of 
discrete active states do not seem capable of accounting for the complexity of current 
observations, even when “energy landscapes” are created from these discrete states 
(Kenakin, 1997). We favor the view that these findings are a result of the fact that each 
ligand induces a unique set of conformational states of its target receptor. Testing of this 
hypothesis and understanding the involved partners are obvious future directions.  
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CHAPTER 3. FUNCTIONALLY SELECTIVE SIGNALING OF NOVEL RIGID 
LIGANDS IS MODIFIED AND INDUCED BY MUTATIONS OF TM5 SERINE 
RESIDUES OF THE D2L DOPAMINE RECEPTOR 
To be submitted for publication in:  
Molecular Pharmacology 
PREFACE 
In the previous Chapter, I demonstrated for the first time that functional 
selectivity could be induced by mutations of the D2L receptor that either directly affected 
ligand binding, or altered receptor structure. The probe ligands that were used in the 
Chapter 2 were chosen because they were well-studied prototypical D2L ligands whose 
functional properties and structural features made them of particular utility. The current 
Chapter now extends that work into a series of rigid ligands originally developed as D1 
agonists, but later found to have both D2 affinity as well as D2 functional selectivity both 
in vitro and in vivo. The structural features of these ligands suggested they would be very 
useful in testing the hypotheses that were tested in the prior Chapter. 
ABSTRACT 
We have previously shown that mutation of TM5 serine residues of the dopamine 
D2L receptor can cause typical agonists to become functionally selective. The current 
experiments focus on three rigid dopamine agonists (dihydrexidine, dinapsoline, and 
dinoxyline) that share common catecholamine pharmacophoric elements, but have 
different functional properties at the WT D2L receptor. Hypotheses were formed by 
docking of the probe and comparator (quinpirole and dopamine) ligands into the hD2L 
active site, and tested by binding and functional [adenylate cyclase inhibition (AC), 
MAPK phosphorylation (MAPK), and AA-release (AA)] analyses of point mutated 
receptors. Binding data were consistent with the following hypotheses: 1) the p-OH of 
dihydrexidine (C10) and dinapsoline (C9) interacts with S5.46; 2) the m-OH of 
dinapsoline (C8) H-bonds with both S5.42 and S5.46, whereas the m-OH of 
dihydrexidine (C11) interacts only with S5.42; 3) dinoxyline (differing from dinapsoline 
only by an ether-methylene substitution) forms H-bonds with m-OH and both S5.42 and 
S5.46, and the ether oxygen with S5.42; 4) dopamine forms H-bonds between p-OH and 
S5.46 and m-OH with both S5.42 and S5.46; and 5) quinpirole forms H-bonds between 
its N2 atom and S5.46, and between N1 and S5.42. Functionally, S5.42 and S5.46A 
mutations abolished all functional activity of dopamine, dinapsoline, and dinoxyline, but 
not quinpirole. Dihydrexidine retained MAPK function but only with S5.42A. 
Interestingly, S5.43A caused a loss of AA function with DNS, DHX, and DA, but did not 
markedly affect other functions. The induction of functional selectivity by receptor 
mutations support the hypothesis that ligand-specific conformational changes, rather than 
trafficking between active states, is the underlying mechanism of this phenomenon.  
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INTRODUCTION 
As was summarized in the previous chapter, studies with the β2-adrenergic 
receptor (Strader et al., 1989), and later with the D2 receptor (Mansour et al., 1992; Cox 
et al., 1992; Woodward et al., 1996; Wiens et al., 1998), elucidated many aspects of the 
role for TM 5 serines in interaction with ligands (Shi and Javitch, 2002), work that 
formed the basis for Chapter 2. One of the foundations of Chapter 2, as well as the 
current study, is that molecules with relatively rigid, conformationally restrained 
structures can be very useful tools in studying a complex phenomenon such as functional 
selectivity. Such rigid ligands may decrease the degrees of uncertainty that occur when 
smaller more flexible ligands are the primary probes (Cox et al., 1992). Thus, in the prior 
Chapter, I used the enantiomers of propylnorapomorphine (RNPA & SNPA) because 
these compounds have a large and relatively rigid backbone as well as pharmacological 
properties justifying their study (Neumeyer et al., 1983; Kula et al., 1985; Campbell et 
al., 1986; Neumeyer et al., 1988; Cox et al., 1988; Neumeyer et al., 1991; 2002).  
The current experiments focus on three rigid analogs, dinapsoline [(+)8,9-
dihydroxy-2,3,7,11b-tetrahydro-1H-napth[1,2,3-de]isoquinoline], dinoxyline [(+)8,9-
dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline], and dihydrexidine 
[trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine]. Dihydrex-
idine (DHX) originally was designed to be a novel D1 agonist in which the accessory 
phenyl ring of needed to give D1 affinity (Charifson et al., 1989; Mottola et al., 1996) 
was tethered to the elements of dopamine locked in the β-rotomer form (Nichols, 1983). 
This pharmacophore (Mottola et al., 1996) ultimately led to the D1 agonist, dinapsoline 
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(DNS; Ghosh et al., 1996), and subsequently dinoxyline, another high affinity D1 ligand 
(DNX; Grubbs et al., 2004).  
Although DHX was designed as a high affinity full dopamine D1 agonist, it was 
soon found also to have D2 affinity similar to the prototypical agonist quinpirole 
(Lovenberg et al., 1989; Brewster et al., 1990). More surprisingly was the unpexpected 
D2 functional profile of DHX (Mottola et al., 1992; Mottola et al., 2002). Like quinpirole, 
DHX exhibited full agonist activity at inhibition of forskolin-stimulated cAMP 
accumulation in rat striatum or various cell lines, and inhibited prolactin secretion in 
vivo. On the other hand, DHX failed to affect D2 mediated release or synthesis of 
dopamine, or firing of nigral dopamine neurons (all functions known to be modulated by 
D2 receptors), and actually had antagonistic effects on the actions of apomorphine in the 
latter assay (Mottola et al., 2002). Consistent with this, studies in isolated cells showed 
that DHX had full agonist activity at inhibition of forskolin-stimulated cAMP 
accumulation, yet little or no intrinsic activity at several other functions (e.g., K+-
stimulated dopamine release or G protein inward-rectifying potassium channels (GIRKs) 
(Kilts et al., 2002), and antagonized quinpirole and dopamine in such systems (Kilts et 
al., 2002). This was possibly the first direct experimental evidence for functional 
selectivity (Mottola et al., 1991), and certainly the first with dopamine receptors. Most 
importantly for the current work, it provided a relatively rigid molecule likely to have 
restricted numbers of docking poses that could be a useful tool for mechanistic studies of 
functional selectivity.  
Full characterization of both DNS and DNX has been conducted in heterologous 
expression systems. In Chinese hamster ovary (CHO) cells expressing hD2L receptor 
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(Gay et al., 2004), DNS had dopamine agonist activity [i.e., full inhibiting cAMP 
accumulation (AC) and fully stimulating p44/p42 MAP kinase phosphorylation 
(MAPK)], yet also had dopamine partial agonist activity [weakly stimulating G 
protein-coupled inward rectifying potassium channels [GIRK)]. These studies (Gay et al., 
2004) also provided evidence that DNX had full intrinsic activity at all three effector 
pathways (AC, MAPK, and GIRK). At a fourth functional pathway [receptor-mediated 
release of [3H]-arachidonic acid (AA)], DNS exhibited partial agonist activity, whereas 
DNX had full intrinsic activity (vide infra). These data are interesting because there are 
only subtle differences in the predicted three-dimensional structure of DNS and DNX. 
Together, these data suggest the hypothesis that ligand-specific interactions are 
responsible for the observed functionally selective activation of pathways.  
The current experiments address this hypothesis by studying the role of specific 
binding interactions that occur between the D2L receptor and DNS, DNX, and DHX. 
Computational modeling was utilized to hypothesize specific binding interactions 
between each ligand-receptor complex. We used an iterative process of modeling and 
experimental validation, with predicted residues being mutated to alanine, and binding 
studies and functional studies (cAMP inhibition, MAPK phosphorylation, and [3H]-AA 
release) used to assess each predicted ligand-residue interaction. The resulting data are 
consistent with the hypothesis that ligand-specific interactions with certain residues of 
the receptor may induce conformational changes that lead to a characteristic pattern of 
activation of one or more signaling pathways.  
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RESULTS 
Molecular modeling predictions 
DHX, DNS, DNX, dopamine, and quinpirole were all docked to the hD2L receptor 
(see Figure 3.1). The DHX-hD2L docking predicted interaction of the ligand para-OH 
(C10) with S5.46, and the ligand meta-OH (C11) with S5.42. Simlarly, the para-OH of 
DNS (C9) was predicted to H-bond with S5.46, yet its meta-OH (C8) accepts a proton 
from both S5.42 and S5.46. In contrast, with DNX we predicted that the meta-OH of 
DNX H-bonds to both S5.42 and S5.46, whereas the ether bridge of DNX H-bonds to 
S5.42. Docking studies conducted with dopamine indicate the involvement of the ligand 
para-OH with S5.46, whereas the meta-OH is involved with H-bonding to S5.42. 
Docking studies conducted with quinpirole predict that the N2 atom donates a proton to 
the hydroxyl group of the S5.46 side chain, whereas the N1 of quinpirole is hypothesized 
to hydrogen bond with S5.42. 
Effect of S5.42A, S5.43A, and S5.46A on receptor expression and antagonist 
radioligand binding 
The hD2L WT, S5.42A, S5.43A, and S5.46A receptors were expressed stably in 
CHO K1 cells, and saturation radioreceptor assays with [3H]-N-methylspiperone were 
used to characterize both receptors. As previously reported (Chapter 2), the WT receptor 
was expressed at 4.8 pmol/mg protein with a dissociation constant (KD) of 0.58 nM 
(Figure 3.2 and Table 3.1). The S5.42A (S193A) mutant receptor was expressed at 4.0 
pmol/mg protein with a KD of 0.59 nM. The S5.43A (S194A) mutant receptor was 
expressed at a much higher density (20.7 pmol/mg protein), but with a somewhat 
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decreased affinity (KD = 1.4 nM). The S5.46A (S197A) mutant receptor was expressed at 
2.3 pmol/mg protein with a KD of 0.5 nM.  
 
Figure 3.1. Three-dimensional molecular models. 3D molecular models of ligands docked to hD2L. 
View is from the extracellular surface, looking down into the receptor. A) DNS, B) DNX, C) DHX, D) 
quinpirole, E) dopamine, F) agonist structures 
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Figure 3.2. Saturation binding for stably expressing mutant and WT hD2L receptors. CHO hD2L 
membrane fragments were incubated with increasing concentrations of [3H]-N-methylspiperone for 15 
min. at 37 °C. Data shown is representative of 3-4 independent experiments conducted in triplicate.  
Effect of S5.42A, S5.43A, and S5.46A on affinity of agonist probe ligands 
The affinity for each probe ligand was determined using competition 
radioreceptor assays versus [3H]-N-methylspiperone in membranes from both WT and 
mutant receptors. An apparent affinity constant, K0.5 (Table 3.1) was determined from 
experimental IC50 values corrected for radioligand KD and concentration using the 
bimolecular Cheng-Prusoff relationship (Cheng and Prusoff, 1973). Competition binding 
studies also were conducted with several structurally different antagonists to rule out 
gross structural changes induced by the receptor. Although all of the antagonists had 
slightly decreased affinity (as found for N-methylspiperone), their rank order and relative 
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affinity was unchanged, suggesting that no major changes to overall receptor structure 
were induced by these mutations.  
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Figure 3.3. Competition binding of test compounds with hD2L WT and mutant receptors. Membrane 
fragments were incubated with [3H]-N-methylspiperone at KD for 15 min. with varying concentrations of 
test compounds. Analysis was conducted using non-linear regression and a sigmoidal equation to 
determine IC50s, reported as corrected affinity values (K0.5) using Prism 4.0. Assays were conducted in 
triplicate and data represents 3-4 independent experiments.    
Representative data for each agonist probe ligand at each receptor are shown in 
Figure 3.3 and summarized in Table 3.1. The differential effects that these mutations had 
on the rigid probe ligands are striking. For example, the S5.42A and S5.46A mutations 
caused a much greater loss of affinity to DNX than to the structurally similar DNS. These 
differential changes can be seen by comparing the rank orders of affinity: WT: DNX > 
DNS > quinpirole = dopamine = DHX; S5.42A: DNS > quinpirole >> DNX >> DHX 
>>> dopamine; S5.43A: DNS = DNX > DHX >> quinpirole = dopamine; and S5.46A: 
DNS > DNX > DHX >> quinpirole = dopamine.  
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Table 3.1. Saturation and competition binding data for rigid analogs at serine 
mutants. 
 Mutant WT S5.42A S5.43A S5.46A 
Saturation Binding     
KD (nM) 0.58 0.59 1.4 0.5 
BBmax (pmol/mg) 4.8 4 20.7 2.3 
Competition Binding     
DNS 144 ± 17 660 ± 190 750 ± 370 330 ± 160 
DNX 83 ± 5 2,700± 990  770 ± 90 580 ± 340 
DHX 490 ± 91 7,400 ± 1000 2,600 ± 50 1600 ± 40 
quinpirole 365 ± 66 1,040 ± 100 27,000 ± 10,000 2,900 ± 820 
dopamine 450 ± 170 80,000 ± 3,000 31,000 ± 6,000 3,500 ± 1,500 
 
Effect of mutations on ligand-induced GTPγS binding 
An estimate of G protein turnover was conducted using non-hydrolyzable 
[35S]-GTPγS (see Figure 3.4 and Table 3.2). The S5.42A mutant decreased DHX potency 
three-fold (EC50 = 1,300 nM) and intrinsic activity, whereas S5.46A decreased potency 
eighteen-fold (EC50 = 6,600 nM) relative to WT (EC50 = 373 nM). Conversely, S5.43A 
increased potency for DHX four-fold (EC50 = 92 nM). Both S5.42A and S5.46A 
abolished DNS stimulated [35S]-GTPγS, but S5.43A (EC50 = 135 nM) exhibited intrinsic 
activity greater than WT (EC50 = 286 nM). S5.46A decreased intrinsic activity for DNX 
(EC50 = 660 nM) compared to WT (550 ± 31 nM), whereas activity was lost with 
S5.42A. Conversely, S5.43A exhibited an eight-fold increased potency for DNX (EC50 = 
69 nM) with intrinsic activity similar to WT. S5.42A and S5.43A minimally affected 
quinpirole (EC50 = 1,700 nM and 203 nM), whereas S5.46A caused decreased potency 
87 
(EC50 = 7,200 nM) compared to WT (EC50 = 735 nM). Dopamine had six- and three-
fold decreased potency for S5.42A and S5.43A (EC50 = 10,700 nM and 4,300 nM 
respectively) versus WT (EC50 = 1,700 nM), whereas activity was nil at S5.46A. These 
data suggest that specific ligand-residue interactions necessary for binding are not 
necessarily critical for G protein coupling (e.g. dopamine at S5.43A). A lack of 
correlation between binding and G protein coupling leads to the hypothesis that 
activation of downstream second messengers with receptor mutants would also be 
affected differentially.  
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Figure 3.4. GTPγS turnover experiments of test compounds with hD2L WT and mutant receptors. 
Membrane fragments were incubated for 15 min. with varying concentrations of test compounds until 
reaching equilibrium. 0.2 nM [35S]-GTPγS was then added for 30 min. and stimulation was measured. 
Analysis was conducted using non-linear regression and a sigmoidal equation (Prism 4.0) to determine 
EC50s reported below in Table 2-2. Assays were conducted in triplicate and data represents 3-4 
independent experiments. 
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Table 3.2. Potency of probe ligands in affecting GTPγS binding.  
Mutant 
DNS DNX 
(nM) 
DHX 
(nM) 
Quinpirole 
(nM) 
Dopamine 
(nM) (nM) 
WT 290 ± 70 550 ± 30  370 ± 180  740 ± 120 1,700 ± 1,040 
S5.42A -- 1,300 ± 410 00 ± 860 10,700 ± 1,500 -- 1,7
S5.43A 135 ± 25 69 ± 17 92 ± 28 203 ± 5 4,300 ± 1600 
S5.46A -- 660 ± 250 6,600 ± 6200 7,200 ± 1900 -- 
Values repre  ± S.E.M. for 3-4 independent experim  conducted in triplicate.  
Functional differences caused by S5.42A 
The hD ptor couples to Gαi/o subunits intracellularly, inhibiting the 
adenylate cyclase (AC) mediated conversion of ATP to cAMP. Measurement of agonist 
inhibition of forskolin-stimulated cAMP accumulation in a whole cell assay system for 
the WT and S5.42A receptors was conducted (see Figure 3.5-3.8, and Table 3.3). In the 
WT pamine) 
robu accumulation. Conversely, inhibition of 
cAMP 
sent EC50 ents
2L rece
 receptor, all dopamine agonists (DNS, DNX, DHX, quinpirole, and do
stly inhibited forskolin-stimulated cAMP 
accumulation with S5.42A mutant was abolished with all ligands tested except 
QP. The D2 antagonist domperidone (10 μM) was tested against WT and all receptor 
mutants. Loss of function was exhibited at all endpoints tested. Domperidone also 
blocked quinpirole activation of all effector endpoints with WT and mutant receptors. All 
of these compounds were tested in non-transfected (CHO K1) cells and were devoid of 
activity. Together, these data suggest that S5.42A is critical for ligand-receptor mediated 
conformational changes associated with inhibitory actions of the D2L receptor at AC.  
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Measurement of a second pathway, agonist stimulation and subsequent 
phosphorylation of the p44/p42 MAP kinase, then was conducted in a whole cell assay 
system for the WT and S5.42A receptors (see Figures 3.5-3.8, and Table 3.3). In the WT 
receptor, all dopamine agonists (DNS, DNX, DHX, quinpirole, and dopamine) fully 
activated MAPK. S5.42A only minimally affected the actions of quinpirole (EC50 = 44 
nM) co
42A receptor (see Table 3.3). The MAPK and AA 
functio
Functional differences caused by S5.43A 
role, and dopamine) fully inhibited cAMP 
accumulation (AC). We hypothesized that mutation of S5.43A would exhibit minimal 
affect on intrinsic activity at all endpoints measured with our test ligands. In support of 
mpared to WT (EC50 = 23 nM). Conversely, the S5.42A mutation had greater 
effects on DHX (EC50 = 69 nM in mutant versus 213 nM in WT), and caused complete 
loss of function with all other ligands.  
Measurement of a third pathway, agonist stimulated [3H]-arachidonic acid release, 
was conducted in a whole cell assay system for WT and S5.42A (see Figure 3.5-3.8, and 
Table 3.3). The potency of quinpirole was decreased by the S5.42A mutation (EC50 = 
223 nM vs 63 nM in WT), but intrinsic activity was unaffected. Conversely, all of the 
other ligands were inactive with the S5.
nal data provide strong evidence that functional effects caused by the S5.42A 
mutation are ligand dependent, and do not represent a generalized crippling of the 
receptor. 
The hypothesis that S5.43A is critical for forming intrahelical H-bonds that 
stabilize the TM5 alpha helix was tested using a functional profiling as detailed above. 
(see Figure 3.5-3.8, and Table 3.3). As previously reported for WT receptor (Chapter 2), 
all of these ligands (DNS, DNX, DHX, quinpi
90 
that hibition versus WT, although changes in 
rank or
ligands
Functional differences caused by S5.46A 
The last residue to be studied in these experiments was S5.46 (see Figures 3.6-
3.8, and Table 3.3). The third serine of the critical catecholamine TM5 residues is located 
deepest in the binding pocket of hD2L. With the WT receptor, all dopamine agonists 
(DNS, DNX, DHX, quinpirole, and dopamine) robustly inhibited forskolin-stimulated 
cAMP accumulation. Conversely, with S5.46A, whereas the actions of quinpirole were 
unaffected at AC, none of the other ligands had activity. In a similar fashion, at both 
MAPK the activity of DNS, DNX, DHX, and dopamine were absent with the S5.46A 
 hypothesis, S5.43A had no affect on AC in
der of potency were observed [WT: DNX > quinpirole > dopamine > DHX > 
DNS; S5.43A: quinpirole > dopamine > DNS > DNX > DHX (see Table 3.3 for EC50s)].  
The MAPK data are shown in Figures 3.5-3.8, and Table 3.3). All of the test 
ligands (DNS, DNX, DHX, quinpirole, and dopamine) fully activated MAPK in both WT 
and the S5.43A mutant, although changes in rank order of potency were observed [WT: 
dopamine = quinpirole = DNX > DNS > DHX vs. S5.43: quinpirole > dopamine > DNS 
> DHX > DNX (see Table 3.3 for EC50s)]. The S5.43A mutation had dramatic effects on 
agonist stimulated [3H]-arachidonic acid release (see Figures 3.5-3.8, and Table 3.3). 
With the mutant receptor, QP and DNX were minimally affected, but activity of the other 
 was lost. Of note, the structurally similar ligands DNS and DNX were affected 
oppositely with S5.43A.  These data indicate that the effects of the S5.43 mutation were 
seen primarily on one function (AA), but not on two others (AC, MAPK) at which the 
full agonist activity at the WT receptor was maintained.  
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mut odest loss of 
potency
ant. Conversely, quinpirole maintained its intrinsic activity, but had m
 (5-8-fold) at both functions. 
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Figure 3.5. Ligand effects on second messenger pathways of hD2L with mutations at S5.42A, 
S5.43A, and S5.46A. Top row: Ligand-mediated inhibition of forskolin-stimulated cAMP accumulation 
(AC); Middle row: Ligand-mediated activation of p44/p42 MAP Kinase (MAPK); Bottom row: Ligand-
mediated potentiation of [3H]-arachidonic acid release. Note that agonists inhibit AC, but stimulate MAPK 
and AA release Data are representative of Emax values for 3-5 independent experiments conducted in 
triplicate.  * p < 0.05 (One way ANOVA, post hoc Dunnet’s).  ** p < 0.05 (Kruskal-Wallace one way 
ANOVA, post hoc Dunn's)..  
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Figure 3.6. Dose response activation of cAMP with ligands at S5.42A, S5.43A, and S5.46A. Agonist 
mediated inhibition of forskolin-stimulated cAMP accumulation. Data are representative of 3-5 
independent experiments conducted in triplicate. 
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Figure 3.7. Dose response activation of MAPK with ligands at S5.42A, S5.43A, and S5.46A. 
Agonist mediated phosphorylation of p44/p42 MAPK. Data are representative of 3-5 independent 
experiments conducted in triplicate. 
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Figure 3.8. Dose response activation of AA-release with ligands at S5.42A, S5.43A, and S5.46A. 
Agonist mediated potentiation of [3H]AA-release. Data are representative of 3-5 independent experiments 
conducted in triplicate. 
)
DISCUSSION 
Functional selectivity is defined as the ability of a ligand to activate diffe
individual receptor pathways linked to a single receptor isoform. Evidence to support this 
concept has surfaced not only in the GPCR field (Kenakin, 1995a; Kenakin, 1995b; Berg 
et al., 1998; Whistler et al., 1999; Watson et al., 2000; Mottola et al., 2002; Kilts et al., 
2002; Gazi et al., 2003; Shapiro et al., 2003; Gay et al., 2004; Mukhopadhyay and 
Howlett, 2005; McLaughlin et al., 2005), but also with nuclear receptors such as the 
estrogen receptors (Dutertre and Smith, 2000). In the prior Chapter, I began to explore 
how three TM3 serine residues of the D2L receptor affected the functional profile of 
norpropylapomorphine enantiomers. The current study builds upon this work by studying 
three rigid dopamine agonists, DNS, DNX, and DHX, two of which were shown 
previously to be functionally selective at the hD2L in vitro, or the rat D2 receptor 
Computational models led to the hypothesis of distinct, but similar binding poses 
for these rigid agonists, that were first tested by examining the binding of these ligands. 
rentially, 
in situ.  
each ligand with a TM3 aspartate (D3.32) (Shi and Javitch, 2002). Both DNS and DNX 
form
docking poses that result in receptor activation, possibly explaining the greater D2L 
As has been shown for many ligands, there is an ionic interaction between an amine of 
were hypothesized to form H-bonds to S5.42 and S5.46. Specifically, the p-OH of DNS 
s H-bonds with S5.46 and the m-OH of DNS forms H-bonds with both serines S5.42 
and S5.46. The methylene-ether change that converts DNS to DNX introduces an 
additional H-bonding partner to the ligand. The m-OH of DNX is hypothesized to be 
centrally located between the serines, forming H-bonds with S5.42 and S5.46. The ether 
of DNX forms an H-bond with S5.42. This may provide opportunity for slightly different 
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intrinsic activity for GIRK channels previously reported for DNX vs. DNS (Gay et al., 
2004). 
2L
 
provide
The effects of each mutation were consistent with these predictions. The next step 
was to assess the functional actions of these ligands at the mutant receptors. Table 3.6 has 
been constructed to provide a summary format of the complex matrix of these data (four 
receptors by five pharmacological endpoints by five ligands). 
We examined [35S]-GTPγS binding as a functional surrogate, although it is clear 
that GTPγS binding does not mirror actual functional events. Like previous studies 
conducted with WT hD  (Gay et al., 2004), DNS and DHX had partial intrinsic activity 
for stimulating [35S]-GTPγS binding, and were less efficacious than DNX, dopamine, or 
quinpirole. Our data suggest a critical role for S5.42 and S5.46 with DNS activation of 
[35S]-GTPγS, whereas only S5.42A was critical for DNX. This is consistent with the 
hypothesis that the ether of DNX creates an additional H-bonding partner that can
 an alternate interaction with the S5.46A mutant. On the other hand, DHX still 
had intrinsic activity with both S5.42A and S5.46A mutants. Although the affinity for 
quinpirole was affected slightly by both S5.42 and S5.43, it retained full intrinsic activity 
at stimulating GTPγS binding.  
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S5.42 and S5.46 were shown to be critical for ligand-mediated activation of the 
β2-adrenergic receptors (Strader et al., 1989) and later with catecholamine receptors 
including the D2 (Mansour et al., 1992; Cox et al., 1992; Woodward et al., 1996; Shi and 
Javitch, 2002). Although the importance of S5.42 and S5.46 for binding or activation by 
dopamine had been well-established, it was notable that these rigid ligands, like dopamine, 
generally required both S5.42 and S5.46 to retain functional activity, consistent with the 
predicted docking poses. With either of these mutants, DHX was a partial agonist at MAPK, 
but was inactive at all other functions. DNS and DNX had no activity at any functions with 
either S5.42 or S5.43 (except DNX at AA-release).  
This is in contrast to prior data (Chapter 2) where RNPA and SNPA were shown to 
be differentially affected by these same mutations, but to retain some activity with each. It is 
interesting to speculate on whether the N-propyl substituent of the NPA enantiomers was a 
key factor in the retention of some functional activity. An interesting future experiment 
would be to compare the effects of the S5.42A and S5.46A mutations on DHX vs. N-n-
propylDHX. The latter compound has slightly higher D2L affinity, but like DHX, has been 
shown to be functionally selective with the WT receptor (Kilts et al., 2002). It is noteworthy 
that N-propylDHX also has behavioral properties (Smith et al., 1997) not consonant with 
those expected from a compound that looks like a typical D2 agonist in many assays (e.g., vs. 
AC or inhibitng prolactin secretion).  
Another interesting result was that the functional profile of quinpirole at the S5.46A 
mutant was essentially identical to the WT receptor. Conversely, S5.42A mutation turned 
quinpirole into a functionally selective ligand. Although its intrinsic activity at GTPγS was 
not affected, quinpirole exhibited nearly full intrinsic activity at AC and MAPK, and was a 
good p
 affinities of all ligands, yet except for 
dopami
ns studied had modest to large effects on binding, such 
change
artial agonist at AA. Again, I believe that such data are difficult to reconcile with 
models that are based on a few discrete receptor active states.  
Prior data had suggested that S5.43 was accessible to the binding site crevice (Javitch 
et al., 1995a), and was directly involved in binding of flexible ligands dopamine and p-
tyramine (Cox et al., 1992). Conversely, the current experiments were based on an 
alternative hypothesis that S5.43 is involved in intrahelical H-bonding and not directly with 
ligands. The current data, like those from Chapter 2, supported this latter hypothesis. 
Consistent with an alteration in receptor structure as opposed to a specific effect on ligand 
interactions, the S5.43A mutation decreased binding
ne, actually increased potency for stimulation of GTPγS binding.  The S5.43A 
mutation had no affect on ligand intrinsic activity for AC or MAPK with any ligand tested, 
yet AA-release was lost for DNS, DA, and DHX but not QP, RNPA, SNPA, and DNX. Thus, 
the S5.43A mutation has created a receptor in which several of the ligands have dramatic 
functional selectivity (i.e., full activity at AC and MAPK, but none or minimal at AA). One 
might dismiss this result as being due to a structure-induced failure of the S5.43A receptor to 
couple to the appropriate G proteins. This competing hypothesis is unlikely, however, as we 
have previously shown (Chapter 2) that RNPA has good intrinsic activity at all functions 
with this receptor.  
In summary, the serine mutatio
s (e.g., in rank order or absolute affinity) being predictable in large measure by 
existing molecular models. Antagonists were essentially unaffected because the binding is 
not dependent on specific types of interaction with these serine residues as agonists. 
Conversely, the mutations caused patterns of effects on the functional activity of the probe 
100 
ligands that was not directly predictable from the binding. There are two competing 
hypotheses that might explain functional selectivity. The first is that ligands can cause 
recepto
d ligands that are available and were used in the current studies, coupled 
with ot
rs to traffic between groups of discrete active states that are linked to specific 
signaling pathways. The alternative that I favor is that each ligand that binds to a receptor 
induces a discrete range of conformational changes that affect in a graded fashion whether 
specific signaling pathways are activated. These two hypotheses differ not only in 
mechanism, but also in the predicted sequelae. If the former hypothesis is to be meaningful, 
the number of active states must have a small and finite limit, otherwise it approaches the 
latter hypothesis. It seems to us that the pattern of functional changes induced by the current 
mutations cannot be reconciled easily with such a limitation, and that more complex 
dynamical models are in play.  
In the ideal, these experiments would have been performed in reconstituted systems 
that contain only limited components (e.g., receptor, G proteins, and transducing enzyme) in 
an appropriate matrix. Unfortunately, such reconstituted systems are rare, and often fail to 
recapitulate the functional properties of either native or even heterologous systems. 
Moreover, for the D2L receptor, such systems have not yet been developed. The current data 
may be evidence for this receptor being an excellent choice for such mechanistic studies. We 
believe that the rigi
her compounds such as used in Chapter 2, will be particularly powerful probes if 
reductionist systems can be developed that retain native properties. It is intriguing to think, 
for example, whether one could detect conformation changes (e.g., Swaminath et al., 2004; 
Swaminath et al., 2005) in the WT receptor for ligands with clear difference in functional 
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profile (like quinpirole vs. dinapsoline). Morever, the effects of specific mutations (such as 
S5.43A) on such systems is equally intriguing.   
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CHAPTER 4. ANALYSIS OF THE ROLE OF THREONINE 3.37 IN MODULATING 
FUNCTIONALLY SELECTIVE LIGAND SIGNALING. 
For publication in:  
Molecular Pharmacology 
PREFACE 
The studies detailed in Chapters 2 and 3 illustrated how the serine residues of TM5, 
known to be critical for interaction with catechol hydroxyls, can effect subtle conformational 
changes that can selectively turn on or off effector pathways mediated through the D2L 
receptor. This chapter focused on T3.37, an amino acid known to be water accessible, but 
whose role in ligand binding and receptor activation is not well understood.  
ABSTRACT 
Ligand interactions of T3.37 in the D2L receptor have not been thought to be 
important in ligand interactions. Molecular modeling studies, however, led to the hypothesis 
tha ds 
including DNS, DNX, RNPA, and d  also was hypothesized to interact 
with S5.46, but with H-bonding . Three other probe compounds 
(3-PPP, DHX, and SNPA) were hypothesized not to form any bonding interactions with 
T3.37A. These hypotheses were tested by site-directed m
DHX, or 3-PPP) stimulated GTPγS binding with T3.37A. Three functional endpoints 
(inhibition of cAMP synthesis, activation of MAPK, and stimulation of AA-release) were 
assessed. At all functional endpoints tested, quinpirole and RNPA had full intrinsic activity 
with the T3.37A receptor relative to WT. Conversely, the other six ligands exhibited no 
measurable responses to any functional endpoint measured with T3.37A. These data support 
the critical role of this residue in the D2L receptors, and are consistent with the hypothesis 
that it affects interhelical interactions that influence conformational changes associated with 
ligand-induced activation of second messenger pathways. 
t there were distinct H-bonding interactions of T3.37 with the p-OH of several D2 ligan
opamine. Quinpirole
that is stabilized by T3.37
utation of this residue, and detailed 
binding and functional characterization. The T3.37A receptor had 3-10 fold decreased 
affinity for both agonists and antagonists, with changes in the rank order of affinity of 
agonists, but not antagonists. All of the agonists tested caused partial or full activation with 
the WT receptor, whereas only quinpirole, RNPA, SNPA, and dopamine (not DNX, DNS, 
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INTRODUCTION 
accessible residue (Javitch et al., 
1995b).  
This chapter used an approach similar to that outlined in Chapters 2 and 3 to test this 
hypothesis. A set of eight probe ligands were used to examine the affinity and function of 
During the past decade, all of the TM residues of D2L receptor have been studied 
using the substituted-cysteine accessibility method (SCAM) (Javitch et al., 1994; Javitch et 
al., 1995a; Fu et al., 1996; Javitch et al., 1998; Javitch et al., 1999; Simpson et al., 1999; 
Javitch et al., 2000; Shi et al., 2001). The knowledge of which residues are water-accessible 
has allowed refinement of a molecular model of the hD2L receptor that was used for 
hypothesis generation of specific ligand-residue interaction(s) in the beginning stages of my 
dissertation project.  
The previous chapters focused on three serine residues common to all catecholamine 
receptors. Mutagenesis studies with single serine residues demonstrated that alterations to 
selected aspects of the receptor that were predicted to interact with ligands could cause 
differential effects on the function of a ligand at the signaling pathways mediated by the D2L 
receptor. These data underscore the fact that all possible ligand-residue contacts must be 
characterized if an understanding is to be gained about how subtle structural changes affect 
ligand-induced signaling. As we integrated the data discussed in Chapters 2 and 3 into the 
existing molecular model, a novel hypothesis was formulated relating to T3.37, a threonine 
residue believed to be located in the floor region of the D2L binding pocket. T3.37 was 
hypothesized to form H-bonds with several of the probe ligands, and also stabilize other 
residues (e.g., S5.46) through H-bonding. What made this hypothesis of interest was that 
prior SCAM studies suggested that T3.37 was not an 
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T3.37A and WT D2L receptors. Unlike the differential results obtained from serine studies, 
this stu
, DNS, DNX, DHX, dopamine, quinpirole, and (-)3-PPP were all 
docked
-bonding between S5.46 and T3.37. 
dy provides clear evidence to suggest a critical role for T3.37 in ligand-residue 
mediated functional responses. This study also provides support to suggest that T3.37 is 
critical for receptor stabilization mediated by TM3-TM5.  
RESULTS 
Molecular modeling 
RNPA, SNPA
 to the hD2L receptor (see Figure 4.1), providing hypotheses that relate to the relative 
roles of TM5 serines and T3.37 (see Chapters 2 and 3 for data on TM5 serines), and how 
they may affect the different functional profiles previously reported for these ligands (Gay et 
al., 2004). The modeling predicted H-bonding of the para-OH of RNPA (C10) with T3.37 
(see Figure 4.2 for schematic of these interactions). In contrast, with SNPA, the para-OH is 
distant from T3.37, leading to H-bonding only with S5.42. The proposed interaction for DNS 
suggests that its para-OH H-bonds with both T3.37 and S5.46, whereas for DNX the para-OH 
(C9) H-bonds only with T3.37. The docking of DHX and (-)3-PPP predicted no involvement 
with T3.37, whereas for dopamine the para-OH should interact with both T3.37 and S5.46. 
The hydroxyl group of (-)3-PPP should hydrogen bond to S5.42 and S5.46. Finally, docking 
studies conducted with quinpirole suggest no direct interaction with T3.37, although the N2 
atom donates a proton to the hydroxyl group of the S5.46 side chain, an interaction stabilized 
through H
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Figure 4.1. Three-dimensional molecular models. 3D molecular models of ligands docked to hD2L. View 
is from the extracellular surface, looking down into the receptor. A) RNPA, B) SNPA, C) DNS, D) DNX, E) 
DHX, F) quinpirole, G) dopamine, H) 3-PPP. 
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gure 4.3. Saturation binding assays for stably expressed T3.37A and WT hD2L receptors.
ragments were incubated with increasing concentrations of [3H]-N-methylspiperone fo
. WT assays used hot saturation, whereas the T3.37A used a cold saturation design (see Methods)
 
Fi  CHO hD2L 
membrane f r 15 min at 
37 °C . Data 
shown are representative of three independent experiments conducted in triplicate.  
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Effect of T3.37A on receptor expression and antagonist radioligand binding 
The hD2L WT receptor and T3.37A were stably expressed in CHO K1 cells, and 
saturation radioreceptor assays with [3H]-N-methylspiperone were used to characterize both 
receptors. The WT receptor was expressed at 4.8 pmol/mg protein with a dissociation 
constant (KD) of 0.58 nM (Figure 4.3). The T3.37A (T119A) mutant receptor was expressed 
at a much higher density (39.5 pmol/mg protein), but with a somewhat decreased affinity for 
the radioligand (KD = 4.8 nM).  For the T3.37A mutant, a cold saturation assay was used to 
decrease the amount of [3H]-N-methylspiperone consumed. In such a design, non-specific 
binding is also dramatically decreased.  
Effect of T3.37A on affinity of agonist probe ligands 
The affinity for each probe ligand was determined using competition radioreceptor 
assays versus [3H]-N-methylspiperone in membranes from both WT and mutant receptors. 
An apparent affinity constant, K0.5, was determined from experimental IC50 values that were 
corrected for radioligand KD and concentration using the bimolecular Cheng-Prusoff 
relationship (Cheng and Prusoff, 1973). Competition binding studies were also conducted 
with several structurally different antagonists to rule out gross structural changes induced by 
the receptor. Although all of the antagonists had slightly decreased affinity (as found for 
N-methylspiperone), their relative affinity (i.e., rank order) was unchanged, suggesting that 
no major changes to overall receptor structure were induced by this mutation. 
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Figure 4.4. Competition binding of test compounds with hD
in
g 
(
ifi
c
Analysis was conducted using non-linear regression and a sigmoidal equation to determine IC50s, reported as 
independent experiments. 
2L WT and T3.37A. Membrane fragments 
were incubated with [3H]-N-methylspiperone at KD for 15 min with varying concentrations of test compounds. 
corrected affinity values (K0.5) using Prism 4.0. Assays were conducted in triplicate and data represents 3-4 
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Table 4.1. Competition binding data for mutants with test compounds.  
WT T3.37A  
Compound nHK0.5 (nM) nH K0.5 (nM) 
R(-)NPA 0.71 ± 0.04  1.3 ± 0.9 0.74 ± 0.03 38 ± 7 
S(+)NPA 0.86 ± 0.02  129 ± 30  0.76 ± 0.04 395 ± 52 
Quinpirole 0.58 ± 0.06  365 ± 66 0.59 ± 0.04 1,180 ± 290 
Dopamine 0.60 ± 0.03  447 ± 172 0.56 ± 0.02 5,140 ± 430 
DNS 0.89 ± 0.06  144 ± 17 0.67 ± 0.03 1,150 ± 440 
DNX 0.66 ± 0.04  83 ± 5 0.57 ± 0.03 1,160 ± 170 
DHX 0.83 ± 0.06  490 ± 91 0.72 ± 0.04 825 ± 78 
(-)3-PPP 0.82 ± 0.02  422 ± 76 0.65 ± 0.02 395 ±21 
Values are m
[ S]-GTPγS (see Figure 4.5 and Table 4.2). Of the full agonists for this function in the WT 
receptor, the T3.37A mutation caused a slight loss of potency for quinpirole, a marked loss of 
potency for RNPA, but did not have significant effects on the intrinsic activity of either 
compound. Conversely, this mutation caused a dramatic decrease in both potency and the 
intrinsic activity of dopamine. Of the partial agonists, there was a complete loss of intrinsic 
activity of DHX, DNS, DNX, and (-)3-PPP, yet only a decrease in potency for SNPA.  
eans ± SEM (n=3-5) 
Effect of mutations on ligand-induced GTPγS binding 
An estimate of G protein turnover was conducted using ligand-induced binding of 
35
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2L Membrane 
Representative data for the agonist probe ligands are shown in Figure 4.4 and 
summarized in Table 4.1. The relative rank order of affinity for the WT receptor [RNPA >> 
DNX > SNPA = DNS > quinpirole > 3-PPP = dopamine = DHX] is fundamentally altered by 
[3
5
TP
γS
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 Q
P
 
Figure 4.5. GTPγS turnover experiments of test compounds with hD WT and T3.37A. 
fragments were incubated for 15 min with varying concentrations of test compounds until reaching equilibrium. 
0.2 nM [35S]-GTPγS was then added for 30 min, and stimulation was measured. Analysis was conducted using 
non-linear regression and a sigmoidal equation (Prism 4.0) to determine EC50s reported below in Table 4.2. 
Assays were conducted in triplicate and data represents 3-4 independent experiments.  
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the T3.37A m
dopami
tation had no 
0.5) on the 
arked 
increases in the K
tendency for this m
 
utation [RNPA >> 3-PPP = SNPA > DHX > DNS = DNX = quinpirole >>> 
ne]. The four ligands (quinpirole, SNPA, DHX, and 3PPP) that were predicted not to 
interact with T3.37 (Figure 4.2) were the least affected by the T3.37A. The mu
affect on 3-PPP binding, and caused only modest effects (2-3 fold increases in K
binding of quinpirole, DHX, or SNPA. On the other hand, T3.37A resulted in m
0.5 of RNPA (30-fold), DNS (8 fold), and DNX (12-fold). There also was a 
utation to increase the Hill slope of most of the ligands (e.g., see Figure 
4.4), although not for RNPA.  
Table 4.2. EC50 values for GTPγS binding experiments.. 
Compound WT T3.37A 
R(-)NPA 1.0 ± 1.3 94 ± 41 
S(+)NPA 1,200 ± 30 3,400 ± 900 
Quinpirole 740 ± 120 2,000 ± 100 
Dopamine 1,700 ± 1,000 5,700 ± 800 
DNS 286 ± 71 -- 
DNX 550 ± 31 -- 
DHX 370 ± 180 -- 
(-)3-PPP 770 ± 10 -- 
Values represent EC50 ± S.E.M. for 3-4 independent experiments   
conducted in triplicate 
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Effects of T3.37A on ligand-mediated signal transduction 
Measurement of ligand inhibition of forskolin-stimulated cAMP accumulation was 
conducted (Figures 4-6 and 4-7, and Table 4.3). With the WT receptor, quinpirole, dopamine, 
RNPA, DNS, DNX, and DHX all exhibited full intrinsic activity whereas 3-PPP and SNPA 
exhibited partial agonist activity. None of these ligands had activity in untransfected cells, 
and their activity in cells transfected with hD2L was blocked by various D2 antagonists like 
domperidone. The T3.37A mutation caused a complete loss of intrinsic activity for all tested 
ligands except RNPA and quinpirole.  
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Figure 4.6. Activa er pathways of hD2L with ligands at T3.37A. Top: Ligand-mediated 
inhibition of forskolin-stimulated cAMP accumulation, Middle: Ligand-mediated activation of p44/p42 MAP 
Kinase, Bottom: Ligand-mediated potentiation of [3H]-Arachidonic acid release. Note that agonists inhibit AC, 
but stimulate MAPK and AA release Domperidone alone had no effect on rhese systems. Data are 
representative of Emax values for 3-5 independent experiments conducted in triplicate. 
tion of second messeng
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Measurement of a second pathway, agonist stimulation of the MAPK pathway, gave 
similar results (Figures 4-6 and 4-7, and Table 4.3). In the WT receptor, quinpirole, 
dopamine, DNS, DNX, DHX, and RNPA had full intrinsic activity, whereas SNPA and 
3-PPP were partial agonists. Similar to inhibition of cAMP accumulation with T3.37A, only 
RNPA and quinpirole had intrinsic activity, although with modestly decreased potency.  
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Figure 4.7. Dose response curves of activation of second messenger pathways of hD2L with ligands at 
T3.37A. Top: Ligand-mediated inhibition of forskolin-stimulated cAMP accumulation, Middle: Ligand-
mediated activation of p44/p42 MAP Kinase, Bottom: Ligand-mediated potentiation of [3H]-Arachidonic acid 
release. Data are representative of 3-5 independent experiments conducted in triplicate.  
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A third pathway (ligand-stimulated [3H]-arachidonic acid release) also was assessed 
(Figures 4.6-4.7, and Table 4.3). Quinpirole, dopamine, DNX, DHX, and RNPA were all full 
agonists, but the classical partial agonists SNPA and 3-PPP also had full intrinsic activity. 
Conversely, DNS was only a partial agonist with the WT receptor. As above, the T3.37A 
mutation caused a loss of intrinsic activity for all ligands except RNPA and quinpirole. The 
overall changes of the T3.37A mutation on intrinsic activity across all three functional 
DISCUSSION  
agonists in the D
e of 
utant 
d here is 
discrimi
 evidence that the 
T3.37A receptor was still reasonably intact. Fi
to cause functional activation similar to that seen with the WT receptor.  
pathways are shown in Figure 4.6.  
These studies are the first to hypothesize a role for T3.37 in the binding interaction of 
2L receptor or any Class A GPCR. The overall hypothesis underlying this 
work was that T3.37 has two possible roles for how the D2L receptor interacts with som
its ligands (see Figure 4.2). The docking studies predicted that SNPA, DHX, and 3-PPP do 
not interact directly with T3.37, whereas RNPA, DNS, and DNX do. Another prediction was 
that quinpirole, although not interacting directly with T3.37, had its binding stabilized by this 
residue. This hypothesis was explored by generation of a stable non-conservative m
receptor (T3.37A), and in depth characterization of the mutant versus wild-type receptor with 
a series of rationally selected probe ligands.  
One of the difficulties in mutagenesis studies such as those performe
nating changes due to global effects from those that are affected by alterations of 
specific aspects of ligand-receptor interactions. In this regard, there is some
rst, both N-methylspiperone and domperidone 
bound T3.37A with similar affinity as WT receptor.  Finally, some of the ligands were able 
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Table 
ligands at T3.37A.  
4.3. EC50 values for activation of second messenger pathways of hD2L with 
Function AC MAPK AA 
Compound WT T3.37A WT T3.37A WT T3.37A 
Quinpirole 172 ± 6 49 ± 13 26 ± 5 152 ± 94 63 ± 12 231 ± 37 
Dopamine 157 ± 22 -- 28 ± 7 -- 49 ± 26 -- 
RNPA 0.2 ± 1.4 4.5 ± 0.3 1.9 ± 0.9 9.5 ± 0.5 18 ± 1.9 77 ± 16 
SNPA 118 ± 18 -- 26 ± 19 -- 1,300 ± 250 -- 
DNS 193 ± 63 -- 72 ± 68 -- 345 ± 177 -- 
DNX 5.6 ± 0.3 -- 27 ± 17 -- 101 ± 12 -- 
DHX 93 ± 10 -- 213 ± 105 -- 395 ± 119 -- 
3PPP 32 ± 31 -- 145 ± 99 -- 80 ± 7 -- 
Values represent EC50 ± S.E.M. for 3-4 independent experiments conducted in triplicate. 
 
DHX, DNS, and DNX were originally developed as D1 full agonists ligands 
(Brewster et al., 1990; Ghosh et al., 1996; Grubbs et al., 2004), and are known to have very 
similar pharmacophoric elements (Mottola et al., 1996). Thus, although it was not surprising 
that all three rigid compounds were hypothesized to have somewhat similar binding poses, 
the predicted differences between them (specifically that only the p-OH of DNS and DNX 
would form H-bonds with T3.37) were unexpected, at least based on their similar 
interactions with the D1 receptor (Brewster et al., 1990; Mottola et al., 1996; Ghosh et al., 
1996; Grubbs et al., 2004).   
117 
The most straightforward prediction from the receptor modeling was that the binding 
of som nds (i.e., , DNS, DNX, q ) would be more affected by the 
mutation that that of others (SNPA, DHX, and 3PPP). This was, in fact, what was found in 
our experiments. Of equal interest was the fact that the slope of the competition curves for all 
of the ligands except RNPA were significantly steeper. Since the expression level in the 
T3.37A stable cells was much h er tha , this could have been explained by a higher 
p n of T ep er co  pr at t  of 
q le, dopa  RNP urves anged gests serv ns are 
ligand-specific, and not simply  to ch recept ensity tagon  often 
have competitio f norm eas agonist curves are shallower, and this 
might suggest that the mutation was going to lead to alterations in functional profile, as was 
found (vide infra). 
GTPγS binding studies were then used to provide a rough estimate on overall G 
protein turnover. The T3.37A mutation caused a complete loss of acitivty for all of the 
ligands
 Figure 4.6, an identical pattern of intrinsic activity was seen in 
each of the three pathways examined (AC, MAPK, and AA) as was seen with GTPγS 
e liga RNPA uinpirole
igh n in WT
roportio 3.37A rec tors that w e not pre upled to G oteins. Th he shape
uinpiro mine, and A c  was unch  sug  that these ob atio
due anges in or d . Indeed, an ists
n curves o al steepness, wher
 except quinpirole, RNPA, and SNPA. These effects are consistent with the 
steepening of the competition curves discussed above. Interestingly, the potency of RNPA 
was decreased far more than its affinity (90- vs. 30-fold, respectively), whereas the potency 
and affinity of quinpirole were affected equally (2.6- vs 3.2-fold, respectively.  These results 
provide further support for the hypothesis that the effects of this mutation are ligand specific 
and not global effects on the mutant receptor. It was therefore of interest to determine if a 
simlar pattern would be seen in several functional pathways modulated by this receptor.  
As was summarized in
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binding
al., 1995). The opposite effects of the mutation on the potency of 
quinpir
ract 
favorab
. With the T3.37A mutant, there was no intrinsic activity with SNPA, DNS, DNX, 
DHX, 3-PPP, or dopamine. Conversely, T3.37A had minimal effect on the intrinsic activity 
of RNPA or quinpirole. What is interesting however, are the effects that the T3.37A mutation 
had on the potency of quinpirole and RNPA in these three functional assays. Although the 
mutation decreased the potency of quinpirole about five-fold in the MAPK and AA assays, it 
increased the potency of quinpirole in the AC assay. On the other hand, this mutation also 
caused a four-fold decrease in the potency of RNPA for MAPK and AA, yet caused more 
than a 20-fold decrease in potency in the AC assay. As noted earlier, one of the potential 
confounding features of our study was the much higher expression level of the T3.37A 
receptor vs. the WT. One could have hypothesized that the potency differences in the various 
assays are simply a result of different requirements for receptor reserve in each of these assay 
systems (Watts et 
ole vs. RNPA in the AC assay, yet with similar effects in the other assays, argue 
against these effects simply being due to differences in receptor reserve.  
Why T3.37A minimally affects the function of quinpirole and RNPA while 
abolishing that of the other tested ligands remains to be addressed. One possible explanation 
involves the necessity of stabilizing H-bonds between TM3 and TM5 residues. Our 
molecular model (Figure 4.1) with quinpirole docked into the active site hypothesizes that an 
intra-molecular H-bond exists between T3.37 and S5.46. This H-bond is an important 
interaction between two TM regions, and our data suggests that it is critical for 
ligand-residue interaction/induction of G protein activation. Quinpirole and RNPA inte
ly with both T3.37 and S5.46, and the steric bulk associated with each ligand’s 
interaction in this axis of the active site suggests that these ligands are capable of maintaining 
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stability between TMs with T3.37A. Dopamine and 3-PPP are, however, flexible and lack the 
steric bulk that might be associated with maintaining stability between TM3/TM5 with 
T3.37A. Likewise, SNPA is hypothesized to interact nearer S5.42 and thus the steric bulk of 
this ligand will be directed away from the S5.46-T3.37 intra-molecular H-bonding, thus 
SNPA is incapable of stabilizing T3.37A. DNS and DNX however, interact in the binding 
site similarly to RNPA, yet neither compound elicits functional response with T3.37A 
compared to RNPA.  
There are some clear ways to explore these issues further. The use of double 
(S5.46A/T3.37A) and reciprocal mutants (S5.46T, T3.37S, and S5.46T/T3.37S) provide an 
alternative method of studying these critical interactions, possibly deducing the exact critical 
nature of these particular ligand-residue interactions. Additionally, it is possible that RNPA 
retained functional activity because of stabilizing effects of its N-n-propyl moiety. In this 
regard, the N-n-propyl analogs of DNS, DNX, and DHX have all been reported previously 
(Knoerzer et al., 1995; Sit et al., 2002; Qandil et al., 2003; Grubbs et al., 2004), and study of 
these compounds with this mutant would provide one test of whether the N-propyl moiety, 
known to increase D2 affinity, also plays a key role in functional activation. In either case, 
these studies of the role of T3.37 provide additional evidence for the unique effects 
individual ligands may have on signaling. These data are consistent with the hypothesis that 
ligands unique conformational states that can favor turning on or off specific effector 
pathways mediated through that receptor, rather than selecting from a pool of preexisting 
active states.  
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C 5. H 6.55HAPTER   ANALYSIS OF THE ROLE OF ISTIDINE  IN MODULATING 
FUNCTIONALLY SELECTIVE LIGAND SIGNALING. 
To be submitted for publication in:  
Molecular Pharmacology 
PREFACE 
The work presented in Chapters 2-4 provided new information that helps explain the 
role of certain TM3 and TM5 hydroxyl-containing amino acid residues in the functionally 
selective ligand activation of effector pathways mediated through the hD2L receptor.  This 
chapter will focus upon a residue that does not directly interact with the agonists tested 
within this dissertation.  Instead, the H6.55 residue will be studied for the role it plays in 
affecting the global conformational changes associated with receptor activation.  Previous 
studies with several Class A GPCRs suggest the critical nature of this residue and 
neighboring TM6 residues for receptor activation.  This study will address the necessity, or 
lack thereof, of H6.55 interactions when tested with a subset of our functionally selective 
ligands, specifically looking at how differences in the rigidity of the test ligands may affect 
receptor conformations that ultimately mediate downstream signaling pathways.   
ABSTRACT 
Histidine 6.55 has been suggested to be critical for global conformational changes of 
catecholamine receptors that lead to activation of receptor signaling pathways. This study 
exa  a 
set of typical and functional rect H6.55 interaction was 
predicted.  The H6.55A mutation  the binding of either antagonists 
or the four agonist ligands (dopamine, quinpirole, dihydrexidine, RNPA) studied. 
Downs
mined how H6.55 affected binding to and activation of the dopamine hD2L receptor by
ly selective ligands for which no di
did not significantly affect
tream second messenger pathways (e.g. inhibition of cAMP synthesis, activation of 
MAPK, and potentiation of AA-release) were measured with each ligand and the mutant 
receptor. Our findings suggest that H6.55 is necessary for activation of the second messenger 
pathways linked to cAMP inhibition and AA-release, but not critical for a third pathway, 
phosphorylation of p44/p42 MAP kinase.  These data suggest that H6.55 is not only critical, 
but that ligand-specific interactions affect receptor conformational changes such that some 
receptor state populations can be activated (e.g. MAPK) while others cannot (e.g. cAMP and 
AA-release).  Further understanding of the unique nature of H6.55, and how it contributes to 
activation of only one effector endpoint when mutated, could help elucidate the mechanistic 
basis for ligand-selective activation of receptor pathways.  
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INTRODUCTION 
es (Javitch et al., 1998) support 
H6.55 accessibility in the hD2L binding pocket, the only data about direct interactions 
between H6.55 and dopamine ligands is with antagonist binding (Woodward et al., 1994).   
Recently, studies have been conducted that show that H6.55 and H6.60 is a Zn2+ 
binding site on the dopamine D2L receptor (Liu et al., 2006).  Zinc allosterically modulates 
antagonist interactions of the D2L receptor (Schetz and Sibley, 1997; Schetz et al., 1999), 
further suggesting the importance of H6.55.  There have been no subsequent studies of H6.55 
Site-directed mutagenesis has been used to characterize the specific interactions that 
occur between a ligand and receptor.  One of the difficulties in such studies is differentiating 
direct effects of the mutation(s) on ligand-receptor interactions from mutation-induced 
conformational changes that may cause global, rather, than ligand-specific changes. It has 
been known for more than a decade that a cluster of TM6 aromatic amino acid residues are 
critical for agonist-mediated activation of bovine rhodopsin and β2-adrenergic receptors 
(Nakayama and Khorana, 1991; Zhang and Weinstein, 1994; Farrens et al., 1996; Gether et 
al., 1997; Sheikh et al., 1999).  Nakayama and Khorana (1991) provided evidence to support 
a direct interaction between W6.55 and retinal of bovine rhodopsin.  The W6.55A mutant 
had a significant reduction of chromophore regeneration, suggesting the critical nature of this 
residue for receptor activation.  Studies conducted with the galanin receptor GalR1 (Gαi/o 
coupled) showed that H6.55A mutation decreased galanine binding and impaired 
agonist-mediated inhibition of cAMP accumulation (Berthold et al., 1997).  In addition, it 
has been shown that the β-OH of isoproterenol and N6.55 interact directly in the 
β2-adrenergic receptor (Wieland et al., 1996), providing further evidence for critical roles of 
6.55 residues in Class A GPCRs. Although SCAM studi
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that explore their potential role in the action of dopamine agonists.  We sought to address the 
necessi
2L
ty of this receptor residue through mutagenesis studies using a set of ligands with 
unique functional profiles. Our initial hypothesis from molecular modeling studies was that 
no direct interactions take place between our test compounds and H6.55, but that mutation of 
this residue might provide additional information to support what I have termed the energy 
landscape hypothesis of functional activation. We ascertained the effects of the H6.55A 
mutation of ligand binding and receptor function.  Further understanding of how H6.55 
contributes to activation could help elucidate the mechanistic basis for ligand-selective 
activation of receptor pathways in the D  and possibly other Class A GPCRs.   
RESULTS 
Effect of mutation on receptor expression and radioligand binding 
The hD2L WT receptor and H6.55A were stably expressed in CHO K1 cells, and 
saturation radioreceptor assays with [3H]-N-methylspiperone were used to characterize both 
receptors.  The WT receptor was expressed at 4.8 pmol/mg protein with a dissociation 
constant (KD) of 0.58 nM (Figure 5.1 and Table 2-1).  The H6.55A (H393A) mutant receptor 
was expressed at a lower density (919 fmol/mg protein) with a KD of 0.37 nM.   
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Figure 5.1.  Saturation binding assays for stably expressed mutant and WT hD
l
ot
ei
at 37 °C.  Data shown are representative of three independent experiments conducted in triplicate. 
The affinity for each probe ligand was determined using competition radioreceptor 
s [3H]-N-methylspiperone in membranes from both WT and mutant receptors.  
An C50 values that 
were c
hat no major 
changes to overall receptor structure were induced by this mutation. 
None of the four compounds tested were hypothesized to interact directly with H6.55.  
Representative data for the agonist probe ligands are shown in Figure 5.2 and summarized in 
Table 5.1. Although Table 5.1 shows no significant differences in absolute affinity, a paired 
t-test of experiments run with mutant and WT receptor on the same day indicated that the 
H6.55A mutant had significantly lower affinity for dopamine, and that RNPA had both 
higher affinity and a steeper slope.     
2L receptors.  CHO hD2L 
membrane fragments were incubated with increasing concentrations of [3H]-N-methylspiperone for 15 minutes 
Effect of H6.55A on affinity of agonist probe ligands 
assays versu
apparent affinity constant, K0.5, was determined from experimental E
orrected for radioligand KD and concentration using the bimolecular Cheng-Prusoff 
relationship (Cheng and Prusoff, 1973).  Competition binding studies also were conducted 
with several structurally different antagonists to rule out gross structural changes induced by 
the receptor.  Although all of the antagonists had slightly decreased affinity (as found for 
domperidone), their rank order and relative affinity was unchanged, suggesting t
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Figure 5.2.  Competition binding of test compounds with hD WT and H6.55A.  Membrane fragments 
Analysis was conducted using non-linear regression and a sigmoidal equation to determine IC50s, reported as 
Saturation Binding Competition Binding [K0.5 (nM)] 
g 
(%
3H]-N-methylspiperone at KD  for 15 min. with varying concentrations of test compounds.  
corrected affinity values (K0.5) using Prism 4.0. Assays were conducted in triplicate and data represents 3-4 
independent experiments.          
Table 5.1. Summary of saturation and competition binding data.  
Mutant (pmol/mg R(-)NPA quinpirole dopamine DHX KD 
Bmax 
(nM) ) 
WT 0.58 4.8 1.3 ± 0.9 365 ± 66 447 ± 172 490 ± 90 
H6.55A 0.37 0.92 0.22 ± 0.01* 443 ± 76 1440 ± 590** 490 ± 170
*p < 0.103, ** p < 0.007. 
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Effect of mutations on ligand-induced GTPγS binding 
An estimate of G protein turnover was conducted using non-hydrolyzable 
35S]-GTPγS (see Figure 5.3 and Table 5.2).  All four agonists stimulated [35S]-GTPγ
binding with similar intrinsic activity in H6.55A as in WT, with all except DHX being full 
agonists.  Conversely, H6.55A decreased potency for [35S]-GTPγS coupling with all four 
ligands tested.  Specifically, H6.55A exhibited significant decreased potency with dopami
and RNPA compared to WT.  H6.55A minimally affected quinpirole and DHX compared to 
T.  The obvious hypothesis from these data is that the potency, but not intrinsic activity of 
these ligands (especially dopamine and RNPA), will be decreased at downstream effector 
pathways in the H6.55A versus WT receptor  
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2L WT and H6.55A.  Membrane 
fragments were incubated for 15 min. with varying concentrations of test compounds until reaching 
equilibrium.  0.2 nM [35S]-GTPγS was then added for 30 min. and stimulation was measured.  Analysis was 
conducted using non-linear regression and a sigmoidal equation (Prism 4.0) to determine EC50s reported 
below in Table 2-2.  Assays were conducted in triplicate and data represents 3-4 independent experiments. 
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Figure 5.3. GTPγS turnover experiments of test compounds with hD
127 
Tab ues represent EC50 ± S.E.M. 
for 3-4 independent experiments conducted in triplicate.   
GTPγS (nM) 
le 5.2. EC50 values for GTPγS turnover experiments.  Val
Mutant R(-)NPA quinpirole dopamine DHX 
WT 1.0 ± 1.3 735 ± 120 1711 ± 1039 373 ± 184 
H6.55A 38 ± 17 1336 ± 205 6497 ± 3049 919 ± 127 
T3.37A: Activation of second messenger pathways 
The hD2L receptor couples to Gαi/o subunits resulting in inhibition of adenylate 
cyclase (AC) activity.  Measurement of agonist inhibition of FSK-stimulated cAMP 
accumulation in a whole cell assay system for WT and H6.55A was conducted (see Figure 
5.4). All four agonists robustly inhibit FSK-stimulated cAMP accumulation with WT 
 
activ
receptor.  Conversely, and in contrast to effects on [35S]-GTPγS binding, no inhibition of AC 
was seen with any ligand with H6.55A.  
Measurement of agonist stimulated [3H]-arachidonic acid release then was conducted 
in a whole cell assay system for WT and H6.55A (see Figure 5.4).  All four test compounds 
robustly stimulated [3H]-arachidonic acid with WT.  Conversely, none of these ligands 
potentiated [3H]-arachidonic acid release with H6.55A, consistent with the loss of agonist 
effects caused by H6.55A on ligand-induced inhibition of adenylate cyclase. 
Finally, assessment of a third pathway, agonist-induced stimulation of p44/p42 MAP 
kinase phosphorylation was conducted in a whole cell assay system for WT and H6.55A. 
Similar to cAMP and AA-release assays, all four agonists tested exhibited full agonist 
ity as expected when evaluated with the WT receptor (see Figures 5.4 and 5.5).  
Measurement of MAPK activation yielded quite different results to those expected from the 
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adenylate cyclase and AA-release experiments, with all four test compounds being able to 
activate MAPK with the H6.55A receptor (see Figure 5.5).  The intrinsic activity of all 
compounds was lower, with the effects being greatest for quinpirole relative to WT.  There 
were only modest effects on the potency of these ligands (see Table 5.3).  
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Figure 5.4.  Activation of second messenger pathways of hD with ligands at WT and H6.55A 
activation of p44/p42 MAP Kinase, Bottom) agonist mediated potentiation of [ H]-arachidonic acid release.  
 
2L 
receptors.  Top) agonist mediated inhibition of FSK-stimulated cAMP accumulation, Middle) agonist mediated 
3
Domperidone was without effect alone in these assays, but blocked the effects of quinpirole (data not shown). 
Data are representative of Emax values for 3-5 independent experiments conducted in triplicate. 
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Table 5.3. Potency estimates (EC50 in nM) for functional response of test ligands with 
Ligand Receptor cAMP MAPK AA-release 
WT and H6.55A hD2L. 
Quinpirole WT 172 ± 5.5 26 ± 5 63 ± 12 
 H6.55A -- 73 ± 31  -- 
Dopamine WT 157 ± 22 28 ± 7 49 ± 26 
 H6.55A -- 109 ± 25 -- 
RNPA WT 0.18 ± 1.4 1.85 ± 0.9 18 ± 1.9 
 H6.55A -- 0.43 ± 2.2  -- 
DHX WT 93 ± 10 213 ± 105 395 ± 119 
 H6.55A -- 740 ± 110 -- 
Values represent EC50 ± S.E.M. for 3-5 independent experiments conducted in triplicate 
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H6.55A.  Agonist mediated activation of p44/p42 MAP Kinase.  Data shown is representative of 3-5 
independent experiments conducted in triplicate.   
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DISCUSSION 
work examined the role This of H6.55 mediation of receptor signaling with a set of 
typical and functionally selective compounds.  Previous studies with H6.55 mutants provide 
support for agonist-receptor residue interactions with β2-adrenergic, GalR1, and bovine 
rhodopsin receptors (Nakayama and Khorana, 1991; Zhang and Weinstein, 1994; Wieland et 
al., 1996; Farrens et al., 1996; Gether et al., 1997; Berthold et al., 1997; Sheikh et al., 1999), 
but the only data with the D  receptor suggest an interaction between H6.55 and dopamine 
antagonists (Woodward et al., 1994).  Additionally, recent studies have provided evidence to 
support H6.55 and H6.60 as the zinc sensitive sites of hD  (Liu et al., 2006).  Our molecular 
modeling studies suggest that none of the eight compounds in this dissertation directly 
inte H6.55 might 
diated 
through hD
all 
2L
2L
ract with H6.55.  Together, the available information suggested that 
influence receptor conformational changes associated with second messenger signaling. 
Because of our hypothesis of ligand-specific changes in patterns of signaling, H6.55A was 
tested with two functionally selective compounds (RNPA and DHX), with the prototypical 
agonist quinpirole, and the endogenous ligand dopamine for its effects on receptor binding, 
ligand-induced coupling to GTPγS, and activation of second messenger pathways me
2L.  
This mutation did not cause marked effects on either the affinity of our test ligands or 
the ability of these ligands to stimulate GTPγS binding. Based on these results, we 
hypothesized that agonist-mediation of downstream signaling would show only sm
differences in potency or intrinsic activity with the H6.55A versus the WT receptor. Thus, it 
was quite surprising that none of the four test compounds were capable of either inhibiting 
FSK-stimulated adenylate cyclase activity or AA-release as they were with the WT receptor.  
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Equally surprising was that each of these ligands retained a reasonable level of intrinsic 
activity
2L
d affinity could be the result of the elimination of steric hindrance for RNPA 
binding
 for activation of a third second messenger pathway, MAPK, although H6.55A 
reduced the intrinsic activity of quinpirole to a greater extent than it affected RNPA, 
dopamine, or DHX.   
The lack of dramatic effects of the H6.55A mutation on the binding of either agonists 
or antagonists suggests that this residue does not play a direct role in the D  binding pocket. 
A prior mutagenesis study suggested that F6.51 interacts with dopamine through orthogonal 
pi-stacking interactions (Floresca and Schetz, 2004).  H6.55 is located one helical turn above 
F6.51 and is predicted itself to interact with F6.51 through pi-stacking.  Mutagenesis of this 
residue (H6.55A) could affect the torsional angle of the alpha carbon of F6.51 such that 
orthogonal pi-stacking with dopamine is abolished, hence causing the modest decreased in 
the affinity of dopamine.  Less likely is the possibility of a direct interaction between 
dopamine and both F6.51 and H6.55.  The basis for the slightly increased affinity and 
increased slope for RNPA with H6.55A is much less clear.  My prior work (see Chapters 2 
and 3) hypothesized interactions of RNPA and quinpirole with S5.46 and T3.37 in the floor 
of the binding site.  The fact that H6.55A has no affect on quinpirole binding whereas RNPA 
slightly increase
.  Because DHX was not so affected, an alternate possibility is that it is the presence 
of a propyl group that differentiates these compounds. It would be interesting to determine 
how N-n-propyldihydrexidine compares to RNPA and DHX itself.  
The TM6 aromatic amino acid cluster has also been shown to be critical for 
conformational changes associated with activation of several receptors (Zhang and 
Weinstein, 1994; Farrens et al., 1996; Gether et al., 1997; Sheikh et al., 1999; Floresca and 
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Schetz, 2004).  This is clearly relevant to the finding of greatest interest here, the differential 
effects of the H6.55A mutation on functional patterns. The current data collectively suggest 
that the H6.55A mutation altered the receptor in such a way that GTPγS binding and MAPK 
activation were only modestly affected, whereas agonist-induced effects on either adenylate 
cyclase
 effects on MAPK and 
AA-rel
 or AA-release were completely lost. Traditional views of ligand-mediated activation 
of receptor would posit that all second messenger pathways would be similarly affected by 
H6.55A, in stark contrast to the current results.  H6.55A is unique because each ligand tested 
(regardless of structural differences or hypothesized critical binding interactions with the 
receptor) induced activation of only a single hD2L-mediated second messenger pathway. The 
question this raises are the possible mechanisms. 
GTPγS binding is known to be only a rough estimate of GPCR function, as it reflects 
the stoichiometry of which alpha subunits are available and their rate of turnover rather than 
a specific function (Gazi et al., 2003). Nonetheless, it is quite surprising that the intrinsic 
activity of GTPγS binding was essentially the same in the H6.55A and WT receptors whereas 
the mutant showed no agonist stimulation of two of the three measured functions. Indeed, 
inhibition of adenylate cyclase by the hD2L receptor clearly is associated with activation of 
Gαi/o (Missale et al., 1998; Neve et al., 2004), and these α-subunits are thought to comprise a 
major part of the GTPγS signal. It would be of interest to determine if there are marked 
changes in specific labeling of this population of α-subunits that might explain the lack of 
effect on adenylate cyclase. On the other hand, GPCR mediated
ease pathways have been hypothesized to be mediated in large measure through Gβγ 
signaling (Neve et al., 2004), although this can also occur indirectly through cAMP-mediated 
processes.  Analysis of MAPK activation via Gβγ signaling in the presence of added 
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pertussin could rule out the role of pertussin-sensitive Gαi/o proteins.  Further analysis of the 
permutations of Gβγ with fusion proteins could be utilized to determine the specificity of 
interactions with G protein-H6.55A receptor compared to G protein-WT receptor.  
Subsequent studies with purified G protein subunits and purified receptor systems could 
enhance these studies by providing key information to correlate conformational changes of 
the receptor with agonist-selective activation of specific G protein complexes.  
In conclusion, the current data underscore the complexity of signaling and the likely 
involvement of other partners in signal transduction (Urban et al., 2006a). The interesting 
anomaly reported in this work not only opens the door for some interesting mechanistic 
studies, but also impacts on the recent debate over concepts of ligand activation. Classic 
pharmacological models have been based on the notion of receptor-active states, starting 
with simple two-stage models that have grown increasingly complex as new data needed to 
be incorporated (see Chapter 1). Another viewpoint that has been offered is that the number 
of possible receptor active states is essentially infinite and depends on the population of 
conformations induced by the binding of a ligand to a receptor (Urban et al., 2006a). The 
latter is markedly influenced by the environment of the receptor, including a variety of 
protein partners as well as the lipid environment (Urban et al., 2006a). It seems difficult to 
reconcile the current data with the classic type of model. In any event, detailed understanding 
of the involved mechanisms are heuristically interesting, and may enhance drug discovery 
endeavors which seek to selectively turn on therapeutic pathways while eliminating 
activation of secondary pathways associated with unwanted side effects. 
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C 6. A 2.50
PREFA
HAPTER  NALYSIS OF THE ROLE OF ASPARTATE  IN ALLOSTERICALLY 
MODULATING FUNCTIONALLY SELECTIVE LIGAND SIGNALING. 
To be submitted for publication in:  
Neuropharmacology 
CE 
Previous chapters addressed specific ligand-residue interactions in the active site of 
the dopamine receptor. The work presented in this Chapter, however, will address the role of 
an allosteric site D2.50(80), the sodium and pH sensitive site of hD2L. Previous studies with 
D2.50A mutant suggest a critical role for cAMP synthesis, but extensive analysis with 
multiple effector endpoints and functionally selective ligands has yet to be conducted. This 
chapter will address D2.50 allosterism and its relationship to ligand-induced conformational 
changes with a set of functionally selective ligands. This chapter will further previous studies 
by utilizing a set of structurally different compounds (including functionally selective 
compounds) to characterize the role of D2.50 allosterism at multiple effector endpoints.    
ABSTRACT 
The most conserved residue of TM2, aspartate D2.50, was studied to understand its 
role in allosterically modulating signaling of functionally selective ligands with the hD2L 
r  
D2.50N can artificially creat studies measured the affect 
of ligand binding affinity, G protein ion of second messenger pathways 
(e.g. cAMP synthesis, MAPK activation, and AA-release) with the test compounds RNPA, 
DHX, D
eceptor. Previous mutagenesis studies of catecholamine receptors suggest that D2.50A and
e functionally selective systems. Our 
 turnover, and activat
A, and QP with D2.50A. All four test compounds had lower affinity for D2.50A than 
WT, with binding curves shifted from shallow to steep, suggesting a possible loss of high 
affinity coupling to G protein. The test compounds were neither able to stimulate GTPγS 
binding with D2.50A, nor activate any of the three receptor-coupled second messenger 
pathways with this mutant receptor. Unlike prior studies with the cannabinoid CB1 and 
α2A-adrenergic receptor studies where selective signaling was maintained with D2.50A and 
D2.50N, hD2L signaling is abolished without this highly conserved aspartate residue.  
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INTRODUCTION 
, 2005; 
Hoare, 2005; Pin et al., 2005), as well as the potential the clinical utility of such allosteric 
ligands (Zobel et al., 2000; Petersen and Sullivan, 2001; Li et al., 2002; Li et al., 2003; 
Grillon et al., 2003; Olesen et al., 2004; Bertini et al., 2004; Poon, 2005; Lindberg et al., 
2005; Kellner et al., 2005). Not surprisingly, dopamine receptors have sites of allosteric 
modulation including Zn2+, Na+, and amiloride sensitivity (Schetz, 2005). Neve first 
discovered the sodium and pH sensitivities of the D2 receptor (Neve, 1991), and subsequent 
site-directed mutagenesis experiments provided evidence to support aspartate D2.50 as the 
sodium-sensitive site (Neve et al., 1991). When mutated, the D2L receptor exhibited 
The focus of drug discovery for decades has been on designing ligands targeting the 
active sites of receptors or enzymes. Although research on orthosteric sites remains most 
common, there has been a recent push to explore the potential of allosteric sites. These can 
be aspects of the target receptor sensitive to interacting proteins, ions, or even other 
endogenous small molecules, but also any portion of the target receptor where ligand binding 
can affect function. Allosterism can affect orthosteric ligand binding, induce conformational 
changes that activate or inactivate receptors, but can also affect the receptor in many other 
ways. The HIV field has benefited greatly from targeting allosteric sites with non-nucleoside 
reverse transcriptase inhibitors such as nevirapine (Pommier et al., 2005). These drugs 
exhibit much greater potency and have significantly longer half lives than the orthosteric 
nucleoside reverse transcriptase inhibitors such as AZT (Pommier et al., 2005). 
A growing literature supports the existence of allosteric sites within G protein 
coupled receptors (GPCRs) (Birdsall and Lazareno, 2005; Gao et al., 2005; Schetz
137 
decreased affinity for binding and loss of inhibitory action on cAMP accumulation. What is 
interest
1
2
ized that the 
D2.50A 2L
2L
constant (KD) of 0.58 nM (Figure 6.1 and Table 6.1). The D2.50A (D80A) mutant receptor 
ing, however, is that the latter study only examined a single functional D2L endpoint.  
Recent results have shown that such site-directed mutations can differentially affect 
signaling pathways. In addition to data presented in earlier Chapters, D2.50N with the 
cannabinoid receptor CB  exhibited full agonist activity for adenylate cyclase inhibition and 
Ca2+ currents similar to WT, but decreased agonist-mediated potentiation of GIRK channels 
and receptor internalization (Roche et al., 1999). In addition, D2.50N of the α -adrenoceptor 
exhibited agonist-stimulated inhibition of cAMP and Ca2+ currents similar to WT, but 
markedly decreased receptor-mediated Na2+ currents (Surprenant et al., 1992).  
These data suggest that D2.50 not only allosterically regulates ligand-mediated 
function, but that it can exhibit a differential role for activation of specific second messenger 
pathways that signal through a single receptor isoform. We therefore hypothes
 mutation of the hD  receptor would result in differential effects similar to those 
seen with the cannabinoid and adrenoceptors. The current data, however, show that D2.50 is 
critical for the hD , and that mutation to alanine causes a complete loss of G protein 
coupling and subsequent loss of intrinsic activity at several downstream effector pathways. 
RESULTS 
Effect of mutation on receptor expression and radioligand binding 
The hD2L WT receptor and D2.50A were stably expressed in CHO K1 cells, and 
saturation radioreceptor assays with [3H]-N-methylspiperone were used to characterize both 
receptors. The WT receptor was expressed at 4.8 pmol/mg protein with a dissociation 
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was expressed at a much higher density (34.7 pmol/mg protein) with a slightly decreased 
radioantagonist affinity (KD = 0.69 nM). 
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Figure 6.1. Saturation Binding for stably expressing mutant and WT hD2L recept
3
. Data shown is representative of 3-4 independent experiments conducted in triplicate. 
Effect of D2.50A on affinity of agonist probe ligands 
The affinity for each probe ligand was determined using competition radioreceptor 
assays versus [3H]-N-methylspiperone in membranes from both WT and mutant receptors. 
An apparent affinity constant, K0.5, was determined from experimental IC50 values and were 
corrected for radioligand KD and concentration using the bimolecular Cheng-Prusoff 
relationship (Cheng and Prusoff, 1973) as reported in Table 6.1. Competition binding studie
changes induced by the receptor. Although all 
ity (as found for N-methylspiperone), their rank order and relativ
ged, suggesting that no major changes to overall receptor structure were induced by 
this mutation.  
Representative data for the agonist probe ligands are shown in Figure 6.2 and 
summarized in Table 6.1. Most notably, the relative rank order of affinity for WT (RNPA > 
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DHX > DA ≈ QP) is greatly affected by D2.50A (RNPA > DHX > QP >> DA). Specifically, 
D2.50A caused large affinity shifts with DA and RNPA compared to WT whereas D2.50A 
had only modest effects on QP and DHX. Interestingly, the Hill coefficients for RNPA, DA, 
QP, and DHX with WT all shifted to steeper slope with D2.50A, suggesting loss of the high 
affinity (G protein-coupled) state.  
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Figure 6.2. Competition binding of test compounds with hD2L WT and D2.50A. Membrane fragments 
were incubated with [3H]-N-methylspiperone at K for 15 min. with varying concentrations of test compounds. 
Analysis was conducted using non-linear regression and a sigmoidal equation to determine IC50s, reported as 
corrected affinity values (K
D 
independent experiments.  
0.5) using Prism 4.0. Assays were conducted in triplicate and data represents three 
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Table 6.1. Saturation and competition binding data for D2.50A mutant and WT. 
 Receptor 
 WT D2.50A 
Saturation  
KD (nM) 0.58 0.69 
Bmax (pmol) 4.8 34.7 
Competition  
 Ligand  K0.5 (nM) 
R(-)NPA 16 ± 5 63 ± 2 
QP 3100 ± 50 9500 ± 80 
DA 3050 ± 390 41400 ± 7200 
DHX 1990 ± 530 5950 ± 150 
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Figure 6.3. GTPγS turnover experiments of test compounds with hD2L WT and D2.50A. Membrane 
fragments were incubated for 15 minutes with varying concentrations of test compounds until equilibrium was 
reached. [35S]-GTPγS (0.2 nM) was then added for 30 minutes and stimulation was measured. Assays were 
cond
s on ligand-induced GTPγS binding 
An estimate of G protein turnover was conducted using non-hydrolyzable 
[35S]-GTPγS (see Figure 6.3 and Table 6.2). All four test compounds robustly stimulated 
[35S]-GTPγS turnover with WT receptor. In contrast, D2.50A inhibited all compounds from 
ucted in triplicate and data represents Emax values of 3-4 independent experiments. 
 
Effect of mutation
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stimulating [35S]-GTPγS turnover. These results suggest that D2.50A affects ligand-induced 
receptor conformations necessary for G protein co  hypothesized that downstream 
effector pathways would also be devoid of function.  
Table 6.2. EC50 values for GTPγS turnover experiments. 
EC50 (nM) 
upling. We
Mu PA DHX tant R(-)N  QP DA 
W 1.0 ± 1.3 120 1710 ± 370 ± 180 T 740 ±  1040 
D2.50A NA NA NA NA 
NA = no activity 
Values repres 0 ± S.E.M. for 3-4 periments c plicate. 
Measurement of agonist inhibition of FSK-stimulated cAMP accumulation in a whole 
cond
whole cell assay system for WT and D2.50A (see Figure 6.4). In the WT receptor, all four 
ligands fully stim utation 
elimina 3
ent EC5  independent ex onducted in tri
 
cell assay system for WT and D2.50A was conducted (see Figure 6.4). At the WT receptor, 
all four test compounds exhibited full dopamine agonist activity, robustly inhibiting 
FSK-stimulated cAMP accumulation. In contrast, the D2.50A mutation eliminated any 
stimulatory effect of these four compounds. In addition, in this experiment the effects of 
domperidone alone, and domperidone plus quinpirole were also assessed, with neither 
ition causing stimulation or inhibition versus forskolin alone (data not shown).  
Measurement of agonist activation of MAPK phosphorylation was conducted in a 
ulated MAPK phosphorylation. Conversely, the D2.50A m
ted this activity. Measurement of agonist stimulated [ H]-arachidonic acid release 
was conducted in a whole cell assay system for WT and D2.50A (see Figure 6.4). At the WT 
142 
receptor, all four test compounds robustly stimulated [3H]-arachidonic acid release. 
Conversely, the D2.50A mutation eliminated activity of all four test compounds.  
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MAP Kin
domperidone or quinpirole plus domperidone with any of the assays with the D2.50A mutant. Data are 
DISCUSSION 
allosterically regulating receptor conformations based on its Na+ and pH sensitivities (Neve 
Figure 6.4. Activation of second messenger pathways of hD with ligands at D2.50A. Top
 inhibition of FSK-stimulated cAMP accumulation, Middle) Agonist mediated activation of p44/p42 
ase, Bottom) Agonist mediated potentiation of [3H]-arachidonic acid release. There were no effects of 
representative of Emax values for 3-5 independent experiments conducted in triplicate. 
This dissertation chapter studied the allosteric nature of the TM2 conserved aspartate 
residue of hD2L. Previous research has suggested that D2.50 plays a critical role in 
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et al., 1991). This study addressed the necessity of D2.50 regulation of signaling when 
typical or functionally selective ligands were tested at three distinct second messenger 
endpoints of hD . Critical to this study was the evaluation of multiple endpoints, as the 
over basal observed with WT. This finding further suggested the critical nature of D2.50 
tion of hD2L signaling. Second messenger endpoints were subsequently 
studied, with the hypothesis that D2.50A would inhibit agonist activation of these pathways. 
As expected, none of the four test compounds activated any of the functional endpoints 
2L
previous mutagenesis work (Neve et al., 1991) focused on only receptor binding and one 
function (i.e., agonist inhibition of adenylate cyclase). D2.50 is located greater than 10 Å 
from the orthosteric site, and modeling suggests that this residue does not form any direct 
contact points with ligands used in this study. Our goal, however, was to determine if there 
was an interaction between changes induced by functionally selective ligands at the active 
site and allosteric regulation of second messenger pathways mediated by this aspartate.     
 The data gained from binding studies suggested significantly decreased binding of 
test ligands to the mutant receptor. The shapes of the binding curves also proved significant. 
Ligand binding with WT suggested that a mixture of high and low affinity receptor states 
were present, indicated by a shallow Hill slope (nH < 1). Conversely, ligand binding to 
D2.50A exhibited not only a decreased affinity, but also a shift of Hill slope from less than 
unity (mixed population of receptor states) to unity or greater. These data suggest that ligand 
binding with D2.50A is to an uncoupled receptor.  
Ligand-receptor activation of G protein turnover was evaluated following binding 
studies. In agreement with the binding data hypotheses, none of the four compounds 
stimulated coupling to [35S]-GTPγS with D2.50A, unlike their robust stimulation of coupling 
allosteric regula
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measured with D2.50A whereas each of the four test compounds robustly activated these 
functional endpoints with hD2L WT. Together, these data provide overwhelming evidence to 
support the critical role of D2.50 in regulating ligand-induced conformational changes that 
activate second messenger pathways coupled to D2L.  
Complete loss of G protein coupling and subsequent function could be explained by 
our choice of an alanine point mutant. Replacement of aspartate with alanine removes the 
polar carboxyl group that interacted with Na+ to affect binding affinity, hence the decreased 
affinity observed with D2.50A. Removal of this charge however, could also significantly 
affect the intra- and interhelical interactions that take place between D2.50 and the 
surroun
n addition to information about binding 
affinity
ding amino acids of hD2L. While receptor binding with antagonist did not reveal any 
significant changes in affinity, such studies would not provide information about the loss of 
subtle contact points that could be critical for conformational changes associated with 
receptor-G protein coupling. Replacement of the –OH moiety with –NH2 (D2.50N) or 
extension of the carbon chain (D2.50E) might have served as better substitutes than alanine 
(D2.50A). D2.50E or D2.50N might have provided further information about the H-bonding 
interactions and steric interactions respectively i
, G protein turnover, and activation of second messenger pathways. The data herein, 
however, suggest that removal of the aspartic side chain significantly impairs turnover and 
activation of second messenger pathways regardless of the type of ligand (functionally 
selective or endogenous) selected for study.  
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 C 7. S , C , AND FUTURE DIRECTIONS 
SUMM
Analysis of TM5 serine residues 
The focus of Chapters 2 and 3 addressed the role of each of the three conserved serine 
residues of TM5. Previous studies conducted with these serines suggest that S5.42 and S5.46 
are of significance for dopamine agonist interactions with hD2 receptors (Mansour et al., 
HAPTER  UMMARY  ONCLUSIONS
ARY OF STUDIES CONDUCTED  
Overview of original goals 
A firm understanding of ligand-specific interactions with particular receptor locales 
and their subsequent effects on second messenger signaling is critical for elucidating 
mechanisms of functional selectivity. The initial hypotheses for this research came from an 
existing computational model that led to experiments using lines of CHO stably expressing 
D2L WT and mutant receptors. A set of structurally diverse and rationally selected probe 
ligands [including functionally selective ligands (RNPA, SNPA, DNS, DNX, DHX), partial 
agonists (3-PPP, SNPA), and endogenous and prototypical full agonists (dopamine, 
quinpirole)] were used in the testing of the specific hypotheses. The resulting data are the 
first to provide evidence showing how specific regions of a receptor can modulate, in a 
differential fashion, activation of individual effector pathways mediated through a single 
receptor isoform. The work of this dissertation provides evidence which lays the groundwork 
for future studies that include isolation of ligand-specific G protein activation and further 
design of pathway-selective ligands.   
 
 1992; Cox et al., 1992; Woodward et al., 1996; Wiens et al., 1998). My studies provide 
results to suggest that these two serines are critical for activation of signaling pathways via 
effects on direct ligand-residue interactions. Analysis of second messenger pathways with 
S5.42A m
t AC inhibition (quinpirole and RNPA are 
unaffected). Activation of MAPK with S5.42A, however, was critical for some ligands 
(dopam
at S5.43 is not directly involved in interactions with 
these ligands, but instead plays a role in receptor stabilization and/or activation. The S5.43A 
mutant significantly affected binding of all ligands, but had minimal affects on GTPγS, AC 
inhibition, and MAPK. Conversely, S5.43A exhibited differential affects on Arachidonic 
acid release (loss of function for dopamine, DNS, and DHX, but minimal affects on the other 
utant provided evidence to support the critical necessity of this receptor-ligand 
interaction with most all test compounds a
ine, DNS, DNX, SNPA, and 3-PPP) but not RNPA, quinpirole, and DHX, whereas 
S5.42 was critical for activation of AA-release with all ligands but RNPA and quinpirole. 
RNPA, quinpirole, and 3-PPP exhibited intrinsic activity for AC inhibition similar to WT 
with S5.46A, whereas all other ligands exhibited loss of function. Activation of MAPK with 
S5.46A significantly impaired DNS, DNX, DHX, and dopamine, but had minimal affects on 
RNPA, SNPA, quinpirole and 3-PPP. Conversely, S5.46A significantly impaired agonist 
potentiation of AA-release for all ligands but RNPA and quinpirole. Binding and coupling 
data do not correlate in a one-to-one fashion with functional observations, suggesting that 
each ligand interaction with receptor is unique and this interaction may or may not subtly 
affect ligand-induced activation of second messenger pathways.  
The other serine located in this region of TM5, S5.43, also has  been suggested as 
critical for dopamine and p-tyramine interactions (Cox et al., 1992). Our modeling data and 
my experiments suggest, however, th
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 ligands studied). These findings suggest that this mutation results in a receptor with which 
most “typical” D2 agonists that tends to have a high degree of functional selectivity. One 
implication of these data is that the mutation results in different patterns of induced 
conformations than WT receptor, suggesting that each ligand-specific receptor state uniquely 
affects activation of second messenger pathways.  
Chapter 4 addressed the role of a novel threonine residue in TM3. Previous literature 
utilizing SCAM techniques suggested that T3.37 was not water-accessible to antagonist 
binding (Javitch et al., 1995a). Molecular modeling studies conducted with our agonists 
suggested otherwise. Results from these studies suggest that not only is T3.37 critical for 
binding to select ligands (RNPA, quinpirole, dopamine, DNS, DNX), but that function is 
significantly impaired with the mutant receptor. Only RNPA and quinpirole exhibit intrinsic 
activity for the second messengers assayed with T3.37A. All other ligands exhibit complete 
loss of function. Interestingly, SNPA and dopamine markedly increased GTPγS binding, but 
lose second messenger activity. We do not however understand what this means. It is 
conceivable that T3.37A impairs SNPA and dopamine coupling to inhibitory G proteins but 
Analysis of TM3 threonine residue 
that T3.37A allows promiscuous coupling to other G proteins.  Subsequent studies have yet 
to be conducted to address these observations but should be considered.  
Structural inference from RNPA and quinpirole interactions with T3.37 and S5.46 
suggests the hypothesis that T3.37 might not only be critical for binding, but could involve a 
significant interaction between the helices of TM3 and TM5. The working hypothesis is that 
T3.37 and S5.46 interact across the receptor pocket, H-bonding in the absence of ligand. 
Mutagenesis to either residue removes a key interaction between TM3 and TM5, rendering 
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 the receptor inactive. RNPA and quinpirole interact in the pocket differently than our other 
test ligands, and mutagenesis has minimal affect on ligand interaction between TMs 3 and 5 
and subsequent coupling and second messenger function is maintained. This hypothesis 
needs to be tested further, as understanding of the structural implications of T3.37 may 
provide insight into mechanisms of receptor activation, and the rational design of 
functionally selective compounds.  
An
ot. Agonist-induced 
couplin
alysis of TM6 histidine residue 
Chapter 5 addressed the role of the TM6 histidine residue. The 6.55 position is 
critical for Class A GPCRs. Direct agonist interaction at this locus has been shown for the 
β2AR, GalR1, and for bovine rhodopsin (Nakayama and Khorana, 1991; Zhang and 
Weinstein, 1994; Wieland et al., 1996; Farrens et al., 1996; Gether et al., 1997; Berthold et 
al., 1997; Sheikh et al., 1999). Although no dopamine agonist in this study was hypothesized 
to interact with H6.55, there are data to support an interaction between H6.55 and dopamine 
antagonists (Woodward et al., 1994). Additionally, recent studies have provided evidence to 
support H6.55 and H6.60 as the zinc-sensitive sites of hD2L (Liu et al., 2006). Such data 
suggest the hypothesis that H6.55 can influence receptor conformational changes associated 
with second messenger signaling. My studies with H6.55A suggest that RNPA and dopamine 
receptor binding is affected, whereas that of quinpirole and DHX are n
g to GTPγS is minimally affected at best. Conversely, AC inhibition and AA-release 
with H6.55A are completely lost, suggesting the critical necessity of H6.55 for receptor 
activation. Interestingly, H6.55A had no effect on ligand mediated MAPK activation vs. WT, 
but significantly decreased intrinsic activity for quinpirole. These data, again, seem 
inconsistent with the notion of limited numbers of discrete active states.  
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 Analysis of TM2 aspartate residue 
Chapter 6 addressed the role of the highly-conserved TM2 aspartate residue D2.50. 
After the sodium and pH sensitivity of D2.50 was discovered (Neve et al., 1991), D2.50 was 
hypothesized to form direct contacts with dopamine agonists. With the availability of the first 
GPCR crystal structure (Palczewski et al., 2000), homology analysis made it likely that 
D2.50 was quite distant (> 10 Å) from the ligand-binding site. Nonetheless, the report of 
allosteric regulation of binding affinity by sodium (Neve et al., 1991) led to studies with 
many GPCRs. The latter work suggested that D2.50 was differentially involved in receptor 
activation, that is, mutagenesis abolished activation of one pathway while maintaining WT-
like activation of a second pathway (Surprenant et al., 1992; Roche et al., 1999). My data 
suggest that D2.50 is critical for receptor mediated activation of all functional pathways. 
Mutagenesis decreased affinity and shifted receptor binding curves (n  < 1 with WT, n  > 1 
with D2.50A). GTPγS binding studies exhibited complete loss of coupling consistent with 
the binding data (increased Hill slopes), and subsequent activation of second messenger 
pathways was lost. Together, these data support a critical role for D2.50 regulation of 
ligand-induced conformational changes that activate second messenger pathways coupled to 
D .    
an approach that is 
H H
2L
Implications of this work 
The work presented in this dissertation provides a wealth of new information that 
broadens our understanding of how ligand-receptor interactions affect function. Previous 
work, including extensive SCAM studies, provided a plethora of data to characterize the 
ligand-receptor interactions of hD2L. Built on this foundation, my research focused on how 
this affected signaling through multiple second messenger endpoints, 
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 vital to an in-depth understanding the mechanisms of activation, and ultimately, the 
mechan
Many studies have focused on the mechanisms involved in GPCR activation. 
Receptor mutagenesis can provides evidence to test hypotheses about specific interactions 
between ligand-receptor complexes, residue-residue contacts, and residue-G protein 
complexes (Shi and Javitch, 2002). The availability of the GPCR crystal structure of bovine 
rhopdopsin (Palczewski et al., 2000) and genome analysis of sequence alignments has 
facilitated molecular structural studies by providing a roadmap of residues for study. This 
interface has been further implemented, combining mutagenesis via SCAM (see Shi and 
isms of functional selectivity. My research suggests that rather than digital activation 
of a few active states of a receptor, that each ligand induces a landscape of conformations 
unique to that ligand-receptor complex. For example, the S5.43A mutant alters 
ligand-induced coupling of G protein such that heterotrimeric subunits signaling through this 
mutant do not potentiate AA-release (for dopamine, DNS, and DHX), yet activate AC and 
MAPK similar to WT (for these same ligands). Signaling at all endpoints with S5.43A was 
unhindered for the other agonists tested in this dissertation. These data suggest that 
individual ligands can selectively induce a conformation of the receptor that preferentially 
activates a single effector pathway while turning off other effector pathways. The potential 
for drug discovery with functionally selective ligands is very promising. To understand the 
specific heterotrimeric components activated and their direct links to physiological processes 
would significantly enhance future therapeutics.  
RELATED STUDIES 
Structural changes involved in GPCR activation 
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 Javitch for review) with rational design of homology models of other GPCRs (Ballesteros et 
al., 2001b). This multicollaborative effort has made possible the rigorously studied and 
continuously tested molecular model of hD2L that was a foundation of my research. One of 
the major weaknesses of receptor mutagenesis studies, however, has been the difficulty of 
separating mutation-induced changes on ligand interaction from mutation-induced changes to 
receptor structure. In many cases, these alternate (although sometimes related phenomena) 
and can be resolved by the data, but in other cases this is difficult. I believe my research has 
shown that the analysis of multiple functional endpoints, although experimentally painful, 
markedly aids in the discrimination of these two alternate mechanisms.  
Further mutagenesis studies have elucidated key receptor residues that participate in 
conformational changes (upon ligand binding) that activate the receptor. Termed the “ionic 
lock,” D3.49, R3.50, and E6.30, located at the cytoplasmic ends of TM3/TM6 are 
responsible for activation of the β2AR (Ballesteros et al., 2001a). Additionally, studies have 
suggested that C6.47, W6.48, and F6.52 are involved in modulating a TM6 proline kink. 
er changes with these residues in what has been 
term  activation (Shi et al., 2002).  
2
These data provide evidence to support rotam
ed a “rotamer toggle switch” mechanism of receptor
One way to explore some of the underlying mechanisms in a direct fashion is to 
utilize fluorescent labeling of receptor residues. Such studies have been conducted with 
β AR whereby a sulfhydryl-reactive fluorescent probe (fluorescein maleimide, FM) has been 
attached to a cysteine residue (Cys-265) in the carboxy-terminal region of IC3. Agonist 
activation leads to conformational changes that are manifested as changes in fluorescence 
characteristics that are proportional to the biological efficacy of the agonist. This technology 
was used to observe a rotation and/or tilting of TM6 upon agonist activation (Ghanouni et al., 
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 2001b). Further use of FM provided evidence to support ligand-induction of distinctly 
different conformations for partial agonist, full agonist, and antagonist ligands (Ghanouni et 
al., 2001a). One additional step was implemented such that structurally related catechol 
derivatives could induce ligand-specific structural interactions with the receptor, essentially 
isolating unique conformational states (Swaminath et al., 2004). Probing the differences in 
binding and activation with agonists and partial agonists of β2AR suggested that GPCR 
activation is a multistep process (Swaminath et al., 2005). In my view, these studies provide 
strong support for ligand-selective activation of unique receptor states.  
Crystallographic studies can, under optimal conditions, provide conclusive evidence 
for suc
d have 
provide
h structural interactions. Unfortunately, the only available data are with a protein 
(bovine rhodopsin) that is in the same superfamily, but does not have dissociable ligands, and 
for which only an inactive state structure exists. Fortunately, functional selectivity is not 
limited to GPCRs. There exists a subset of ligands (e.g. tamoxifen and raloxifene) that act 
upon estrogen receptors (nuclear receptors) as functionally selective ligands, although that 
phenomenon has been termed “selective estrogen receptor modulation” (SERM; Dutertre and 
Smith, 2000). Crystallographic studies with estrogen receptors bound to SERM ligan
d a wealth of evidence to suggest that ligand-specific receptor conformational states 
exist (Shiau et al., 1998; Pike et al., 1999). Structural studies conducted with both ERα (2.03 
Å) and ERβ (0.93 Å) provide evidence for induction of distinctly different conformational 
states by ligands of various classes including full agonists, partial agonists, and antagonists. 
In addition, these studies provide conclusive evidence to support a physiological role for 
ligand-induced conformational states. What currently is not understood, however, is how 
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 these unique ligand-receptor sub-states affect functional measurements with G protein-
coupled receptors.  
in vitro
demonstrated in vivo if physiological relevance is to be established. Indeed, as was 
summarized in Chapter 3, my host laboratory entered the arena of functional selectivity 
kicking and screaming when it was found that dihydrexidine (DHX), a ligand originally 
Functional Selectivity in vivo 
Data presented in this dissertation provides overwhelming evidence to support 
functional selectivity . It is imperative, however that functional selectivity be 
designed to be a D1
2
2
weight gain compared to placebo (Kane et al., 2002). Because aripiprazole is a high affinity 
 dopamine agonist showed functional selectivity in rat brain preparations 
(Mottola et al., 1991); (Mottola et al., 2002). Studies in preparations not confounded by other 
dopamine receptors, such as pituitary lactotrophs and MN9D cells confirmed, showed 
conclusively that DHX, as well as a D -selective analog propylDHX, were indeed 
functionally selective. This provided clear evidence for the unexpected behavioral responses 
observed with propylDHX in which there were dose-dependent decreases in locomotion as 
opposed to the increases expected for dopamine agonists (Smith et al., 1997). These data 
make a compelling case for functional selectivity in vitro being able to predict novel effects 
in vivo, although it would be very interesting to determine the relative behavioral effects of 
DHX, propylDHX, and a typical drug like quinpirole, in D -receptor knockout mice.  
A particularly controversial area of direct relevance relates to the recently introduced 
antipsychotic drug aripiprazole (Abilify). Unlike the other antipsychotics available on the 
market, aripiprazole exhibits no significant extrapyramidal side effects (e.g. akathisia, 
dystonia, parkinsonism, and tardive dyskinesia), no hyperprolactinemia, and no significant 
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 D2 ligand (Lawler et al., 1999; Shapiro et al., 2003), this is surprising because all other high 
affinity and highly selective D2 antagonists cause a characteristic side effect profile that 
includes akathisia, dystonia, and parkinsonism. Preclinical studies showed that aripiprazole 
had  unique behavioral and neurochemical actions, such that it activated presynaptic D  
autoreceptors, whereas it antagonized D  postsynaptic receptors (Kikuchi et al., 1995). The 
developers of the drug have postulated that this novel clinical profile is due to the fact that 
aripiprazole is a D  partial agonist. They theorize that aripiprazole would boost dopamine 
to the 
phenom
2
2
2
signaling in areas of hypofunction, and decrease dopamine signaling in regions of 
hyperfunction (Burris et al., 2002). An alternate hypothesis that has been proposed, and for 
which strong supporting data using a variety of functional endpoints, is that aripiprazole is a 
functionally selective D2 ligand (Lawler et al., 1999; Shapiro et al., 2003; Urban et al., 
2006b). It seems quite clear that the behavioral and neurochemical data of Kikuchi et al. 
(1995) can only be explained by functional selectivity, not partial agonism. These data 
suggest that further understanding of the complex signaling mechanics of aripiprazole could 
significantly enhance future drug discovery endeavors in this realm of central nervous system 
therapeutics.  
FUTURE STUDIES 
The primary goal of this dissertation was to explore mechanisms related 
enon of functional selectivity, knowing that such studies would also impact our 
understanding of mechanisms of receptor-mediated/signaling. These studies tested the 
hypothesis that selective interactions between ligand and critical receptor residues would 
differentially affect signaling through hD2L. There are at least three major conclusions that I 
have drawn from my experiments. First, that specific interaction between ligand and receptor 
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 significantly affect signaling patterns observed through a single receptor isoform. Second, 
that mutagenesis of receptor can create an artificial system in which either the endogenous 
ligand or non-functionally selective drugs become functionally selective. Last, that functional 
selectivity reflects the dynamic nature of ligand-receptor interactions that might be 
considered to reflect an energy landscape unique for a given ligand and its signaling 
complex. These ideas suggest a variety of follow-up directions for future experimentation.  
The mutations discussed in this dissertation were based upon hypotheses generated 
from molecular modeling techniques. Except for H6.55 and S5.43, the other target residues 
were hypothesized to form direct contact with ligands. There are however, other receptor 
residues in the active site that could indirectly affect binding of our ligands. The 
phenylalanines F6.51 and F6.52 are solvent accessible (Javitch et al., 1998) residues that 
comprise part of the TM6 aromatic amino acids that have been hypothesized as critical for 
receptor activation (Zhang and Weinstein, 1994; Farrens et al., 1996; Gether et al., 1997; 
Sheikh et al., 1999; Floresca and Schetz, 2004). Previous mutagenesis studies support F6.51 
interaction with dopam
Further mutagenesis studies 
ine through orthogonal pi-stacking (Floresca and Schetz, 2004). F6.51 
andidates for extensive mutagenesis studies and characterization of 
recepto
and F6.52 are good c
r signaling. Further understanding of these subtle interactions (whether direct or 
indirect) will add to our knowledge base of ligand-induced receptor activation.  
The results discussed in Chapter 4 of this dissertation support a novel interaction not 
previously supported in the literature. SCAM studies concluded that T3.37 was not 
accessible to the binding site crevice (Javitch et al., 1995a), but our molecular modeling did 
lead to hypothesized interactions with ligands, a hypothesis supported by some of the current 
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 data. What made this residue interesting, however, was that only two ligands (quinpirole and 
RNPA) exhibited functional activity. These findings and data with S5.46A suggested that 
some interhelical interplay might take place. Such data lead to the hypothesis that S5.46 and 
T3.37 may form an H-bond across the pocket of the active site. Altering this interaction 
through mutagenesis leads to loss of signaling for most all ligands except quinpirole and 
RNPA. This hypothesis could be tested by a reciprocal double-mutant (i.e., T3.37S and 
S5.46T), and this is currently being studied, utilizing quinpirole and RNPA as test ligands. 
Increased understanding of TM3 and TM5 interactions
y α-subunits 
(Gerha
 at this location in the active site could 
alter the approaches used to design dopamine agonists.  
Involved signaling partners 
As functional selectivity became a focus of our laboratory, mechanistic studies begun. 
One obvious target was the specific heterotrimeric partners that couple to receptors activated 
with functionally selective ligands. These studies were conducted by testing ligand-induced 
activation of GTPγS coupled to an immunoprecipitation pulldown assay with antibodies 
selective for individual Gαi/o subunits. Unfortunately, these studies yielded minimal results 
due to poor selectivity of currently available antibodies. Such studies are crucial if we are to 
understand ligand-selective activation of heterotrimeric G proteins.  
Another viable approach for determining G protein specificity involves the use of 
fusion constructs. CHO cells used in this dissertation contain three inhibitor
rdt and Neubig, 1991), three β-subunits, and ten γ-subunits (unpublished results) that 
contribute to the diverse signaling profiles observed with functionally selective ligands. 
C-terminal peptides are of interest because previous work suggests that the C-termini of α-
subunits form direct contacts to receptors (Hamm et al., 1988). C-terminal peptide fusion 
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 constructs of each α-subunit can be generated and tested for differences in binding affinity in 
the presence of different functionally selective ligands. Less structural information is known 
for β- and γ-subunits, and thus more work must be conducted to understand the structural 
interaction with receptor before screening with peptide constructs can be conducted. After 
isolating the specific receptor-Gα interactions, further work with reconstitution systems, and 
the total G protein heterotrimer would need to be done. An understanding of ligand-selective 
activation of specific heterotrimeric components at the molecular level would provide a 
wealth of data to assist screening techniques for selection/or design of future drugs. 
Energy landscape visualization 
 a ligand have been studied with fluorescent probes, 
isolatin
at type of spectrum a 
functio
Individual components of
g the kinetic role of each component in the activation of effector pathways 
(Swaminath et al., 2004; Swaminath et al., 2005). These studies and earlier work provided 
evidence to support distinct conformational changes for partial agonists, full agonists, and 
antagonists (Ghanouni et al., 2001a; Ghanouni et al., 2001b; Cohen et al., 2005). In light of 
the previously discussed energy landscape hypotheses outlined in this dissertation and the 
data to support this hypothesis, it would be of interest to study our functionally selective 
ligands using fluorescent techniques. One has to ask just wh
nally selective ligand would exhibit? How would the endogenous ligand, which can 
be made functionally selective with receptor mutant, be affected? My hypothesis is that each 
ligand would exhibit a unique fluorescence profile in a manner similar to my functional data. 
If that were the case, not only would the differential activation of effector pathways be 
observed quantitatively (this dissertation), but the actual induction of an energy landscape of 
conformations unique to each ligand-receptor complex would be observed. Further studies 
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 that seek to parse the subtle kinetic differences between activation of one pathway over 
another with fluorescent analyses would also provide further visual evidence that distinct 
conformational states do exist, and that no distinct set of rigid states mandates signaling 
through GPCRs.  
Behavioral profiling 
A great deal of in vitro research is required before we can fully understand how a 
single ligand can interact with its target, induce a unique conformational state that selectively 
couples to a specific heterotrimeric unit, and activate a single effector pathway preferentially 
over  vitro data to in vivo studies is a giant leap that we are 
not rea
 another. The translation of this in
dy to tackle, however, the data within this dissertation offers some interesting places 
to start. Current technology provides one clear direction by which my research might be 
translated into physiologically-relevant systems. One would be to test some of the most 
important hypotheses using transgenic mice. Assume for example, that a specific mutation 
caused a marked change in the signaling profile of one ligand. Using an example I cited in 
the Discussion of Chapter 3, the S5.43 mutation completely abolishes AA signaling for 
dopamine, SNPA, DNS, and DHX, but not for RNPA, quinpirole, and DNX. The signaling 
of these compounds at other pathways (e.g., AC and MAPK) was largely unaffected. Thus, 
one could prepare a transgenic mouse expressing S5.43 rather than the WT D2 receptor. One 
could then use a variety of levels of analysis ranging from overall behavioral responses, to 
cellular response (e.g., isolated lactotrophs) to single unit recordings (e.g., in the substantia 
nigra) to ascertain whether the change in signaling in vitro translated into effects in situ. Of 
course, it would be equally of interest (if unexpected) if the development of the mice was 
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 affected markedly. This would suggest that those pathways no longer activated by dopamine 
(AA in the S5.43A example) have a critical development role.  
Ramifications of this work 
The work detailed in this dissertation provides an abundance of new information to 
suggest that functional selectivity not only exists, but that there are distinctly different 
mechan
throughput screens (HTS) by creating receptor chimeras that are amenable to devices like 
isms involved with such signaling patterns than that currently accepted by the general 
scientific community. If we are to make progress in this ever increasing world of 
pharmacology, the interface between rational drug design, receptor screening, and detailed 
pharmacological analyses must be reevaluated. At present, ligand-based and structure-based 
drug design can suggest new compounds that then are tested for functionality through a 
variety of screening processes. Missing from current approaches is consideration for the 
complexity if signaling through a single receptor. Generally, new compound screening 
involves only binding affinity, often with studies of a single effector pathway (e.g. for hD2L 
receptors AC inhibition is the gold standard). There are two inherent weaknesses in this 
strategy that can be illustrated using the D2L receptor as an example. If one is looking for an 
agonist, and if a “hit” in a binding assay fails to inhibit AC, one would assume the compound 
is completely inactive. Indeed, some such “rejected” compounds may actually have useful 
activity at another D2L-Gαi/o regulated pathway. The potential of such functionally selective 
drugs thus will never be known. It seems to me that in the future, doing basic research to 
elucidate the signaling pathways important to the physiological processes modulated by a 
given receptor would provide the necessary foundation for truly rational drug design.  
Another implication of my work relates to a common strategy of developing high-
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 FLIPPR. One common approach is to convert a Gαi/o receptor into a Gαq receptor that will 
then couple to calcium mobilization that can be assessed by fluorescence. Although very cost 
effective, my research would suggest that such chimeric receptor systems are very artificial, 
and may markedly alter the signaling profile of a given ligand. Although this may be of 
lesser importance when looking for neutral antagonists, it may be crucial if agonist-type 
ligands are being sought. On the other hand, if one is seeking new functionally selective 
ligands, the use of a selective mutational strategy with key target residues (such as employed 
in this research) may be of potential value as one may be able to detect such functional 
differences that might not be found using only the WT receptor. In its entirety, my work 
suggests that there is both richness and subtlety in how ligands may activate multiple 
signaling pathways that is scientifically interesting, and may have profound impact on drug 
discovery and the approaches of medicinal chemists.   
 
 
 
 
 
 
 
 
 
 
 
161 
 OVERALL REFERENCE LIST 
 
American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental 
Disorders DSM-IV-TR Fourth Edition (Text Revision). 
 
Anden NE, Carlsson A, Dahlstroem A, Fuxe K, Hillarp NA, Larsson K. (1964) 
530. 
 
Anden NE, Dahlstroem A, Fuxe K, Larsson K. (1965) Further evidence for the presence of 
Anden NE, Dahlstrom A, Fuxe K, Larsson K. (1966) Functional role of the nigro-neostriatal 
dopamine neurons. Acta Pharmacol Toxicol (Copenh) 24: 263-274. 
 
Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci 3: 523-
nigro-neostriatal dopamine neurons in the rat. Am J Anat 116: 329-333. 
 
Ariens EJ. (1954) Affinity and intrinsic activity in the theory of competitive inhibition. I. 
Problems and theory. Arch Int Pharmacodyn Ther 99: 32-49. 
 
Ariens EJ, De Groot WM. (1954) Affinity and intrinsic-activity in the theory of competitive 
inhibition. III. Homologous decamethonium-derivatives and succinyl-choline-esters. 
Arch Int Pharmacodyn Ther 99: 193-205. 
 
Ariens EJ, Simonis AM. (1954) Affinity and intrinsic-activity in the theory of competitive 
inhibition. II. Experiments with paraamino-benzoic acid derivatives. Arch Int 
Pharmacodyn Ther 99: 175-187. 
 
Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, Javitch JA. (2001a) 
Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between 
the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 276: 29171-
29177. 
 
162 
 Ballesteros JA, Shi L, Jav icry in G protein-coupled 
receptors: implications of the high-resolution structure of rhodopsin for structure-
function analysis of rhodopsin-like receptors. Mol Pharmacol 60: 1-19. 
allesteros JA, Weinstein H. (1995) Integrated methods for the construction of three-
dimensional models and computational probing of structure-function relations in G 
 
ellini C, Leff P, Clarke WP. (1998) Effector 
pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for 
 
erthold M, Kahl U, Jureus A, Kask K, Nordvall G, Langel U, Bartfai T. (1997) 
 Villa P, Di GM, Martin F, 
Gentile M, Santoni A, Corda D, Poli G, Mantovani A, Ghezzi P, Colotta F. (2004) 
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 
 
m at muscarinic receptors: ligands and 
 
irkmayer W, Hornykiewicz O. (1961) [The L-3,4-dioxyphenylalanine (DOPA)-effect in 
Parkinson-akinesia.]. Wien Klin Wochenschr 73: 787-788. 
Bre
90) trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a 
highly potent selective dopamine D1 full agonist. J Med Chem 33: 1756-1764. 
itch JA. (2001b) Structural mim
 
B
protein-coupled receptors. Methods Neurosci 25: 366-428. 
Berg KA, Maayani S, Goldfarb J, Scaram
agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54: 94-104. 
B
Mutagenesis and ligand modification studies on galanin binding to its GTP-binding-
protein-coupled receptor GalR1. Eur J Biochem 249: 601-606. 
 
Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di 
C, V, Cesta MC, Galliera E, Martinez FO, Di BR, Troiani G, Sabbatini V, D'Anniballe G, 
Anacardio R, Cutrin JC, Cavalieri B, Mainiero F, Strippoli R,
and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 101: 11791-
11796. 
Birdsall NJ, Lazareno S. (2005) Allosteris
mechanisms. Mini Rev Med Chem 5: 523-543. 
B
 
wster WK, Nichols DE, Riggs RM, Mottola DM, Lovenberg TW, Lewis MH, Mailman 
RB. (19
163 
 Brink CB, Wade SM, Neubig RR. (2000) Agonist-directed trafficking of porcine alpha(2A)-
adrenergic receptor signaling in Chinese hamster ovary cells: l-isoproterenol selectively 
activates G(s). J Pharmacol Exp Ther 294: 539-547. 
 
Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. (2002) 
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine 
D2 receptors. J Pharmacol Exp Ther 302: 381-389. 
 
Cagampang FR, Antoni FA, Smith SM, Piggins HD, Coen CW. (1998) Circadian changes of 
type II adenylyl cyclase mRNA in the rat suprachiasmatic nuclei. Brain Res 810: 279-
282. 
 
Campbell A, Baldessarini RJ, Teicher MH, Neumeyer JL. (1986) Behavioral effects of 
apomorphine isomers in the rat: selective locomotor-inhibitory effects of S(+)N-n-
propylnorapomorphine. Psychopharmacology (Berl) 88: 158-164. 
 
Carlsson A, Lindqvist M, Magnusson T.
Nature 180: 1200. 
catecholamines to receptor subtypes. FEBS Lett 399: 9-13. 
Cha
 
Carlsson A, Lindqvist M. (1963) Effect of chlorpromazine or haloperidol on formation of 3-
methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 
(Copenh) 20: 140-144. 
 (1957) 3,4-Dihydroxyphenylalanine and 5-
hydroxytryptophan as reserpine antagonists. 
 
Carlsson A, Lindqvist M, Magnusson T, Waldeck B. (1958) On the presence of 3-
hydroxytyramine in brain. Science 127: 471. 
 
Cavalli A, Fanelli F, Taddei C, De Benedetti PG, Cotecchia S. (1996) Amino acids of the 
alpha1B-adrenergic receptor involved in agonist binding: differences in docking 
 
lmers DT, Behan DP. (2002) The use of constitutively active GPCRs in drug discovery 
and functional genomics. Nat Rev Drug Discov 1: 599-608. 
164 
 Charifson PS, Bowen JP, Wyrick SD, Hoffman AJ, Cory M, McPhail AT, Mailman RB. 
(1989) Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-
benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands. J Med Chem 
32: 2050-2058. 
 
Che
nt inhibition (I50) of an enzymatic 
reaction. Biochem Pharmacol 22: 3099-3108. 
 
Che
5-204. 
 
Choi EY, Jeong D, Won K, Park, Baik JH. (1999) G protein-mediated mitogen-activated 
 
Clarke WP. (2005) What's for lunch at the conformational cafeteria? Mol Pharmacol 67: 
 
Cohen BE, Pralle A, Yao X, Swaminath G, Gandhi CS, Jan YN, Kobilka BK, Isacoff EY, 
nctional and clinical data. 
Psychopharmacologia 45: 243-254. 
 
ng Y, Prusoff WH. (1973) Relationship between the inhibition constant (K1) and the 
concentration of inhibitor which causes 50 per ce
rn Y. (2000) Regulation of adenylyl cyclase in the central nervous system. Cell Signal 
12: 19
 
Chern Y, Lee EH, Lai HL, Wang HL, Lee YC, Ching YH. (1996) Circadian rhythm in the 
Ca(2+)-inhibitable adenylyl activity of the rat striatum. FEBS Lett 385: 205-208. 
protein kinase activation by two dopamine D2 receptors. Biochem Biophys Res Commun 
256: 33-40. 
1819-1821. 
Jan LY. (2005) A fluorescent probe designed for studying protein conformational change. 
Proc Natl Acad Sci U S A 102: 965-970. 
 
Cools AR, Van Rossum JM. (1976) Excitation-mediating and inhibition-mediating 
dopamine-receptors: a new concept towards a better understanding of 
electrophysiological, biochemical, pharmacological, fu
165 
 Cooper JR, Bloom FE, Roth RH. 2006. The Biochemical Basis of Neuropharmacology. pp. 
293-351. 
 
orbin AE, Meltzer HY, Ninteman FW. (2000) PD 158771, a potential antipsychotic agent 
with D2/D3 partial agnoist and 5-HT(1A) actions.  II.  Preclinical behavioral effects. 
 
ox BA, Henningsen RA, Spanoyannis A, Neve RL, Neve KA. (1992) Contributions of 
conserved serine residues to the interactions of ligands with dopamine D2 receptors. J 
 
Cox RF, Neumeyer JL, Waszczak BL. (1988) Effects of N-n-propylnorapomorphine 
 
Davis KL, Kahn RS, Ko G, Davidson M. (1991) Dopamine in schizophrenia: a review and 
 
De LA, Stadel JM, Lefkowitz RJ. (1980) A ternary complex model explains the agonist-
 
Declercq JP, Evrard C, Lamzin V, Parello J. (1999) Crystal structure of the EF-hand 
 
el Castillo J, Katz B. (1957) Interaction at end-plate receptors between different choline 
derivatives. Proc R Soc Lond B Biol Sci 146: 369-381. 
C
Neuropsychopharmacology. 39: 1185-1194. 
C
Neurochem 59: 627-635. 
enantiomers on single unit activity of substantia nigra pars compacta and ventral 
tegmental area dopamine neurons. J Pharmacol Exp Ther 247: 355-362. 
 
Creese I, Burt DR, Snyder SH. (1976) Dopamine receptor binding predicts clinical and 
pharmacological potencies of antischizophrenic drugs. Science 192: 481-483. 
reconceptualization. Am J Psychiatry 148: 1474-1486. 
specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J 
Biol Chem 255: 7108-7117. 
parvalbumin at atomic resolution (0.91 A) and at low temperature (100 K). Evidence for 
conformational multistates within the hydrophobic core. Protein Sci 8: 2194-2204. 
D
166 
 Doupnik CA, Davidson N, Lester HA, Kofuji P. (1997) RGS proteins reconstitute the rapid 
gating kinetics of gbetagamma-activated inwardly rectifying K+ channels. Proc Natl 
Acad Sci U S A 94: 10461-10466. 
 
Dut
Ther 295: 431-437. 
e efficacy. Mol Pharmacol 63: 36-43. 
 recording. 
J Neurosci 11: 3727-3737. 
 
Far dvall G. (1992) Positron emission 
tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients 
treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. 
 
Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. (1996) Requirement of rigid-
body motion of transmembrane helices for light activation of rhodopsin. Science 274: 
 
Felder CC, Williams HL, Axelrod J. (1991) A transduction pathway associated with 
receptors coupled to the inhibitory guanine nucleotide binding protein Gi that amplifies 
 
ertre M, Smith CL. (2000) Molecular mechanisms of selective estrogen receptor 
modulator (SERM) action. J Pharmacol Exp 
 
Ebersole BJ, Visiers I, Weinstein H, Sealfon SC. (2003) Molecular basis of partial agonism: 
orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A 
receptor determines relativ
 
Ehringer H, Hornykiewicz O. (1960) [Distribution of noradrenaline and dopamine (3-
hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal 
system.]. Klin Wochenschr 38: 1236-1239. 
 
Einhorn LC, Gregerson KA, Oxford GS. (1991) D2 dopamine receptor activation of 
potassium channels in identified rat lactotrophs: whole-cell and single-channel
de L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Se
Arch Gen Psychiatry 49: 538-544. 
768-770. 
ATP-mediated arachidonic acid release. Proc Natl Acad Sci U S A 88: 6477-6480. 
167 
 Floresca CZ, Schetz JA. (2004) Dopamine receptor microdomains involved in molecular 
recognition and the regulation of drug affinity and function. J Recept Signal Transduct 
Res 24: 207-239. 
 
Fu D, Ballesteros JA, Weinstein H, Chen J, Javitch JA. (1996) Residues in the seventh 
membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site 
crevice. Biochemistry 35: 11278-11285. 
 
Fur
 
Garau L, Govoni S, Stefanini E, Trabucchi M, Spano PF. (1978) Dopamine receptors: 
 
Gay EA, Urban JD, Nichols DE, Oxford GS, Mailman RB. (2004) Functional selectivity of 
 
azi L, Nickolls SA, Strange PG. (2003) Functional coupling of the human dopamine D2 
receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for 
 
erhardt MA, Neubig RR. (1991) Multiple Gi protein subtypes regulate a single effector 
mechanism. Mol Pharmacol 40: 707-711. 
 
Gether U, Ballesteros JA, Seifert R, Sande
Structural instability of a constitutively active G protein-coupled receptor. Agonist-
independent activation due to conformational flexibility. J Biol Chem 272: 2587-2590. 
chgott RF. (1966) Metabolic factors that influence contractility of vascular smooth 
muscle. Bull N Y Acad Med 42: 996-1006. 
 
Gao ZG, Kim SK, Ijzerman AP, Jacobson KA. (2005) Allosteric modulation of the adenosine 
family of receptors. Mini Rev Med Chem 5: 545-553. 
pharmacological and anatomical evidences indicate that two distinct dopamine receptor 
populations are present in rat striatum. Life Sci 23: 1745-1750. 
D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of 
ligand-specific receptor states. Mol Pharmacol 66: 97-105. 
G
agonist regulation of G protein selectivity. Br J Pharmacol 138: 775-786. 
G
rs-Bush E, Weinstein H, Kobilka BK. (1997) 
168 
 Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, Kobilka BK. 
(2001a) Functionally different agonists induce distinct conformations in the G protein 
coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276: 24433-24436. 
97-6002. 
a potent full dopamine D1 agonist containing 
a rigid-beta-phenyldopamine pharmacophore. J Med Chem 39: 549-555. 
 
Gri  Anxiolytic effects of a novel group 
II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle 
paradigm in humans. Psychopharmacology (Berl) 168: 446-454. 
Grubbs RA, Lewis MM, Owens-Vance C, Gay EA, Jassen AK, Mailman RB, Nichols DE. 
(2004) 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), 
a high affinity and potent agonist at all dopamine receptor isoforms. Bioorg Med Chem 
 
Guo W, Shi L, Filizola M, Weinstein H, Javitch JA. (2005) Crosstalk in G protein-coupled 
receptors: changes at the transmembrane homodimer interface determine activation. Proc 
 
Guo W, Shi L, Javitch JA. (2003) The fourth transmembrane segment forms the interface of 
the dopamine D2 receptor homodimer. J Biol Chem 278: 4385-4388. 
Hamm HE, Deretic D, Arendt A, Hargrave PA, Koenig B, Hofmann KP. (1988) Site of G 
protein binding to rhodopsin mapped with synthetic peptides from the alpha subunit. 
 
 
Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK. (2001b) Agonist-induced 
conformational changes in the G-protein-coupling domain of the beta 2 adrenergic 
receptor. Proc Natl Acad Sci U S A 98: 59
 
Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE. (1996) 9-Dihydroxy-2,3,7,11b-
tetrahydro-1H-naph[1,2,3-de]isoquinoline: 
llon C, Cordova J, Levine LR, Morgan CA, III. (2003)
 
12: 1403-1412. 
Natl Acad Sci U S A 102: 17495-17500. 
 
Science 241: 832-835. 
169 
 Hamon J, Paraire J, Velluz J. (1952) [Effect of R. P. 4560 on maniacal agitation.]. Ann Med 
Psychol (Paris) 110: 331-335. 
 
Harper JF, Brooker G. (1975) Femtomole sensitive radioimmunoassay for cyclic AMP and 
 
Hashimoto E, Frolich L, Ozawa H, Saito T, Maurer K, Boning J, Takahata N, Riederer P. 
 
Hill AV. (1909) The mode of action of nicotine and curari determined by the form of the 
 
oare SR. (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B G-
protein-coupled receptors. Drug Discov Today 10: 417-427. 
 
Howard EI, Sanishvili R, Cachau RE, Mitschler A, Chevrier B, Barth P, Lam
Joachimiak A, Podjarny A. (2004) Ultrahigh 
resolution drug design I: details of interactions in human aldose reductase-inhibitor 
complex at 0.66 A. Proteins 55: 792-804. 
 
Hwa J, Perez DM. (1996) The unique nature of the serine interactions for alpha 1-adrenergic 
receptor agonist binding and activation. J Biol Chem 271: 6322-6327. 
Idanpaan-Heikkila J, Alhava E, Olkinuora 
treatment with clozapine. Eur J Clin Pharmacol 11: 193-198. 
Ikeda H, Hatta S, Ozawa H, Ohshika H, Saito 
ouse striatum. Alcohol Clin Exp Res 23: 7S-10S. 
cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution. J Cyclic 
Nucleotide Res 1: 207-218. 
(1998) Reduced immunoreactivity of type I adenylyl cyclase in the postmortem brains of 
alcoholics. Alcohol Clin Exp Res 22: 88S-92S. 
contraction curve and the method of temperature coefficients. J.Physiol. 39: 361-373. 
H
our V, Van ZM, 
Sibley E, Bon C, Moras D, Schneider TR, 
 
M, Palva IP. (1997) Agranulocytosis during 
 
T. (1999) Effect of chronic ethanol treatment 
of Ca2+-inhibited adenylyl cyclase in m
 
170 
 Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL. (1998) [D-Arg1,D-
Phe5,D-Trp7,9,Leu11]Substance P acts as a biased agonist toward neuropeptide and 
chemokine receptors. J Biol Chem 273: 3097-3104. 
 
Jav
in the binding-site crevice of the D2 receptor: contributions 
of the second membrane-spanning segment. Biochemistry 38: 7961-7968. 
 
Jav
amine D2 receptor is accessible in the 
binding-site crevice. Biochemistry 37: 998-1006. 
 
Jav the 
dopamine D2 receptor exposed in the binding-site crevice. Biochemistry 34: 16433-
16439. 
Javitch JA, Fu D, Chen J, Karlin A. (1995b) Mapping the binding-site crevice of the 
dopamine D2 receptor by the substituted-cysteine accessibility method. Neuron 14: 825-
 
Javitch JA, Li X, Kaback J, Karlin A. (1994) A cysteine residue in the third membrane-
spanning segment of the human D2 dopamine receptor is exposed in the binding-site 
crevice. Proc Natl Acad Sci U S A 91: 10355-10359. 
Javitch JA, Shi L, Simpson MM, Chen J, Chiappa V, Visiers I, Weinstein H, Ballesteros JA. 
(2000) The fourth transmembrane segment of the dopamine D2 receptor: accessibility in 
itch JA, Ballesteros JA, Chen J, Chiappa V, Simpson MM. (1999) Electrostatic and 
aromatic microdomains with
itch JA, Ballesteros JA, Weinstein H, Chen J. (1998) A cluster of aromatic residues in the 
sixth membrane-spanning segment of the dop
itch JA, Fu D, Chen J. (1995a) Residues in the fifth membrane-spanning segment of 
 
831. 
 
the binding-site crevice and position in the transmembrane bundle. Biochemistry 39: 
12190-12199. 
 
Jelsema CL, Axelrod J. (1987) Stimulation of phospholipase A2 activity in bovine rod outer 
segments by the beta gamma subunits of transducin and its inhibition by the alpha 
subunit. Proc Natl Acad Sci U S A 84: 3623-3627. 
 
171 
 Kane J, Honigfeld G, Singer J, Meltzer H. (1988) Clozapine for the treatment-resistant 
schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 
45: 789-796. 
 
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. (2002) 
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with 
schizophrenia and schizoaffective disorder. J Clin Psychiatry 63: 763-771. 
atry 155: 921-928. 
nism for receptor cross-talk? Mol Pharmacol 67: 1697-1704. 
 
ebabian JW, Greengard P. (1971) Dopamine-sensitive adenyl cyclase: possible role in 
synaptic transmission. Science 174: 1346-1349. 
 
Keb
milarity to the "dopamine receptor". Proc Natl 
Acad Sci U S A 69: 2145-2149. 
 
Kapur S, Zipursky RB, Remington G. (1999) Clinical and theoretical implications of 5-HT2 
and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. 
Am J Psychiatry 156: 286-293. 
 
Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. (1998) 5-
HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am 
J Psychi
 
Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. (2005) Concurrent stimulation of 
cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a 
mecha
 
Kebabian JW, Calne DB. (1979) Multiple receptors for dopamine. Nature 277: 93-96. 
K
abian JW, Petzold GL, Greengard P. (1972) Dopamine-sensitive adenylate cyclase in 
caudate nucleus of rat brain, and its si
 
172 
 Kellner M, Muhtz C, Stark K, Yassouridis A, Arlt J, Wiedemann K. (2005) Effects of a 
metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety 
induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. 
Psychopharmacology (Berl) 179: 310-315. 
 
Ken
 
Kenakin T. (1997) Agonist-specific receptor conformations. Trends Pharmacol Sci 18: 416-
 
enakin T. (2002) Efficacy at G-protein-coupled receptors. Nat Rev Drug Discov 1: 103-
110. 
 
Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Mi
(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-
14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor 
l Exp 
Ther 274: 329-336. 
 
Kil  Lawler CP, Oxford GS, O'Malley KL, 
Todd RD, Blake BL, Nichols DE, Mailman RB. (2002) Functional selectivity of 
dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected 
 
Klabunde T, Hessler G. (2002) Drug design strategies for targeting G-protein-coupled 
receptors. Chembiochem 3: 928-944. 
 
akin T. (1995a) Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor 
promiscuity. Trends Pharmacol Sci 16: 188-192. 
 
Kenakin T. (1995b) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. 
Trends Pharmacol Sci 16: 232-238. 
417. 
K
wa T, Oshiro Y, Morita S. (1995) 7-(4-[4-
agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmaco
ts JD, Connery HS, Arrington EG, Lewis MM,
MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 301: 1179-1189. 
173 
 Knoerzer TA, Watts VJ, Nichols DE, Mailman RB. (1995) Synthesis and biological 
evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 
dopamine receptors. J Med Chem 38: 3062-3070. 
 
Kramer BC, Yabut JA, Cheong J, Jnobaptiste R, Robakis T, Olanow CW, Mytilineou C. 
sci 19: 280-286. 
 HEL 92.1.7 cells. Br J Pharmacol 132: 1477-1484. 
orphines on dopamine receptors in striatal and limbic tissue of rat brain. Life Sci 37: 
1051-1057. 
 
Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, Nichols DE. (2003) A complex signaling 
cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement 
of MAP kinases. J Neurochem 86: 980-991. 
Kuz
 
awler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, 
Mailman RB. (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) 
 
Lee SP, O'Dowd BF, George SR. (2003a) Homo- and hetero-oligomerization of G protein-
coupled receptors. Life Sci 74: 173-180. 
(2004) Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic 
acid and its lipoxygenase metabolites. Eur J Neuro
 
Kukkonen JP, Jansson CC, Akerman KE. (2001) Agonist trafficking of G(i/o)-mediated 
alpha(2A)-adrenoceptor responses in
 
Kula NS, Baldessarini RJ, Bromley S, Neumeyer JL. (1985) Effects of isomers of 
apom
 
hikandathil EV, Yu W, Oxford GS. (1998) Human dopamine D3 and D2L receptors 
couple to inward rectifier potassium channels in mammalian cell lines. Mol Cell Neurosci 
12: 390-402. 
 
Laborit H, Huguenard P. (1951) [Artificial hibernation by pharmacodynamical and physical 
means.]. Presse Med 59: 1329. 
L
with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20: 612-627. 
174 
 Lee SP, O'Dowd BF, Ng GY, Varghese G, Akil H, Mansour A, Nguyen T, George SR. 
(2000) Inhibition of cell surface expression by mutant receptors demonstrates that D2 
dopamine receptors exist as oligomers in the cell. Mol Pharmacol 58: 120-128. 
chemistry 42: 11023-
11031. 
 
Lef  
Sciences 16: 89-97. 
 
Lef
s Pharmacol Sci 18: 355-362. 
p Ther 305: 950-955. 
for Ser-2035.42 in ligand binding to and activation of the 
beta 2-adrenergic receptor. J Biol Chem 275: 37779-37788. 
 
Lim
 
Lee SP, O'Dowd BF, Rajaram RD, Nguyen T, George SR. (2003b) D2 dopamine receptor 
homodimerization is mediated by multiple sites of interaction, including an 
intermolecular interaction involving transmembrane domain 4. Bio
f P. (1995) The 2-State Model of Receptor Activation. Trends in Pharmacological
f P, Scaramellini C, Law C, McKechnie K. (1997) A three-state receptor model of agonist 
action. Trend
 
Li X, Conklin D, Ma W, Zhu X, Eisenach JC. (2002) Spinal noradrenergic activation 
mediates allodynia reduction from an allosteric adenosine modulator in a rat model of 
neuropathic pain. Pain 97: 117-125. 
 
Li X, Conklin D, Pan HL, Eisenach JC. (2003) Allosteric adenosine receptor modulation 
reduces hypersensitivity following peripheral inflammation by a central mechanism. J 
Pharmacol Ex
 
Liapakis G, Ballesteros JA, Papachristou S, Chan WC, Chen X, Javitch JA. (2000) The 
forgotten serine. A critical role 
bird LE. (1996) Cell surface receptors: a short course on theory and methods (2nd 
edition).  
 
175 
 Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl 
FE, Klassen PS, Guo MD, Albizem MB, Coburn JW. (2005) Cinacalcet HCl, an oral 
calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis 
and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 
16: 800-807. 
Liu
endent potassium current in N18TG2 x 
mesencephalon hybrid cell (MES-23.5) via distinct G proteins. Synapse 31: 108-118. 
 
Liu r., Sibley DR, Chiodo LA. (1996) D2L, D2S, and D3 dopamine 
receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium 
current via distinct G protein mechanisms. Synapse 24: 156-164. 
Liu Y, Teeter MM, DuRand CJ, Neve KA. (2006) Identification of a Zn2+-binding site on 
the dopamine D2 receptor. Biochem Biophys Res Commun 339: 873-879. 
Lopez-Ilasaca M. (1998) Signaling from G-protein-coupled receptors to mitogen-activated 
protein (MAP)-kinase cascades. Biochem Pharmacol 56: 269-277. 
 
Lov
, a novel selective high potency full dopamine D-1 
receptor agonist. Eur J Pharmacol 166: 111-113. 
 
Lyn
-589. 
receptors (a lesson for drug discovery). Med Chem Res 13: 115-126. 
 
 LX, Burgess LH, Gonzalez AM, Sibley DR, Chiodo LA. (1999) D2S, D2L, D3, and D4 
dopamine receptors couple to a voltage-dep
 LX, Monsma FJ, J
 
 
enberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, 
Mailman RB. (1989) Dihydrexidine
ch MA. (1998) Age-related impairment in long-term potentiation in hippocampus: a role 
for the cytokine, interleukin-1 beta? Prog Neurobiol 56: 571
 
Mailman RB, Gay EA. (2004) Novel mechanisms of drug action: functional selectivity at D2 
dopamine 
 
176 
 Mailman RB, Nichols DE, Lewis MM, Blake BL, Lawler CP. 1998. Functional Effects of 
Novel Dopamine Ligands: Dihydrexidine and Parkinson's Disease as a First Step. In: 
Jenner P, Demirdemar R, editors. Dopamine Receptor Subtypes: From Basic Science to 
Clinical Application.IOS Stockton Press. pp. 64-83. 
 
Mailman RB, Nichols DE, Tropsha A. 1997. Molecular Drug Design and Dopamine 
 
Manning DR. (2002) Measures of efficacy using G proteins as endpoints: differential 
 
ansour A, Meng F, Meador-Woodruff JH, Taylor LP, Civelli O, Akil H. (1992) Site-
directed mutagenesis of the human dopamine D2 receptor. Eur J Pharmacol 227: 205-
 
Mark MD, Herlitze S. (2000) G-protein mediated gating of inward-rectifier K+ channels. Eur 
 
McLaughlin JN, Shen L, Holinstat M, Brooks JD, Dibenedetto E, Hamm HE. (2005) 
 
Meltzer HY, Matsubara S, Lee JC. (1989) Classification of typical and atypical antipsychotic 
Milligan G. (1999) Signal Transduction:  A Practical Approach.  
Receptors. In: Neve KA, Neve RL, editors. The Dopamine Receptors. Totowa, 
NJ:Humana Press. pp. 105-133. 
engagement of G proteins through single receptors. Mol Pharmacol 62: 451-452. 
M
214. 
J Biochem 267: 5830-5836. 
Functional selectivity of G protein signaling by agonist peptides and thrombin for the 
protease-activated receptor-1. J Biol Chem 280: 25048-25059. 
drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp 
Ther 251: 238-246. 
 
Meltzer HY, Stahl SM. (1976) The dopamine hypothesis of schizophrenia: a review. 
Schizophr Bull 2: 19-76. 
 
177 
 Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. (1998) Dopamine receptors: from 
structure to function. Physiol Rev 78: 189-225. 
 
onod J, Wyman J, Changeux JP. (1965) On the nature of allosteric transitions: a plausible 
model. J Mol Biol 12: 88-118. 
 
Mottola DM, Brewster W s DE, Mailman RB. (1992) Dihydrexidine, a 
novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther 262: 383-393. 
Mottola DM, Cook LL, Jones SR, Booth 
Dihydrexidine, a selective dopamine receptor agonist that may discriminate postsynaptic 
D2 receptors. Soc Neurosci Abstr 1991818. 
 
Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop 
DK, Piercey M, Wightman RM, Lawler CP, Nichols DE, Mailman RB. (2002) Functional 
selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic 
 
Nakayama TA, Khorana HG. (1991) Mapping of the amino acids in membrane-embedded 
. (1986) Arachidonic acid 
metabolism. Annu Rev Biochem 55: 69-102. 
M
K, Cook LL, Nichol
 
RG, Nichols DE, Mailman RB. (1991) 
dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301: 1166-
1178. 
 
Mottola DM, Laiter S, Watts VJ, Tropsha A, Wyrick SD, Nichols DE, Mailman RB. (1996) 
Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment 
and receptor mapping. J Med Chem 39: 285-296. 
 
Mukhopadhyay S, Howlett AC. (2005) Chemically distinct ligands promote differential CB1 
cannabinoid receptor-Gi protein interactions. Mol Pharmacol 67: 2016-2024. 
helices that interact with the retinal chromophore in bovine rhodopsin. J Biol Chem 266: 
4269-4275. 
 
Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB
178 
 Neumeyer JL, Froimowitz M, Baldessarini RJ, Campbell A, Gao YG. (1988) 
Neuropharmacology and stereochemistry of dopamine receptor agonist and antagonist 
enantiomeric pairs. J Recept Res 8: 83-96. 
 
Neu , Baldessarini RJ. (1991) R and S enantiomers of 11-
hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine 
receptors in rat brain tissue. J Med Chem 34: 24-28. 
Neumeyer JL, Reischig D, Arana GW, Campbell A, Baldessarini RJ, Kula NS, Watling KJ. 
(1983) Aporphines. 48. Enantioselectivity of (R)-(-)- and (S)-(+)-N-n-
propylnorapomorphine on dopamine receptors. J Med Chem 26: 516-521. 
 
Neve KA. (1991) Regulation of dopamine D2 receptors by sodium and pH. Mol Pharmacol 
39: 570-578. 
Nev
ylyl cyclase. Mol Pharmacol 39: 733-739. 
 
Nevo I, Avidor-Reiss T, Levy R, Bayewitch M, Heldman E, Vogel Z. (1998) Regulation of 
meyer JL, Gao YG, Kula NS
 
 
e KA, Cox BA, Henningsen RA, Spanoyannis A, Neve RL. (1991) Pivotal role for 
aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition 
of aden
 
Neve KA, Seamans JK, Trantham-Davidson H. (2004) Dopamine receptor signaling. J 
Recept Signal Transduct Res 24: 165-205. 
adenylyl cyclase isozymes on acute and chronic activation of inhibitory receptors. Mol 
Pharmacol 54: 419-426. 
 
Nichols DE. 1983. The development of novel dopamine agonists. In: Kaiser C, Kebabian JW, 
editors. Dopamine Receptors. Washington, D.C.:American Chemical Society. pp. 201-
218. 
 
179 
 Nickolls SA, Fleck B, Hoare SR, Maki RA. (2005) Functional selectivity of melanocortin 4 
receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational 
states. J Pharmacol Exp Ther 313: 1281-1288. 
agent. Br J Pharmacol 124: 1651-
1658. 
 
O'D
. J Biol Chem 
280: 37225-37235. 
 
Old n EN, Preininger AM, Hubbell WL, Hamm HE. (2006) Mechanism of the 
receptor-catalyzed activation of heterotrimeric G proteins. Nat Struct Mol Biol 13: 772-
777. 
Ole  D, Meier U, Pollentier S, Lesko LM. 
(2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute 
treatment of migraine. N Engl J Med 350: 1104-1110. 
Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le T, I, Teller DC, 
Okada T, Stenkamp RE, Yamamoto M, Miyano M. (2000) Crystal structure of 
 
Petersen KF, Sullivan JT. (2001) Effects of a novel glucagon receptor antagonist (Bay 27-
9955) on glucagon-stimulated glucose production in humans. Diabetologia 44: 2018-
 
Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, 
Gustafsson JA, Carlquist M. (1999) Structure of the ligand-binding domain of oestrogen 
receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 18: 4608-
4618. 
 
Nilsson CL, Hellstrand M, Ekman A, Eriksson E. (1998) Direct dopamine D2-receptor-
mediated modulation of arachidonic acid release in transfected CHO cells without the 
concomitant administration of a Ca2+-mobilizing 
owd BF, Ji X, Alijaniaram M, Rajaram RD, Kong MM, Rashid A, Nguyen T, George 
SR. (2005) Dopamine receptor oligomerization visualized in living cells
ham WM, Va
 
sen J, Diener HC, Husstedt IW, Goadsby PJ, Hall
 
rhodopsin: A G protein-coupled receptor. Science 289: 739-745. 
2024. 
180 
 Pin JP, Kniazeff J, Liu J, Binet V, Goudet C, Rondard P, Prezeau L. (2005) Allosteric 
functioning of dimeric class C G-protein-coupled receptors. FEBS J 272: 2947-2955. 
 
Pollock NJ, Manelli AM, Hutchins CW, Steffey ME, MacKenzie RG, Frail DE. (1992) 
 
ommier Y, Johnson AA, Marchand C. (2005) Integrase inhibitors to treat HIV/AIDS. Nat 
Rev Drug Discov 4: 236-248. 
 
Poon G. (2005) Cinacalcet hydrochloride (Sensipar). Proc (Bayl Univ Med Cent ) 18: 181-
184. 
Qandil AM, Lewis MM, Jassen A, Leonard SK, 
acological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline 
analogues) as D1 and D2 dopamine receptor ligands. Bioorg Med Chem 11: 1451-1464. 
Rau
ine(2C) receptor. J 
Pharmacol Exp Ther 299: 83-89. 
Rem
ographic study. J Clin 
Psychopharmacol 18: 82-83. 
Robas N, O'
Curr Opin Pharmacol 3: 
121-126. 
Rob
Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand 
interactions and receptor activation. J Biol Chem 267: 17780-17786. 
P
 
Mailman RB, Nichols DE. (2003) Synthesis 
and pharm
 
ser L, Savage JE, Meltzer HY, Roth BL. (2001) Inverse agonist actions of typical and 
atypical antipsychotic drugs at the human 5-hydroxytryptam
 
ington G, Kapur S, Zipursky R. (1998) The relationship between risperidone plasma 
levels and dopamine D2 occupancy: a positron emission tom
 
Reilly M, Katugampola S, Fidock M. (2003) Maximizing serendipity: strategies 
for identifying ligands for orphan G-protein-coupled receptors. 
 
inson SW, Caron MG. (1997) Selective inhibition of adenylyl cyclase type V by the 
dopamine D3 receptor. Mol Pharmacol 52: 508-514. 
181 
 Roche JP, Bounds S, Brown S, Mackie K. (1999) A mutation in the second transmembrane 
region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor 
internalization. Mol Pharmacol 56: 611-618. 
 
Rud
ed human alpha2A-
adrenoceptor to adenylyl cyclase. Br J Pharmacol 127: 877-886. 
 
Sam  Lefkowitz RJ. (1993) A mutation-induced activated state 
of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 
268: 4625-4636. 
Schetz JA. (2005) Allosteric modulation of dopamine receptors. Mini Rev Med Chem 5: 555-
561. 
Sch  
dopamine receptors through distinct molecular mechanisms. J Pharmacol Exp Ther 289: 
956-964. 
Schetz JA, Sibley DR. (1997) Zinc allosterically modulates antagonist binding to cloned D1 
and D2 dopamine receptors. J Neurochem 68: 1990-1997. 
 
Sel
(P2U)receptor-stimulated responses by neuropeptide Y Y1 
Gi/o-coupled receptors. Biochem J 328 ( Pt 1): 153-158. 
 
Sha
t-induced activation of 5-hydroxytryptamine 2A serotonin receptors that 
involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 
277: 11441-11449. 
ling JE, Kennedy K, Evans PD. (1999) The effect of site-directed mutagenesis of two 
transmembrane serine residues on agonist-specific coupling of a clon
ama P, Cotecchia S, Costa T,
 
 
etz JA, Chu A, Sibley DR. (1999) Zinc modulates antagonist interactions with D2-like
 
bie LA, King NV, Dickenson JM, Hill SJ. (1997) Role of G-protein beta gamma subunits 
in the augmentation of P2Y2 
piro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. (2002) Evidence for a model 
of agonis
 
182 
 Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. 
(2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust 
pharmacology. Neuropsychopharmacology 28: 1400-1411. 
elices III and VI block 
activation. J Biol Chem 274: 17033-17041. 
 
Shi
gments and second extracellular loop. Annu Rev Pharmacol Toxicol 42: 
437-467. 
 
Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. (2002) Beta2 adrenergic 
receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer 
toggle switch. J Biol Chem 277: 40989-40996. 
Shi n MM, Ballesteros JA, Javitch JA. (2001) The first transmembrane segment of 
the dopamine D2 receptor: accessibility in the binding-site crevice and position in the 
transmembrane bundle. Biochemistry 40: 12339-12348. 
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. (1998) The 
structural basis of estrogen receptor/coactivator recognition and the antagonism of this 
 
Simmons MA. (2005) Functional Selectivity, Ligand-Directed Trafficking, Conformation-
Specific Agonism: What's In A Name? Mol Interv 5: 154-157. 
Sim
itch JA. (1999) Dopamine D4/D2 receptor selectivity is determined 
by A divergent aromatic microdomain contained within the second, third, and seventh 
membrane-spanning segments. Mol Pharmacol 56: 1116-1126. 
 
Sheikh SP, Vilardarga JP, Baranski TJ, Lichtarge O, Iiri T, Meng EC, Nissenson RA, Bourne 
HR. (1999) Similar structures and shared switch mechanisms of the beta2-adrenoceptor 
and the parathyroid hormone receptor. Zn(II) bridges between h
 L, Javitch JA. (2002) The binding site of aminergic G protein-coupled receptors: the 
transmembrane se
 
 L, Simpso
 
interaction by tamoxifen. Cell 95: 927-937. 
 
pson MM, Ballesteros JA, Chiappa V, Chen J, Suehiro M, Hartman DS, Godel T, Snyder 
LA, Sakmar TP, Jav
183 
 Singh R, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, Guarnieri F. (2002) Activation 
of the cannabinoid CB1 receptor may involve a W6 48/F3 36 rotamer toggle switch. J 
Pept Res 60: 357-370. 
 
Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski 
TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G. 
(2002) (+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel 
dopamine agonist. J Med Chem 45: 3660-3668. 
: 19894-19900. 
 
Stephenson RP. (1956) A modification of receptor theory. Br J Pharmacol Chemother 11: 
 
trader CD, Candelore MR, Hill WS, Sigal IS, Dixon RA. (1989) Identification of two serine 
residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem 264: 
 
Sugden PH, Clerk A. (1997) Regulation of the ERK subgroup of MAP kinase cascades 
 
 
Smith FD, Oxford GS, Milgram SL. (1999) Association of the D2 dopamine receptor third 
cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein. J Biol 
Chem 274
 
Smith HP, Nichols DE, Mailman RB, Lawler CP. (1997) Locomotor inhibition, yawning and 
vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J 
Pharmacol 323: 27-36. 
 
Steck H. (1954) [Extrapyramidal and diencephalic syndrome in the course of largactil and 
serpasil treatments.]. Ann Med Psychol (Paris) 112, 2: 737-744. 
379-393. 
S
13572-13578. 
through G protein-coupled receptors. Cell Signal 9: 337-351. 
184 
 Surprenant A, Horstman DA, Akbarali H, Limbird LE. (1992) A point mutation of the alpha 
2-adrenoceptor that blocks coupling to potassium but not calcium currents. Science 257: 
977-980. 
 
Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, Kobilka B. (2005) Probing 
the beta2 adrenoceptor binding site with catechol reveals differences in binding and 
activation by agonists and partial agonists. J Biol Chem 280: 22165-22171. 
 
Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK. (2004) Sequential 
 
Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A. (1992) Pharmacologic 
 
ang WJ, Krupinski J, Gilman AG. (1991) Expression and characterization of calmodulin-
activated (type I) adenylylcyclase. J Biol Chem 266: 8595-8603. 
 
aussig R, Tang WJ, Hepler JR, Gilman AG. (1994) Distinct patterns of bidirectional 
regulation of mammalian adenylyl cyclases. J Biol Chem 269: 6093-6100. 
 
zavara ET, Pouille Y, Defer N, Hanoune J. (1996) Diurnal variation of the adenylyl cyclase 
type 1 in the rat pineal gland. Proc Natl Acad Sci U S A 93: 11208-11212. 
 
Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka BK, Weinstein H, Javitch JA, 
Roth BL, Christopoulos A, Sexton P, Miller K, Spedding M, Mailman RB. (2006a) 
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol 
 
Urban JD, Vargas GA, von ZM, Mailman RB. (2006b) Aripiprazole has Functionally 
Selective Actions at Dopamine D(2) Receptor-Mediated Signaling Pathways. 
Neuropsychopharmacology. 
binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate 
conformational states. J Biol Chem 279: 686-691. 
properties of (-)-3PPP (preclamol) in man. J Neural Transm Gen Sect 88: 165-175. 
T
T
T
Exp Ther. 
185 
 Versteeg HH, Nijhuis E, van den Brink GR, Evertzen M, Pynaert GN, van Deventer SJ, 
Coffer PJ, Peppelenbosch MP. (2000) A new phosphospecific cell-based ELISA for 
p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and 
cAMP-response-element-binding protein. Biochem J 350 Pt 3: 717-722. 
 
Vis
 329-371. 
armacol 58: 1230-1238. 
nists. 
Synapse 21: 177-187. 
 
We rnary complex receptor-
occupancy model. III. resurrecting efficacy. J Theor Biol 181: 381-397. 
 
We f microtubule-
associated protein kinase (Erk) and p70 S6 kinase by D2 dopamine receptors. J 
Neurochem 70: 2139-2146. 
Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M. (1999) Functional dissociation of 
mu opioid receptor signaling and endocytosis: implications for the biology of opiate 
 
Wieland K, Zuurmond HM, Krasel C, Ijzerman AP, Lohse MJ. (1996) Involvement of Asn-
293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic 
receptor. Proc Natl Acad Sci U S A 93: 9276-9281. 
iers I, Ballesteros JA, Weinstein H. (2002) Three-dimensional representations of G 
protein-coupled receptor structures and mechanisms. Methods Enzymol 343:
 
Watson C, Chen G, Irving P, Way J, Chen WJ, Kenakin T. (2000) The use of stimulus-biased 
assay systems to detect agonist-specific receptor active states: implications for the 
trafficking of receptor stimulus by agonists. Mol Ph
 
Watts VJ, Lawler CP, Gonzales AJ, Zhou QY, Civelli O, Nichols DE, Mailman RB. (1995) 
Spare receptors and intrinsic activity: studies with D1 dopamine receptor ago
iss JM, Morgan PH, Lutz MW, Kenakin TP. (1996) The cubic te
lsh GI, Hall DA, Warnes A, Strange PG, Proud CG. (1998) Activation o
 
tolerance and addiction. Neuron 23: 737-746. 
 
186 
 Wiens BL, Nelson CS, Neve KA. (1998) Contribution of serine residues to constitutive and 
agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-
specific active conformations. Mol Pharmacol 54: 435-444. 
 
Williams JH, Errington ML, Lynch MA, Bliss TV. (1989) Arachidonic acid induces a long-
drugs. J Neurochem 62: 1664-1669. 
. Neuroreport 7: 
2965-2970. 
 
Yor
 
Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. (2000) Effects of 
 
 
term activity-dependent enhancement of synaptic transmission in the hippocampus. 
Nature 341: 739-742. 
 
Woodward R, Coley C, Daniell S, Naylor LH, Strange PG. (1996) Investigation of the role of 
conserved serine residues in the long form of the rat D2 dopamine receptor using site-
directed mutagenesis. J Neurochem 66: 394-402. 
 
Woodward R, Daniell SJ, Strange PG, Naylor LH. (1994) Structural studies on D2 dopamine 
receptors: mutation of a histidine residue specifically affects the binding of a subgroup of 
substituted benzamide 
 
Yamamoto M, Ozawa H, Saito T, Frolich L, Riederer P, Takahata N. (1996) Reduced 
immunoreactivity of adenylyl cyclase in dementia of the Alzheimer type
k DH. (1970) Possible dopaminergic pathway from substantia nigra to putamen. Brain 
Res 20: 233-249. 
 
Zhang D, Weinstein H. (1994) Polarity conserved positions in transmembrane domains of G-
protein coupled receptors and bacteriorhodopsin. FEBS Lett 337: 207-212. 
the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major 
depression: the first 20 patients treated. J Psychiatr Res 34: 171-181. 
187 
